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Outline and aims of the thesis
Currently premature neonates have a relatively good survival rate from 24-25 weeks 
of gestation onwards (1,2) and this will likely improve even more in the future due 
to the continuing expansion of knowledge of neonatal physiology, drugs and the 
better integration of this knowledge with engineering and computational power. 
With improved survival rates, new questions surfaced: How does this impact (late) 
gestational organ development and are there long term consequences of preterm 
birth and all interventions associated with it? This field of research was established by 
David Barker, who hypothesized that early life events have a definitive programming 
effect on our physiology, which may only show an effect in later life (3,4). Barker 
postulated that this is a result of a misbalance in nutrient state during organ 
development causing the body to redirects the available energy to vital organs for 
survival, relatively neglecting the other ones. This hypothesis is named ‘the 
developmental origins of health and disease (DOHaD) and has its own international 
society formed around it (www.dohadsoc.org). With more efforts invested, evidence 
for this hypothesis is starting to accumulate for metabolic, cardiovascular and brain 
organ systems (5-8), however with regards to the kidney there is limited data available, 
but it was suggested that a lower energy state could result in less nephrons being 
formed (9). 
 The Barker thesis is closely related to another well-known renal paradigm, namely 
the hyperfiltration hypothesis established by Brenner in 1982 (10,11). The hypothesis 
states that a low glomerular number in the kidney results in additional stress for the 
remaining glomeruli, which first results in hypertrophy and subsequently hyperfiltra-
tion. In the next stage local- and later on systemic blood pressure is increased resulting 
eventually in scarring of the glomeruli and loss of functional nephrons. Progressively, 
this cycle results in renal disease in the end. Although originally established as a 
chronic kidney disease paradigm, the starting point for both paradigms is a low 
glomerular number. Both hypothesis can therefore be linked as shown in figure 1. 
Additionally Luyckx and Brenner have published quite compelling and convincing 
overviews of all supporting evidence in both animal and human for the hyperfiltration 
hypothesis, identifying many risk factors for a lower glomerular number (13,14). Some 
of these, such as intrauterine growth restriction, are well studied, but for others 
stressors many uncertainties remain on how they affect kidney development. 
 In the last few decades evidence is accumulating for a ‘two-hit hypothesis’ in 
kidney disease, where a first hit such as a congenital defect (e.g. low birth weight, 
intrauterine growth retardation) leads to a predisposition and a second hit (e.g. Aging, 
renal disease) results in progressive renal disease (15).
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Most of these studies so far have focused on evaluating the effect of a single 
congenital factor, however neonates are often exposed to a combination of these 
factors. In light of the DOHaD the concept that multiple stressors have an increased 
chance to affect the normal nutritional balance is very plausible. Therefore it is 
important that the interactions between individual factors for low glomerular 
numbers are studied as well. 
 Therefore we chose to further study the impact of two factors and their 
interaction, namely drug treatment (nephrotoxic medication) and the ‘environmental’ 
stressor extrauterine growth restriction.
 We chose to investigate drugs for three different neonatal indications: (1) sepsis, 
(2) closure of a patent ductus arteriosis and (3) fluid retention, which are normally 
treated with antibiotics, NSAIDs and diuretics respectively. These complications are 
quite prevalent in preterm born children as shown in statistics from the Netherlands 
Perinatal Registry. Antibiotics are administered to 62%, NSAIDs to 16% and diuretics to 
19% of neonates born before 32 weeks in the Netherlands (16). Additionally to neonatal 
treatment, the drugs may also be taken by pregnant women (although contraindicat-
Figure 1   Integration of renal programming (‘Barker’ hypothesis) with hyperfiltration 
hypothesis. (reprinted with permission from Schreuder et al. (12))
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ed) for similar or other indications (infections, water retention/high blood pressure, 
pain killer or tocolycant). 
 It is known that some drugs for these indications have a risk of causing acute 
kidney toxicity (aminoglycosides, Non-steroidal anti-inflammatory drugs (NSAIDs). 
However with regard to the DOHaD hypothesis we have to consider that these drugs 
may have an impact on (late) development of the kidney and may cause a predisposition 
to disease in later life. Therefore we have to reconsider the safety of these drugs even 
though the acute risk/benefit ratio may be very good in sight of survival. The 
developmental toxicity profiles of these drugs are well defined in preclinical safety 
testing but these experiments cannot comprise all the complex interactions that may 
be present in a clinical environment. Due to these drug-drug or drug-environment 
interactions, dose levels that were proven safe may still have a delayed (adverse) 
effect. We focused our work on a first-line treatment drug used in the Netherlands 
(gentamicin, indomethacin and furosemide) and a second drug that is also suitable 
to treat the aforementioned indications (ceftazidime, ibuprofen and hydrochloro-
thiazide).
 We selected our second stressor in the form of extrauterine growth restriction to 
evaluate interactions between drug treatment and this ‘environmental’ stressor. Due 
to all the necessary treatments (and accompanied side effects) in preterm born 
children, extrauterine growth restriction is one of the most difficult stressors to 
prevent in the neonatal care unit. Furthermore, models for extrauterine growth 
restriction have shown to negatively impact glomerulogenesisis. (17-20). This makes 
this stressor suitable as a second-hit for studying additive or synergic interactions 
with drug treatments. 
My hypothesis is that drug treatment within the neonatal clinical dose range can 
cause subtle programming effects on kidney development and can thereby cause 
a predisposition for renal disease in later life. Secondary I hypothesize that adding 
a second stressor in the form of extrauterine growth restriction can increase the 
toxicity of drug treatment. 
12
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In order to test this hypothesis, we aimed to provide answers to the following questions 
in this thesis: 
1.  Are currently used kidney morphometric parameters such as size or surface area 
good predictors for the state of kidney development? 
2.  What is the impact of drug treatment on early- and late kidney development? 
How does such an impact affect the function of the kidney in later life? Are there 
alternatives for drugs used in the current first-line treatment?
3.  Does an additional stressor in the form of extrauterine growth restriction indeed 
modulate drug toxicity according to the two-hit hypothesis? 
To answer these questions we have performed experiments described in the following 
chapters of this thesis. A more detailed outline of the chapters is presented below.
 To supplement this short introduction to the thesis, we provided more background 
information on the known drug effects of our selected compounds on renal development 
In chapter 2.
 Currently there is no direct way of counting glomeruli in humans in vivo, therefore 
estimations are often made based on renal weight and/or renal size. We questioned 
the value of these morphometric predictions and investigated the validity of renal size 
in chapter 3 by comparing the available literature on individual patient data. Papers 
were included in which both renal sizes were reported as well as unbiased results for 
glomerular numbers using stereology. 
 We further examined renal morphology markers in chapter 4 where we assessed 
the validity of metanephron surface area for ureteric bud differentiation, a well-studied 
kidney development endpoint. In chapter 3 we also investigated the effect of gentamicin, 
ceftazidime and meropenem on early kidney development by evaluating ureteric bud 
differentiation and mRNA expression of specific targets in important differentiation 
pathways.
 In chapter 5 we investigated the effect on glomerular numbers of both gentamicin 
and ceftazidime when administered in a clinical dose range at a later phase of kidney 
development, which is comparable to the developmental stage of a human premature 
neonate. Additionally, we introduced a ‘second hit’ in this chapter in the form of extra 
uterine growth restriction to study the interaction between this environmental stressor 
and drug treatment. The effects on glomerular numbers, proliferation/apoptosis 
and expression of important genes in renal development or renal function were 
studied by means of stereology, immunohistochemistry and quantitative polymerase 
chain reaction.
 Other drug classes such as non-steroidal anti-inflammatory drugs (NSAID’s) and 
diuretics are also frequently administered to premature neonates, but also have their 
uses in pregnant women. Therefore the effects of the NSAID’s ibuprofen and 
13
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indomethacin, and the diuretics furosemide and hydrochlorothiazide were studied in 
chapter 6. Similar endpoints compared with chapter 3 were used to evaluate toxicity.
 The impact of NSAIDs with or without extrauterine growth restriction on late 
kidney development and long term sequelae were further studied in an in vivo rat 
study in chapter 7, where in addition to the parameters measured in chapter 5, kidney 
function and blood pressure were followed up to 9 months by determining electrolyte 
and creatinine clearance in serum and urine, and using radio telemetry blood pressure 
measurement devices.
 Finally we studied the effects of furosemide and hydrochlorothiazide treatment 
with or without extrauterine growth restriction during late nephrogenesis and their 
long -term consequences for kidney function in chapter 8. The same study set-up was 
chosen as in chapter 7, with exception of the blood pressure measurements. Due to 
the difficulties of obtaining physiological blood pressure readings by telemetry in 
chapter 7, tail cuff measurements were used to determine blood pressure. 
 All considerations for our choice of techniques used in this thesis and the overall 
thesis findings and future recommendations for research are discussed in chapter 9.
14
CHAPTER 1
Reference list
1. Effer SB, Moutquin JM, Farine D, Saigal S, Nimrod C, Kelly E, Niyonsenga T. Neonatal survival rates in 860 
singleton live births at 24 and 25 weeks gestational age. A Canadian multicentre study. BJOG 2002;109(7): 
740-745.
2.  Kutz P, Horsch S, Kuhn L, Roll C. Single-centre vs. population-based outcome data of extremely preterm 
infants at the limits of viability. Acta Paediatr 2009;98(9): 1451-1455.
3.  Barker DJ. The fetal and infant origins of adult disease. BMJ 1990;301(6761): 1111.
4.  Barker DJ. The origins of the developmental origins theory. J Intern Med 2007;261(5): 412-417.
5.  Richards M, Hardy R, Kuh D, Wadsworth ME. Birthweight, postnatal growth and cognitive function in a 
national UK birth cohort. Int J Epidemiol 2002;31(2): 342-348.
6.  Rogers LK, Velten M. Maternal inflammation, growth retardation, and preterm birth: insights into adult 
cardiovascular disease. Life Sci 2011;89(13-14): 417-421.
7.  Martinez SR, Gay MS, Zhang L. Epigenetic mechanisms in heart development and disease. Drug Discov 
Today 2015;20(7): 799-811.
8.  Sosa-Larios TC, Cerbon MA, Morimoto S. Epigenetic alterations caused by nutritional stress during fetal 
programming of the endocrine pancreas. Arch Med Res 2015;46(2): 93-100.
9.  Reyes L, Manalich R. Long-term consequences of low birth weight. Kidney Int 2005;Suppl(97): S107-111.
10.  Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: 
the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular 
sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307(11): 652-659.
11.  Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney 
Int 1996;49(6): 1774-1777.
12.  Schreuder MF, Nauta J. Prenatal programming of nephron number and blood pressure. Kidney Int 
2007;72(3): 265-268.
13.  Luyckx VA, Brenner BM. Low birth weight, nephron number, and kidney disease. Kidney Int 2005;Suppl(97): 
S68-77.
14.  Luyckx VA, Brenner BM. Birth weight, malnutrition and kidney-associated outcomes--a global concern. 
Nat Rev Nephrol 2015;11(3): 135-149.
15.  Nenov VD, Taal MW, Sakharova OV, Brenner BM. Multi-hit nature of chronic renal disease. Curr Opin 
Nephrol Hypertens 2000;9(2): 85-97.
16.  The Netherlands Perinatal Registry. The Netherlands Perinatal Registry: Perinatal care in the Netherlands 
2005. 2008 Utrecht.
17.  Langley-Evans SC, Welham SJ, Jackson AA. Fetal exposure to a maternal low protein diet impairs 
nephrogenesis and promotes hypertension in the rat. Life Sci 1999;64(11): 965-974.
18.  Huizinga CT, Engelbregt MJ, Rekers-Mombarg LT, Vaessen SF, Delemarre-van de Waal HA, Fodor M. 
Ligation of the uterine artery and early postnatal food restriction - animal models for growth retardation. 
Horm Res 2004;62(5): 233-240.
19.  Schreuder MF, Nyengaard JR, Remmers F, van Wijk JA, Delemarre-van de Waal HA. Postnatal food 
restriction in the rat as a model for a low nephron endowment. Am J Physiol Renal Physiol 2006;291(5): 
F1104-1107.
20.  de Oliveira JC, Grassiolli S, Gravena C, de Mathias PC. Early postnatal low-protein nutrition, metabolic 
programming and the autonomic nervous system in adult life. Nutr Metab (Lond) 2012;9(1): 80.
15
INTRODUCTION AND AIMS OF THE THESIS
1

Radboud University Nijmegen Medical Centre, 1Department of Pediatric Nephrology,  
2Department of Laboratory Medicine, Laboratory for Genetic, Endocrine and Metabolic Diseases,  
and 3Department of Pharmacology and Toxicology, Nijmegen, The Netherlands.
Schreuder MF, Bueters RR, Huigen MC, Russel FG, Masereeuw R, van den Heuvel LP. 
Effect of drugs on renal development. Clin J Am Soc Nephrol. 2011 Jan;6(1):212-7.
Impact of drugs on renal development
MF Schreuder1
RR Bueters1
MC Huigen2
FGM Russel3
R Masereeuw3
LP van den Heuvel1,2
2
18
CHAPTER 2
Abstract
Many nephrotoxic effects of drugs have been described, whereas the impact on renal 
development has received less attention. Nephrogenesis ceases around the 36th week 
of gestation, indicating that drugs administered both to pregnant women as well as to 
preterm born neonates may influence kidney development. 
 Such impact on renal development may lead to a wide spectrum of renal 
malformations (congenital anomalies of the kidney and urinary tract, CAKUT), ranging 
from renal agenesis to a reduced nephron number. Any of these anomalies may have 
long-term sequelae and CAKUT is the primary cause for renal replacement therapy in 
childhood. This review focuses on research into the impact of drug treatment during 
active nephrogenesis, both during pregnancy as well as in preterm born infants. As 
the effects of many widely used drugs have not been unravelled yet, more research is 
needed to study the impact on renal development and long-term renal sequelae after 
drug treatment during nephrogenesis.
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Introduction
The kidney is vulnerable to toxic effects of many drugs, as recently reviewed by 
Perazella in this journal (1). However, drug treatment can also have an impact on 
development of the kidney. As nephrogenesis ceases around 36 weeks of gestation in 
man (2), most developmental nephrotoxic effects can be expected during treatment 
of pregnant women. In addition, premature born neonates are exposed to extrauterine 
life before completion of nephrogenesis, and many of them will be treated with drugs 
during active renal development. In this review, we focus on the effects of drug 
treatment on the developing kidney, both prenatal as well as postnatal.
Renal development
Nephrogenesis is the highly complex process that leads to the formation of nephrons, 
the functioning units of the kidney (2). The ureteric bud reciprocally induces the 
metanephric mesenchyme, which leads to condensation of the mesenchyme. Via 
branching morphogenesis and several stages of immature nephrons (comma- and 
S-shaped bodies), mature nephrons with a fully developed and elongated tubular 
system are formed. This process starts around the 5th week and ceases around the 36th 
week of gestation in man (2), around which time about 1 million nephrons per kidney 
are present with a very wide inter-individual range (~250,000 to 2,000,000 nephrons 
per kidney) (3,4). 
 After term birth, no new nephrons are formed: growth of the kidney to adult size 
is solely based on hypertrophia. However, it has been consistently shown that 
intrauterine growth restriction leads to a reduced number of nephrons (5). There is 
data suggesting that premature birth, i.e. before completion of nephrogenesis, is also 
associated with a reduced nephron endowment (6,7). This may be due to extrauterine 
growth restriction, which is very common in premature infants (8) and which we have 
shown to lead to a reduced nephron number in an animal model(9). However, 
nephrotoxic medications used during the postnatal period in premature infants may 
also affect final nephron number. The rate of premature birth (i.e. before 37 weeks of 
gestation and therefore before completion of nephrogenesis) varies widely, with 
about 7.9% of all births in the Netherlands (10) and approximately 12.5% in the US (11), 
illustrating the large number of neonates that enter extrauterine life during active 
nephrogenesis.
Congenital anomalies of the kidney and urinary tract (CAKUT)
Maldevelopment of the kidney and/or the urinary tract can present in many forms (for 
a review see (12). Easily recognizable malformations can be detected during (routine) 
prenatal or postnatal ultrasound screening, and includes renal agenesis or aplasia 
(unilateral or bilateral) and multicystic dysplastic kidney (MCDK). Other frequently 
20
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found abnormalities in the urinary tract may present as a dilated renal pelvis and/or 
ureter, which may be based on urine flow obstruction [i.e. pelvic-ureter junction 
obstruction (PUJO) or posterior urethral valves (PUV)].
 In contrast, renal dysplasia and hypoplasia are entities that may be more difficult 
to identify in vivo, whereas they do involve long-term risks. By definition, hypoplastic 
kidneys contain a reduced number of nephrons that are otherwise normally developed 
(12). Unfortunately, the number of nephrons cannot be determined in vivo yet. As a 
surrogate marker, renal size is used, which has shown some correlation with nephron 
number (3). However, renal size cannot be used to predict an individuals’ nephron 
endowment and is therefore unsuitable for risk stratification.  The normal range of 
nephron number varies almost tenfold, but a two-fold difference has been described 
to be highly relevant: Keller et al. have shown that a 50% reduction in nephron 
numbers (~700,000 vs. 1,400,000 in hypertensive and normotensive individuals, 
respectively) is associated with hypertension, even though kidney weight was similar 
(13). This shows that even in “normal-sized” kidneys, nephron numbers may vary 
widely as do the risks at long-term sequelae such as hypertension. 
 Finally, renal development may be altered without any obvious structural 
aberrations, i.e. by altered expression of (tubular) transporters. An important example 
in the light of drug effects is renal tubular dysgenesis (14). This is characterized by 
kidneys of normal size and appearance on ultrasound, but without any urine 
production or clearance. Renal biopsy shows the absence of proximal tubules, which 
can be explained by abnormal renal development due to underlying mutations in the 
renin-angiotensin system (RAS) or by drugs blocking the RAS.
 Despite the fact that such congenital anomalies may be difficult to diagnose, they 
are important to acknowledge as they form the main cause of end stage renal disease 
in children (15).
Drug treatment during renal development
Two main, distinct categories of drugs can be expected to influence renal development. 
First, drugs with known nephrotoxic effects in mature kidneys (1) may also have toxic 
effects on development. Second, drugs that are not nephrotoxic in fully developed 
kidneys may disturb the fine balance of growth factors that are essential for renal 
development. Unfortunately, information on either toxic effects is lacking for many 
drugs, which may lead to the use of drugs that are potentially unsafe and avoidance of 
drugs that may be considered safe. Here, we will present a brief overview on 
maldevelopment of the kidney and focus on drugs that have been shown or 
hypothesized on basis of clinical, fundamental or experimental research to be of 
influence on kidney development (Table 1).
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Nephrotoxic drugs
Three categories will be discussed, i.e. aminoglycosides, calcineurin inhibitors, and 
prostaglandin synthetase inhibitors. 
 In the Netherlands, 62% of neonates born before 32 weeks are treated with 
amino glycosides, as are 26% of neonates born before 37 weeks of gestation (10). 
However, gentamicin and other aminoglycosides are well-known nephrotoxic drugs 
that can lead to tubular alterations. Similar alterations are found in offspring of 
pregnant rats treated with an aminoglycoside (16). Such offspring has also been 
shown to have a lower nephron number and develop subsequent glomerulosclerosis 
with aging (17-19). In line with these findings, it has been shown that organ culture of 
early metanephroi in media supplemented with gentamicin also leads to impaired 
nephron formation (20).
 Most newborn rats and mice are at an early stage of kidney development with 
only around 20% of mature nephrons present at birth and ongoing nephrogenesis 
until 7-10 days-of-age. Neonatal rats and mice are therefore comparable to premature 
Table 1   Drugs shown to influence renal development
Drug Impact of maternal treatment 
during pregnancy on offspring 
kidney development
Impact of treatment during 
postnatal kidney development
Aminoglycosides tubular alterations (16)
low nephron number (17-19)
tubular damage (21)
low nephron number (19)
Cyclosporin A low nephron number (22)
Prostaglandin 
synthetase inhibitors
tubular alterations  (21)
similar nephron number (28)
glomerular and tubular injury (21)
similar nephron number  (21,26,27)
ACE inhibition/ARB renal insufficiency (31) atrophy of the renal papilla,  
tubular alterations (32)
low nephron number (33)
Dexamethasone altered tubular transporters 
(36,37)
low nephron number (5)
similar nephron number (38)
low nephron number (5,35)
Furosemide renal concentrating defect (40)
Anti-epileptic drugs more congenital malformations, 
specifically MCDK (44)
Mycophenolate 
mofetil
renal agenesis/ectopia (45,46)
Adriamycin bladder agenesis, 
hydronephrosis (48)
Cyclophosphamide hydro(uretero)nephrosis (49)
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born humans regarding the stage of kidney development (Figure 1), and provide a 
suitable model to study the effects of drugs on (postnatal) nephrogenesis. Treating 
neonatal rats with aminoglycosides during this postnatal nephrogenesis has also 
been shown to lead to a reduced nephron endowment (19) and tubular damage (21). 
However, these drugs are still commonly used in premature neonates for the treatment 
of (suspected) infections and a large proportion of premature infants receive amino-
glycosides during active nephrogenesis. Indeed, most Neonatal Intensive Care Units in 
the Netherlands have a first line treatment for (suspected) sepsis that includes 
administration of an aminoglycoside (either gentamicin or amikacin), whereas clinical 
relevant alternatives are available that may have less impact on renal development, 
such as cephalosporines and carbapenems.
 Secondly, a potentially nephrotoxic compound is the calcineurin inhibitor 
cyclosporin A. This is a lipophilic immunosuppressive drug and passes the placenta 
into the fetus. After treatment of pregnant rabbits with cyclosporin A, the offspring 
were shown to have a reduced nephron number (22) with systemic hypertension and 
progressive chronic renal insufficiency in adulthood (23). In mice deficient in calcineurin 
in the developing urinary tract, a defective peristalsis of the pyelo-ureteral junction is 
described (24). PUJO could therefore be expected in children from mothers treated 
with calcineurin inhibitors during pregnancy (e.g. after renal transplantation), but 
clinical data have as yet not been produced that substantiate this hypothesis. 
 A final example of nephrotoxic agents are the prostaglandin synthetase inhibitors, 
such as indomethacin and ibuprofen, that are used to treat a persistent patent ductus 
arteriosus, a frequently diagnosed condition in premature infants (11). Based on data 
from the Netherlands Perinatal Registry, about 1 in every 6 neonates born before 32 
weeks of gestation is treated for a patent ductus arteriosus. These drugs inhibit the 
(renal) cyclo-oxygenase system and a well-known side effect of treatment in 
premature neonates is anuria or oliguria during the course of treatment, which occurs 
less often during treatment with ibuprofen (25). As a normal functioning cyclo-oxy-
genase system is essential for nephrogenesis, it can be expected that these drugs not 
only influence short term renal function, but also impair nephron formation (21,26,27). 
Indeed, harmful renal effects have been shown of acetylsalicyclic acid, another 
prostaglandin synthetase inhibitor (28). 
Drugs disturbing renal developmental factors
First, an adequate functioning RAS is essential for normal renal development (29,30). 
Drugs interfering with this system [like angiotensin converting enzyme inhibitors 
(ACEi) or angiotensin receptor blockers (ARB)] can therefore be expected to alter 
nephrogenesis, and indeed have been shown to do so (ACEi/ARB fetopathy) (31). 
Genetic knock-out mice of either angiotensin II type 1 receptor (AT 1 receptor) or angio-
tensinogen have both resulted in an atrophic renal papilla (29), underlining the role 
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of the RAS in renal development. Several clinical and frequently lethal sequelae have 
been described of RAS-blocking during development, including renal insufficiency, 
oligo hydramnion with hypoplastic lungs and respiratory insufficiency and limb 
contractures (14). Kidney analysis of neonatal ACEi or ARB treated rats confirms the 
atrophy of the renal papilla together with tubular alterations such as fibrosis, atrophy 
and urinary concentration impairment (32), but also shows a reduction in nephron 
numbers (33). 
 Secondly, steroids are often prescribed to pregnant women with premature 
contractions to accelerate fetal lung maturation (34). However, maternal treatment 
with dexamethasone during pregnancy has also been shown to program kidney 
development (5,35) and have an effect on renal tubular transporters (36,37). This has 
resulted in a widely used model in the study for the developmental origins of health 
and disease (5). However, a recent study in monkeys showed no effect of prenatal 
dexamethasone exposure on nephron numbers (38), which underlines the need for 
human data to define the impact of steroid treatment during nephrogenesis on the 
kidney.
Figure 1   Schematic representation of the timing of nephrogenesis in relation  
to normal birth in both humans and rats
prenatal 
35,000 birth 
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nephrons 
1,000,000 
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human 
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 Thirdly, furosemide is a frequently used diuretic in premature neonates, even 
though chronic treatment of neonates has shifted towards other diuretics as 
furosemide increases hypercalciuria and is associated with nephrocalcinosis (39). Rats 
born after maternal treatment with the diuretic furosemide during pregnancy showed 
a renal concentrating defect that persisted after cessation of nephrogenesis (40). This 
may indicate that a different expression pattern of renal sodium transporters is 
induced by furosemide during nephrogenesis. However, furosemide has also been 
shown to reduce nephron formation in organ culture (41). This may be mediated by 
alterations in Pax2 expression (42), a highly important factor in kidney development.
 Fourth, antiepileptic drugs during pregnancy are known teratogens (43) and have 
been described to increase the risk of congenital malformations in general, and of 
MCDK specifically (44). This may be due to increased BCL-2 levels, leading to defective 
apoptosis and thereby defective nephrogenesis (44).
 A final but important drug class are immunosuppressive agents other than 
calcineurin inhibitors. Such agents have also been shown to have an impact on renal 
development, especially mycophenolate mofetil (45,46). The pathways involved have 
not been clarified yet, but a recent study has identified two factors involved, i.e. plate-
let-derived growth factor-B, potently inducing proliferation, and early growth 
response gene-1, a transcription factor (47). Other immunomodulatory drugs that 
have also been shown to influence renal development include adriamycin (48) and 
cyclophosphamide (49).
Perspectives
A wide range of drugs is administered to pregnant women and preterm neonates, 
during which renal development is ongoing. Highly prevalent diseases worldwide, 
such as HIV and malaria, require long-term treatments and bear the risk of renal 
maldevelopment. HIV as well as malaria infections during pregnancy are associated 
with intrauterine growth restriction (IUGR), which in itself leads to a reduced nephron 
endowment (5). The impact of such drugs on nephrogenesis is not yet fully clear. 
Antiretroviral drugs have been associated with nephropathy in children (50), which 
illustrates the possible influence on renal development. Of course, these side-effects 
must be put in perspective with the obvious benefits that are obtained by the use of 
such medications. Information on possible nephrotoxic effects should not be obtained 
or used to rule out the usage of certain drugs, but may be used to come to treatment 
schemes for pregnant women and newborns that provide an optimal balance between 
beneficial drug effects and toxicity. 
 Many drugs have been tested during (fetal) development and been described or 
considered to be safe. However, the spectrum of CAKUT is very broad (12). Specifically 
hypoplasia is a difficult diagnosis, as nephron number estimation is hardly performed 
and renal size is only a crude marker. That implicates that no drug, as far as the authors 
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are aware, has been proven to be definitively safe to use during kidney development. 
As the long-term effects of a low nephron endowment are becoming more and more 
clear (51), it is highly important to study the impact of drugs on renal development. 
There are many modifying effects of environmental insults, such as prematurity and 
IUGR (5,51), therefore, combinations of several drugs and/or factors in order to study 
the interactions should be included in future research as well.
Conclusions
Many renal toxic effects of drugs have been described, whereas the impact on renal 
development has received less attention. However, as renal maldevelopment may 
lead to CAKUT, including a reduced nephron number, long-term sequelae are likely to 
occur. This highlights the need for research into the effects of drug treatment during 
active nephrogenesis, both during pregnancy as well as in preterm born infants.
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Abstract
Background
Renal size is often used as a marker for nephron numbers as estimation of glomerular 
numbers is not yet possible in vivo. However, the validity of an association between 
the two is questionable. As a proper marker for nephron number in an individual is 
needed in clinical practice, this study was designed to assess the association between 
renal size and nephron numbers.
Methods
An individual patient data meta-analysis was performed on data retrieved with a 
PubMed and Embase search. Only studies were included that described individual 
human data on kidney size and nephron numbers determined by stereology, the gold 
standard methodology to estimate nephron numbers. As renal size increases until the 
end of puberty, and nephron numbers decline after the age of 60 years, only data 
from individuals aged 18-60 years without renal disease were included. 
Results
Six papers were identified that provided data on renal weight and nephron numbers 
from 114 individuals. Backward linear regression identified kidney weight and race as 
the only 2 significant factors explaining nephron numbers (R square 0.085, p=0.007). 
Controlling for race, there was a significant correlation between nephron number and 
kidney weight (r=0.231, r square=0.053, p=0.01).
Conclusion
These data indicate that only ~5% of the variation in nephron numbers is explained by 
differences in renal weight. Renal weight is closely correlated with renal volume, but 
in vivo renal volume estimation using any radiological modality is a poor predictor of 
true renal size. Therefore, renal size in adulthood should not be used as a marker for 
nephron numbers in an individual.
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Introduction
Nephron numbers are important in determining renal function and blood pressure. A 
low nephron endowment leads to glomerular hyperfiltration (1) and is associated with 
hypertension (2), glomerular enlargement and glomerulosclerosis (3). As the number 
of nephrons is fixed during prenatal kidney development without the possibility of 
later nephron formation, several perinatal factors, such as intrauterine growth 
restriction and premature birth, have been shown to influence final nephron numbers 
(4) and lead to (pre)hypertension in young adults (5).
 The gold standard method to determine nephron number is by stereology (6). 
Unfortunately, stereological nephron number estimation is currently only possible ex 
vivo, limiting the study of the impact of perinatal insults on kidney development to 
animal research. To circumvent this problem, renal size is often used as a marker for 
nephron number. Indeed, 2 studies have shown a statistically significant association 
between renal weight and nephron number (7,8), explaining up to 45% of the variation 
in nephron numbers. In contrast, the landmark study of Keller et al. (2) showed a 
two-fold difference in nephron numbers between individuals with and without 
hypertension, but no difference in renal weight. 
 This illustrates that it is debatable whether renal size or weight can be used to 
predict nephron endowment in an individual, but it is used that way in an increasing 
number of papers as a variation in nephron numbers may have clinical consequences. 
 In order to assess the association between renal weight and nephron numbers in 
humans, we performed an individual patient data meta-analysis that shows that only 
5% of the variation in nephron number is explained by renal size after correction for 
one other significant factor (race).
Materials and methods
Search strategy
The PRISMA statement was used for this systematic review (9). A review protocol 
was absent before the start of this study.
A PubMed search was conducted for articles published from January 1966 onward 
that contained the keywords “nephron number” or “glomerular number” in combination 
with the keywords “stereology” or “stereological” (total hits 134, 4 June 2013, Figure 1). 
In addition, an EMBASE search was conducted with the same keywords (total hits 109, 
4 June 2013). Two authors screened the title and/or abstract of these records, and 
potentially eligible papers were read in full. Disagreements between reviewers were 
resolved by consensus.
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 After selection, only 5 articles remained. In addition, the “related articles” function 
in PubMed was used from articles that were considered for inclusion. Also, the 
publications from two research groups that have the most experience in stereological 
analysis of the kidney were looked at by searching PubMed with the names of the 
respective senior researchers (JF Bertram and JR Nyengaard). Finally, reference lists 
from included publications were searched manually. These strategies provided 1 
additional article providing individual data on nephron number and renal size and/or 
weight (Figure 1).
Selection of articles
All studies in English describing data in humans of both renal size and/or weight 
together with a stereological estimation of nephron number were considered. As both 
a young age (for the purpose of this study defined as the age of 18 years) as well as an 
older age (at which a decline in nephron number can be expected, i.e. 60 years (8) may 
influence the association between nephron number and kidney weight, the analysis 
was performed on individuals aged 18-60 years. To allow for a meta-analysis of 
individual patient data, such data needs to be presented per individual, rather than an 
average per group. Only studies using stereology were of interest, as stereology is a 
bias-free design-based method that provides a reliable estimation of nephron number 
without any assumption of size and shape (6). Title and/or abstract of all articles 
identified were screened, and relevant original studies were read in full. When several 
articles described (part of) the same cohort, individual data on nephron number, 
height and body weight were compared to guarantee that each individual was only 
included once in the analysis. In order to exclude the influence of renal disease on 
either nephron number or kidney weight, individuals were excluded that were known 
to have chronic renal failure and/or were treated with dialysis or received a renal 
transplant. In total, 6 articles were included in the meta-analysis. No risk of bias of 
individual studies or risk of publication bias was assessed.
Data abstraction
Per individual, the following data were collected: age, gender, race (Caucasian vs. 
African (American)), height, weight, body surface area (BSA), body mass index (BMI), 
kidney weight (measured with a scale at autopsy), and nephron number (estimated 
with stereology). As 4 papers (2,10-12) did not report BSA, but did report height and 
weight, BSA was calculated using Mosteller's formula (13): BSA = ((height*weight)/3600)½, 
using height in cm and weight in kg. For 2 papers (7,8), information on height and BSA 
was available, which was used to calculate weight using an adaptation of Mosteller’s 
formula: weight = ((BSA2)*3600)/height.
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Analysis
With these data an individual patient data meta-analysis was performed. 
 Bivariate correlation analyses between nephron numbers and the other variables 
(age, gender, race, height, weight, BSA, BMI, and kidney weight) were performed using 
Pearson’s correlation analysis. Backward linear regression (criterion F≥0.10) was used 
with all collected data to identify the factors that were significantly associated with 
nephron number. Using these factors, the association between nephron number and 
each of these factors was determined after correction for the other significant 
factor(s) and presented as R or R square. Results are presented as mean (standard 
deviation, SD) unless otherwise stated. Differences between groups were analyzed 
Figure 1   Flow diagram of in- and excluded papers for the individual patient data 
meta-analysis
Pubmed  
134 records identified and screened  
119 records excluded  
- 100 non-human subjects 
- 7 reviews 
- 1 not concerning kidney  
- 11 no nephron numbers  
23 papers assessed for eligibility   
18 papers excluded  
-8 no individual patient data   
-7 no individuals aged 18-60 years   
-2 similar cohorts   
-1 no healthy kidneys    
5 papers included  
1 additional paper identified  
- related articles via PubMed  
- two main stereology groups  
- reference lists of included papers  
6 papers included in  
individual patient data  
meta-analysis 
Embase  
109 records identified and screened  
90 records excluded  
- 77 non-human subjects 
- 7 reviews 
- 1 not concerning kidney 
- 5 no nephron numbers 11 duplicates  
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by one-way ANOVA. Comparison of two proportions of categorical data was done 
by the chi-square test. Statistical differences were considered significant if p<0.05 
(two-tailed). SPSS (version 16.0.2) was used as statistical analysis package. 
Results
From the 6 papers included (Figure 1), 197 individuals were identified. Seven patients 
were excluded on basis of chronic renal failure. Of the 190 individuals remaining, 10 
(5.3%) were aged 17 years or younger, and 66 (34.7%) were aged 60 years or over, 
leaving 114 (60.0%) 18 to 60-years-old patients (Table 1). 
 Bivariate correlation analyses between nephron numbers and the other factors 
(age, gender, race, height, weight, BSA, BMI, and kidney weight) are presented in Table 2. 
Linear regression including all factors explained only 15.0% of the variation in nephron 
numbers (R square 0.150, p=0.02). Backward regression identified kidney weight and 
race as the only 2 significant factors explaining nephron numbers (R square 0.085, 
p=0.007). Every gram increase in kidney weight was associated with an increase in 
Table 1   Characteristics of included studies
Nyengaard 1992 (8) Bendtsen 1992 (7) Keller 2003 (2) McNamara 2008 (10) McNamara 2009 (11) Zimanyi 2009 (12) Cumulative Cumulative 
18-60yr
Number of patients (n) 37 57a 20 28 24 24 190 114
Country of residence Denmark Denmark Germany Senegal Senegal USA
Male:female (n:n) 19:18 32:25 18:2 14:14 24:0 24:0 131:59 91:23
Age (yr) 58.1 (19.8) 63.2 (14.7) 46.2 (6.9) 34.9 (19.7) 41.0 (16.3) 45.3 (10.0) 51.2 (18.9) 42.9 (10.7)
Age < 18yr (n) 1 1 0 8 0 0 10
18-60yr (n) 17 17 20 16 21 23 114 114
≥ 60yr (n) 19 39 0 4 3 1 66
Race Caucasian (n) 37 57 20 12 126 66
African (American) (n) 28 24 12 64 48
Height (cm) 166.4 (8.5) 166.7 (8.1) 176.9 (8.2) 157.3 (23.1) 168.9 (5.0) 179.4 (6.5) 168.2 (12.9) 172.5 (8.5)
Weight (kg) 63.4 (15.2) 68.1 (12.7) 88.8 (16.4) 64.3 (17.6) 69.7 (11.3) 94.1 (20.7) 72.3 (18.7) 78.1 (18.0)
BSA (m2) 1.70 (0.23) 1.77 (0.19) 2.08 (0.20) 1.67 (0.33) 1.80 (0.16) 2.16 (0.25) 1.83 (0.28) 1.93 (0.25)
BMI (kg/m2) 22.7 (4.3) 24.4 (3.7) 28.4 (5.2) 25.9 (4.7) 24.4 (3.9) 29.2 (5.9) 25.3 (4.9) 26.1 (4.9)
Kidney weight (g) 133.0 (35.2) 143.7 (37.6) 180.0 (39.7) 118.8 (35.6) 147.6 (34.6) 199.2 (36.1) 149.3 (43.7) 166.0 (40.8)
Nephron number (n * 1,000) 638.6 (202.3) 612.5 (190.4) 1,074.4 (422.4) 925.5 (225.4) 1,053.4 (306.9) 895.3 (454.7) 803.7 (340.1) 921.5 (351.2)
Data are presented as mean (standard deviation) or as numbers. Individuals with renal failure were excluded  
from analysis. BSA, Body surface area. BMI, Body mass index. a, 7 of the 64 described patients were excluded  
on basis of reduced renal function that could influence the number of nephrons.
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nephron number of 2,029 (95% confidence interval 424 - 3,634). Controlling for race, 
there was a significant correlation between nephron number and kidney weight 
(r=0.231, p=0.01), indicating that 5.3% of the variation in nephron numbers is explained 
Table 1   Characteristics of included studies
Nyengaard 1992 (8) Bendtsen 1992 (7) Keller 2003 (2) McNamara 2008 (10) McNamara 2009 (11) Zimanyi 2009 (12) Cumulative Cumulative 
18-60yr
Number of patients (n) 37 57a 20 28 24 24 190 114
Country of residence Denmark Denmark Germany Senegal Senegal USA
Male:female (n:n) 19:18 32:25 18:2 14:14 24:0 24:0 131:59 91:23
Age (yr) 58.1 (19.8) 63.2 (14.7) 46.2 (6.9) 34.9 (19.7) 41.0 (16.3) 45.3 (10.0) 51.2 (18.9) 42.9 (10.7)
Age < 18yr (n) 1 1 0 8 0 0 10
18-60yr (n) 17 17 20 16 21 23 114 114
≥ 60yr (n) 19 39 0 4 3 1 66
Race Caucasian (n) 37 57 20 12 126 66
African (American) (n) 28 24 12 64 48
Height (cm) 166.4 (8.5) 166.7 (8.1) 176.9 (8.2) 157.3 (23.1) 168.9 (5.0) 179.4 (6.5) 168.2 (12.9) 172.5 (8.5)
Weight (kg) 63.4 (15.2) 68.1 (12.7) 88.8 (16.4) 64.3 (17.6) 69.7 (11.3) 94.1 (20.7) 72.3 (18.7) 78.1 (18.0)
BSA (m2) 1.70 (0.23) 1.77 (0.19) 2.08 (0.20) 1.67 (0.33) 1.80 (0.16) 2.16 (0.25) 1.83 (0.28) 1.93 (0.25)
BMI (kg/m2) 22.7 (4.3) 24.4 (3.7) 28.4 (5.2) 25.9 (4.7) 24.4 (3.9) 29.2 (5.9) 25.3 (4.9) 26.1 (4.9)
Kidney weight (g) 133.0 (35.2) 143.7 (37.6) 180.0 (39.7) 118.8 (35.6) 147.6 (34.6) 199.2 (36.1) 149.3 (43.7) 166.0 (40.8)
Nephron number (n * 1,000) 638.6 (202.3) 612.5 (190.4) 1,074.4 (422.4) 925.5 (225.4) 1,053.4 (306.9) 895.3 (454.7) 803.7 (340.1) 921.5 (351.2)
Data are presented as mean (standard deviation) or as numbers. Individuals with renal failure were excluded  
from analysis. BSA, Body surface area. BMI, Body mass index. a, 7 of the 64 described patients were excluded  
on basis of reduced renal function that could influence the number of nephrons.
Table 2   Correlations between nephron numbers and various parameters
r p
Age -0.076 0.2
Gender 0.216 0.01
Race 0.183 0.03
Height 0.120 0.1
Weight 0.025 0.4
BSA 0.059 0.3
BMI -0.026 0.4
Kidney weight 0.171 0.03
BSA, Body surface area. BMI, Body mass index.
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by variations in kidney weight. Figure 2 shows the linear regression between nephron 
number and kidney weight per race group. The mean number of nephrons showed a 
trend to be higher in African (American) group (Table 3), whereas kidney weight was 
higher in the Caucasian group.
Figure 2   Association between nephron number and kidney weight per race group
Linear regression between nephron number and kidney weight in Caucasians (open circels, y=1897x+535,012; 
r=0.200, p=0.1) and African (Americans) (filled circels, y=2185x+660,823; r=0.279, p=0.05) aged 18-60 years.
Table 3   Characteristics of included individuals per race group
Caucasian African (American) p
Number of patients (n) 66 48
Male:female (n:n) 51:15 40:8 0.4
Age (yr) 45.5 (9.6) 39.5 (11.2) 0.003
Height (cm) 173.7 (8.8) 171.0 (8.0) 0.1
Weight (kg) 81.6 (20.6) 73.3 (12.5) 0.01
BSA (m2) 1.97 (0.27) 1.86 (0.19) 0.02
BMI (kg/m2) 26.9 (5.7) 25.0 (3.4) 0.04
Kidney weight (g) 175.2 (38.2) 153.4 (41.4) 0.004
Nephron number (n * 1,000) 867.3 (362.7) 996.0 (323.8) 0.05
Data are presented as mean (standard deviation) or as numbers. Individuals with renal failure and age 
<18 years or >60 years were excluded from analysis.
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Discussion
Based on this individual patient data meta-analysis, there is a significant association 
between renal weight and nephron numbers. However, renal weight in adulthood 
should not be used as a marker for nephron endowment, as variations in weight only 
explain about 5% of nephron numbers.
 In clinical practice, renal size is estimated by ultrasound using the formula for an 
ellipsoid. Unfortunately, these renal size estimations are a poor predictor of true renal 
size and show an average underestimation of 19-25% and a poor repeatability (14-16). 
Estimations using CT scans seem to perform better (correlation coefficient 0.79, 
p<0.01) (17), but still explain only 62% of variation in renal size. Using optimal MRI 
settings improves this further (18), resulting in the greatest accuracy (at least in vitro) 
(15). As true renal size is a poor predictor of nephron endowment, and in vivo renal size 
estimation using any radiological modality is a poor predictor of true renal size, it is 
doubtful that renal size estimation is helpful in predicting nephron endowment. 
However, many papers still use renal size estimation as a marker for nephron numbers.
Even though renal size is not a proper marker for nephron numbers in adults, there 
have been several studies that show an influence of renal size on functional markers. 
For instance, transplant survival is better in large kidneys when compared with the 
smaller kidneys (19-21). Furthermore, premature birth (i.e. before termination of 
nephrogenesis) has been shown in animal models to negatively influence 
nephrogenesis (4). In a cohort of 20-year-old individuals born very prematurely, 
kidneys were significantly smaller in length and volume than kidneys from term born 
controls with a normal birth weight (22). Such studies highlight that differences may 
be found, just as an association between renal weight and nephron numbers was 
described in some populations (7, 8), but this may be due to chance as this was not a 
consistent phenomenon.
 As stated previously, estimation of nephron numbers is currently only possible ex 
vivo. However, it has recently been shown possible to estimate nephron numbers 
quite reliably by the use of a 9.4 Tesla MRI in embedded kidneys, which shows that 
techniques are progressing towards nephron number estimation in vivo (23).
 Publication bias is a frequently observed phenomenon that prohibits proper 
meta-analysis, for which it may be vital to retrieve non-published data or cohorts. The 
association between renal size and nephron numbers has not been a subject of 
research, but is rather a by-product of studies describing nephron number of size 
variations in populations. We feel that this makes it unlikely that publication bias has 
been of influence on the results and therefore did not contact authors of potentially 
relevant studies.
 This individual patient data meta-analysis has some limitations. First, only 6 cohorts 
were available that described adults in whom nephron numbers were estimated using 
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stereology. As stereology is the only gold standard and bias-free method to estimate 
nephron numbers (6), this criterion was essential to allow for pooling of the data. But 
even with stereology, there may be an inter-observer variability in estimating nephron 
numbers that has an impact on the current meta-analysis. Second, as stated previously, 
only adult data were included, which indicates that no conclusion on the merit of renal 
size in childhood can be provided. Third, most papers have used the right kidney 
predominantly (24). A study that did use kidneys from both sides (7) did not find any 
difference in nephron numbers between left and right (JR Nyengaard, personal 
communication), but differences between the sides in congenital anomalies are well 
noted (25). Any impact of such a potential difference between the sides cannot be 
excluded with the data available. Finally, nephrons are lost in the course of life, which 
was the reason to exclude individuals over 60 years of age from the current analysis. 
However, it may be that nephrons are lost at a higher rate before that age, which may 
have had an impact on the analysis. Keller et al. specifically describe that no large 
numbers of sclerotic glomeruli were found (2), which would argue against a potential 
influence of aging on the data, but other studies did not report such data on glomerulo-
sclerosis. Based on a re-analysis of the data in individuals between the ages of 18 and 
40 that showed similar outcomes (partial correlation between nephron number and 
kidney weight, controlled for race: r=0.273, p=0.08), we feel that early loss of nephrons 
does not have a significant effect on the results.
 In conclusion, this individual patient data meta-analysis shows that renal weight, 
and thereby renal size estimations, in adulthood should not be used as a marker for 
nephron numbers.
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Abstract
Background
Many premature born neonates receive antibiotic drugs to treat infections, which are 
applied during active nephrogenesis. We studied the impact of clinical concentrations 
of gentamicin and alternatives, ceftazidime and meropenem, on ureteric branching.
Methods
Mice metanephroi were dissected at embryonic day 13 and cultured in media with or 
without various concentrations of gentamicin, ceftazidime or meropenem. Zero and 
24 hours kidney size were assessed by surface area measurements, and the ureteric 
tree was visualized by whole mount staining and confocal microscopy. Branching was 
evaluated by counting and gene expression levels of Wt1, Sox9, Bmp7, Fgf8 and Gdnf 
were investigated. 
Results
A concentration of 2000 μM ceftazidime impaired ureteric development. Additionally 
a 4.5 fold and a 2.5 fold down regulation was noted in Fgf8 and Gdnf, respectively. No 
adverse effects were noted after gentamicin or meropenem treatment. No relationship 
was noted between surface area expansion and ureteric bud formation, but surface 
area at explantation related to bud count after 24 hours of culture.
Conclusion
Ceftazidime, but not gentamicin or meropenem reduced ureteric branching in mice 
and suggest a role for Fgf8 and Gdnf in its mechanism. Metanephros surface area 
measurements can be used to reduce intra- and inter litter variation. 
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Introduction
Kidney development, leading to the formation of nephrons, starts around the 5th week 
of gestation and terminates before term birth, around the 34th-36th week of gestation. 
Many factors have been described to disturb this developmental process, leading to 
long-term problems such as hypertension and chronic kidney disease (1).
 One such disturbing factor may be the use of (nephrotoxic) drugs during kidney 
development, such as in pregnant women or neonates born before termination of 
nephrogenesis. Gentamicin, as well as other aminoglycosides, is widely used as part of 
the first line treatment of (suspected) bacterial infection in neonates to combat 
gram-negative infections. Based on data from the Netherlands Perinatal Registry, 62% 
of neonates born before 32 weeks, who can be considered the most vulnerable group, 
are treated with aminoglycosides (2). However, due to the fact that gentamicin is 
classified as a nephrotoxic drug, controversy remains on its safety as aminoglycosides 
have been shown to disturb kidney development and lead to a reduced nephron 
number in some experimental animals (3-6) and organ culture studies (7). 
 The aim of our research was to study the impact of antibiotic treatments on 
nephrogenesis in a model of early nephrogenesis. Gentamicin was studied as well as 
clinically relevant, alternative drug treatments to compare the toxic potentials of 
these drugs in a clinical dose range. As alternative treatments we chose a third 
generation cephalosporin, ceftazidime, and the carbapenem meropenem. These two 
drugs both have properties to deal with gram negative bacteria and have different 
mechanisms of action compared to gentamicin. Although beta-lactams have their 
own potencies to be nephrotoxic, ceftazidime can be given at a fairly high dose before 
proximal tubule damage is noticeable (8). As for meropenem, this drug is regarded as 
one of the safer carbapenems (9) due to its stability to renal dehydropeptidase-I (10), 
which was confirmed in a large clinical trial (11). Although these alternatives to 
gentamicin appear quite safe, information on the potential toxic effects on renal 
branching morphogenesis is lacking. We hypothesized that gentamicin would hamper 
early kidney development, and ceftazidime and meropenem would prove to be safe.
Materials and Methods
Drugs
Gentamicin (G1272) and ceftazidime hydrate (C3809) were obtained from Sigma- 
Aldrich, Zwijndrecht, The Netherlands. Meropenem was obtained from Fresenius 
Kabi, Teramo, Italy.
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Organ culture
Experiments were approved by the Animal Ethics Committee at the Radboud 
University Nijmegen. Embryonic day 13 time pregnant HSD:ICR female mice (Harlan, 
Horst, The Netherlands) were euthanized after arrival by cervical dislocation and 
kidneys were dissected from the embryos by means of two small needles. Intact 
isolated metanephroi were held on ice in pre-cooled Leibovitz medium (Gibco, Paisley, 
UK) until transfer to the organ culture system. Metanephroi were cultured on 0.4 μm 
pore size Millicell cell culture inserts (Millipore, Carrigtwohill, Ireland) placed in a six 
well plate containing DMEM/F-12 (1:1) medium (Gibco), supplemented with 10 mg/L 
insulin, 5,5 mg/L transferrin and 5 μg/L sodium selenite (Sigma-Aldrich, St. Louis, 
Missouri). Depending on treatment, drugs were added to the medium and metanephroi 
were incubated at 37°C and 5% CO2 for 24 hours. For gentamicin, drug concentrations 
of 3, 30 and 300 μM were chosen. Ceftazidime and meropenem were both tested at 
20, 200 and 2000 μM. Concentration levels were calculated as follows: The clinical 
pediatric dosing was used and corrected for plasma binding and volume of distribution 
as detailed in Table 1 (12-18). In addition, concentrations at a factor of 10 above and 
below were studied to take calculation uncertainties into account and to investigate 
a potential dose response relationship. 
All metanephroi from one litter were randomly assigned to one of the treatment 
groups and a separate no-treatment group that consisted of metanephroi from the 
same litter was included for each drug. Per litter, one drug was investigated to rule out 
differences on basis of variability between litters. Multiple litters were studied per 
drug.
Metanephric growth
Growth of the explanted metanephroi was determined by measuring surface areas 
expansion in 24h. Photographs of the metanephroi were obtained with a Canon EOS 
1000D camera attached to a Zeiss Axiovert 25 microscope at a total magnification of 
12.5x. Background light was set on maximal intensity and a shutter speed of 40 ms 
Table 1   Dose selection parameters
Gentamicin Ceftazidime Meropenem
(Neonatal) dose (mg/kg) 4 50 20 
Molecular weight 463.6 546.58 383.46
Plasma binding (%) 0 27 2
Volume of distribution (L/kg) 0.31 0.36 0.3
Data in this table were derived from multiple sources (26-32)
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was used. The photographs were taken with a resolution of 10.1 megapixels and 
surface area size was analyzed with FIJI/ImageJA version 1.45i (19).
Ureteric tip imaging
Whole mount immunostaining of the metanephroi was performed to visualize the 
ureteric tree after 24 hours of culture. The metanephroi were fixed in ice-cold 
methanol for 10 minutes and washed with PBS for 15 minutes. Subsequently, the 
metanephroi were incubated in PBS containing 2% BSA for 12h to block non-specific 
binding. After washing with PBS containing 1% Triton X-100 (PBS-T), metanephroi 
were incubated with an antibody against calbindin-D28k (Sigma Aldrich), diluted 1:100 
in PBS-T, for 24h. Again after washing with PBS-T, incubation with an Alexa 488 IgG 
antibody (Invitrogen, Eugene, Oregon) was performed at a dilution of 1:300 in PBS 
containing 2% BSA for 24h. All incubation and washing steps were performed at 4°C. 
After a final washing step in PBS-T of 15 minutes, the metanephroi were mounted on a 
slide in mounting medium (Dako, Carpinteria, California) and sealed using paraffin.
 For each metanephros, ureteric branching was visualized by confocal laser scanning 
microscopy using a Leica TCS SP2 microscope. Optical sectioning was performed at a 4 
μm interval at a magnification of 10x. Per metanephros, between 18 and 30 images 
were acquired with a resolution of 1024x1024 pixels. Subsequently, the amount of 
ureteric tips was counted with the multipoint tool in FIJI. A tip was defined as an end 
point of the whole branching structure that did not show any signs of branching.
Gene expression analysis
RNA was isolated from the metanephroi by combining the Trizol extraction method 
with the NucleoSpin RNA II isolation kit (Machery-Nagel, Düren, Germany). The 
methanephroi were suspended in Trizol (Invitrogen, Carlsbad, California) and 
incubated for approximately 30 minutes with occasional vortexing. After addition of 
chloroform (Merck), the samples were incubated on ice for 5 minutes and centrifuged 
at 14,000g, 4°C for 15 minutes. The aqueous phase was added 1:1 to 70% ethanol to 
adjust binding conditions and loaded on the Nucleospin column. Further purification 
was performed according to the manufacturers protocol. RNA concentration and 
quality was assessed with the Nanodrop 2000c spectrophotometer (Thermo Fisher 
Scientific, Waltham, Massachusetts.
 Complementary DNA was generated on a Biozym MJ Research PTC-200 Peltier 
thermal cycler using random primers (Promega, Madison, Wisconsin), oligo dT 
(Promega) and M-MLV reverse transcriptase (Invitrogen). mRNA levels of Wt1, Sox9, 
Bmp7, Fgf8, Gdnf, Casp3 and Casp9 were measured by quantitative PCR (qPCR) with 
Actb and Hmbs as internal standards. 
 qPCR was performed on a Biorad CFX96 using the gene expression mix and 
hydrolysis probes (Table 2) as ordered from Applied Biosystems (Applied Biosystems, 
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Pleasanton, California). Delta-delta CT values were investigated and an up or down 
regulation of factor 2 was considered biologically relevant. 
Statistics
Metanephric surface expansion at 24h and metanephric surface area at explantation 
were both investigated for correlation with ureteric bud tip development and tested 
with a Pearsons correlation coefficient.
 Comparison of ureteric bud tip development for each treatment was investigated 
by one-way ANOVA followed with Dunnett as post hoc. For both analysis, statistical 
significance was investigated at the α=0.05 level.
Results
Metanephric growth
First, we studied the usefulness of surface area growth as a good marker for renal 
development. Based on previous studies (7,20,21), a relationship between metanephric 
size expansion and ureteric tip count, a more direct measurement of renal development, 
was expected. However, as can be noted in Figure 1a, surface area expansion did not 
correlate with ureteric tip formation (R square= 0.005, p 0.77) and was therefore not 
used as a marker in our studies. 
 In addition, we noted a variation in metanephric size within a litter (up to 11%) and 
between our litters (±20%), based on differences in surface area measured directly 
after explantation. The impact of this variation on the ureteric bud tip count after 24 
hours was studied. As can be seen in Figure 1b, a significant correlation was noted 
Table 2   Applied Biosystems primer probe sets used in this study
Gene symbol Primer-probe set
Actb endogenous control
Hmbs Mm01143545_m1
Fgf8 Mm00438921_m1
Gdnf Mm00599849_m1
Sox9 Mm00448840_m1
Wt1 Mm00460570_m1
Bmp7 Mm00432102_m1
Casp3 Mm01195085_m1
Casp9 Mm00516563_m1
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between metanephric size and ureteric bud development (R square= 0.5, P<0.01). 
Based on this finding, all ureteric tip counts were corrected for metanephric surface 
area at explantation.
Ureteric tip imaging
Ureteric tip development was studied in the three different antibiotic classes. A range 
of three doses was tested to evaluate the broad drug response and investigate a 
possible dose response relationship (Figure 2).
 As can be noted in Figure 2b, only the 2000 μM ceftazidime concentration 
resulted in a statistically significant lower ureteric tip count after 24 hours of exposure 
(28,37 vs. 48,16, P<0.01). This effect was also clearly detectable visually (Figure 3). No 
effects on development compared to control were noted at the lower and the middle 
dose. In our experiments with gentamicin (Figure 2a) a trend was noticeable towards 
a lower ureteric tip count. Meropenem treatment (Figure 2c) did not show an effect on 
ureteric tip development compared to control at any of the concentrations studied. 
Gene expression analysis
We studied a selection of targets in known nephrogenesis and apoptosis pathways by 
mRNA expression analysis (Figure 4). Robust CT levels indicated that the targets were 
present in our metanephric organ cultures.
 Treatment with ceftazidime in a concentration of 2000 μM resulted in a 2.5 fold 
down regulation of Gdnf mRNA, a well known factor in the ureteric branching pathway 
Figure 1   Correlation (with 95% confidence interval) between surface area 
measurements and ureteric bud formation after 24 hours of organ culture 
(A) and at explantation (B)
Pearsons correlation coefficients were R2=0.005228 and R2=0.5082 for figure A and B respectively.
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(22). Additionally a 4.5 fold down regulation of the Fgf8 mRNA was noted (Figure 4c). 
No changes in expression patterns were noted after treatment with 200 μM  of 
ceftazidime. Gentamicin or meropenem treatment did not have an effect on the 
mRNA levels of our chosen targets. Furthermore, mRNA levels of Caspase 3 and 
Caspase 9 remained similar between controls and high dose treatments of gentamicin 
and ceftazidime. 
Figure 2   Quantitative analysis of ureteric buds in metanephroi cultured for 24hours 
in media with three antibiotic drugs, i.e. gentamicin (A), ceftazidime (B) and 
meropenem (C)
Individual data points as well as means per treatment group are presented. A low, clinical and high 
concentration were tested. Sample sizes of treatment groups were between 15 and 27; 10 and 15; and 10 to 13 
for genatmicin, ceftazidime and meropenem respectively. * p<0.01.
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Discussion
We have shown that an upper clinical range concentration of ceftazidime reduces 
ureteric branching morphogenesis and suggest a role for Fgf8 and Gdnf pathways in 
its toxicity. No adverse effects of gentamicin and meropenem within their postulated 
clinical dose range, were noted on ureteric branching or basic nephrogenesis pathways.
Previous reports have used surface area expansion as a measurement for renal 
development (7,20,21). Our study shows no correlation between the surface expansion 
and a more direct kidney developmental marker such as ureteric bud count. This lack 
of correlation may be explained by flattening of the metanephros in organ culture and 
its partial loss of three dimensional structure as has been reported previously (23). 
However, the impact on actual measurements had not been studied. We show that 
surface area measurements in the first 24 hours after explantation are not a proper 
marker for renal development. 
 Although flattening of the organ rudiment during organ culture renders surface 
analysis unhelpful for quantification of kidney development, surface area at 
explantation can partially predict the amount of tips that will develop in metanephroi. 
We found a significant correlation between the surface area of explant size directly 
after dissection and the amount of ureter tips counted after 24 hours. One could 
expect such a correlation because kidney development is more pronounced in utero 
than in organ culture (24). Therefore, a more evolved (and therefore branched and 
larger) metanephros at time of dissection can be expected to have more end tips after 
24 hours of growth. This data allows for correction of variation in gestational age. By 
Figure 3   Representative immunohistochemic staining of ureteric bud development 
in metanephroi cultured for 24 hours in media with 2000 μM ceftazidime 
(B) or vehicle control (A)
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using our correlation to correct all ureteric tip counts for the measured surface area 
after explantation, variability of developmental stage will be more limited, and more 
precise comparisons between dose groups, but also between litters can be obtained.
Our initial research question was whether clinical relevant levels of gentamicin could 
influence nephrogenesis and whether other classes of antibiotics might be safer.
 The potential of gentamicine to influence nephrogenesis has already been 
established in rat. Studies were mostly performed by either maternal dosing (3-5) or 
postnatal dosing (3,25). In these studies no effect of gentamicin was noted on renal 
Figure 4   Gene expression of important nephrogenesis pathway targets in 
metanephroi cultured for 24 hours in media with three antibiotic drugs,  
i.e. gentamicin (A), ceftazidime (B) and meropenem (C)
Means with SEM are presented for two (A) or three (B+C) experiments, with exception of the caspase targets, 
which were done in two experiments. Concentrations tested were 30 (white bars) and 300 μM (black bars) 
for gentamicin, 200 (white bars) and 2000 μM (black bars) for both ceftazidime and meropenem. 
6-9 metanephroi were pooled per experiment.
A B 
C 
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development after early postnatal dosing during active nephrogenesis. However after 
maternal dosing gentamicin accumulation was confirmed in the fetal kidney. 
Additionally exposure to gentamicine in utero resulted in a reduction of glomerular 
numbers up to 20% and alterations in the tubular structure. However the dose 
administered to the pregnant females in these studies was 75 mg/kg and was almost 
20 fold higher than the 4 mg/kg clinical dose we extrapolated the dose levels from in 
this study.
 Our results indicate that 24 hours exposure of gentamicin did not result into 
impaired ureteric branching or altered expression of key pathways. Even though we 
did notice a trend towards reduced ureteric branching this difference was not 
statistically significant. This contradicts earlier findings of Gilbert et al who found 
reduced ureteric branching in rat organ cultures at a gentamicin concentration of 100 
μM (7). The main difference between our approaches can be found in animal species 
(rat vs. mice in the current study) and in developmental stage. We believe the species 
difference is probably of secondary importance to the developmental stage as effects 
of in utero gentamicin exposure on renal development were reported in rats, mice 
and guinea pigs alike (3-7, 26). Although some differences in susceptibility may be 
present. Comparing Theiler and Witschi developmental stages (27), our E13 mice are 
approximately 12-24 hours more mature compared with the E14 rat embryos. It is well 
known that timing of insults during organ development is of great importance for the 
outcome and that dosing at a day later may completely abolish any effect (28). Taken 
these factors into account, gentamicin has the potential to disturb nephrogenesis, but 
the clinical dose range seemed to be safe when administered in the time frame and 
species that we studied.
 From the data of our selected potential alternatives, we conclude that ceftazidime 
does not appear to be a good substitute for gentamicin. In the high dose group an 
impaired kidney development and down regulation in corresponding pathways was 
identified. 
 We hypothesize that ceftazidime affects the renal progenitor cell population 
causing down regulation of Fgf8 and subsequent down regulation of Gdnf resulting in 
ureteric bud impairment. Fgf8 is important in cell survival of renal progenitor cells, 
which are an important source of Gdnf production (29,30). In contrast no expression 
changes were noted in Bmp7, which is also localized to the progenitor cell population 
(31), suggesting no general progenitor cell loss with possibly cell loss in a specific sub 
population. This finding is supported with the normal expression levels of Caspase 
3 and Caspase 9, markers of apoptotic insults and also important in the normal 
development of the renal tubular network (32). Alternatively, ceftazidime may 
directly affect both the mesenchyme and the ureteric bud. Although this high dose 
is 10 fold higher than our theoretical calculated clinical dose, the actual intracellular 
concentration in human cells is unknown. Based on our results, the safety of 
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ceftazidime for treatment of pregnant women should be reconsidered, as it may be 
harmful for early renal development of the fetus. In addition, ceftriaxone was earlier 
reported to have a negative effect on nephrogenesis in rats (33), which underlines 
the general potential harmful effects of maternal cephalosporine use on fetal 
nephrogenesis. 
 In contrast, meropenem did not show any negative effect on ureteric bud 
branching or mRNA levels of important development pathways, and may therefore be 
a potential useful substitution for gentamicin with regards to nephrogenesis.
 Our studies have some limitations. First, due to the stage of development and the 
method of antibody staining, we are currently unable to evaluate ureteric bud staining 
beyond 24 hours of exposure. Therefore it might be that prolonged exposure to 
gentamicin or meropenem will eventually result in renal damage. Using genetically 
modified mice with intrinsic fluorescent protein expression in the ureteric bud may 
solve this problem and allow for such longer-term studies (24). Secondly, we have no 
data on drug uptake within the cells. Gentamicin has been shown to be detectable 
within embryonic kidney cells after 8 hours of exposure (7). Our ex vivo model is 
slightly more mature and of a different species which could have influence uptake. 
However we noted a dose related trend in our experiments and are therefore confident 
that we had uptake of gentamicin in our model. For ceftazidime and meropenem data 
on uptake in organ culture are not yet available, which may play a role in the absence 
of effects in the meropenem treated metanephroi. However, the reduced formation 
of ureteric bud tips in the high dose ceftazidime group suggests uptake of ceftazidime 
by the metanephros within hours. Furthermore, we investigated a selection of targets 
in the nephrogenesis pathways and studied gene expression rather than protein 
expression. An immunohistochemical approach was attempted, but has not provided 
additional insight so far. Besides the technical difficulties of studying protein expression 
levels in small tissues as metanephroi, we feel that the significant morphological 
change in these cultured metanephroi show the relevance of the altered gene 
expression levels. In order to study apoptosis we decided to study mRNA levels of 
2 different caspases. Alternatively TUNEL could be used to the same extent and should 
be performed in future studies. Finally, at present we do not have data on different 
time points during development at which the kidney may be more vulnerable to 
specific drugs. This would be a very important future step in relating study findings 
to the human embryonic kidney development.
 Our objective was to determine whether these antibiotic compounds could 
interfere with a basal developmental process as ureteric bud differentiation when 
administered in a clinical dose range. Based on our data we can conclude that short- 
term gentamicin or meropenem treatment at this stage of embryonic kidney development 
does not have an adverse impact on nephrogenesis. However, ceftazidime was shown 
to inhibit ureteric branching and the expression of Fgf8 and Gdnf, two important 
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players in kidney development. Furthermore, metanephric surface area growth should 
not be used as a renal developmental predictor, but surface area at explantation can 
be used to correct for intra- and inter litter variation in developmental stages. 
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Abstract
Background
Up to two-thirds of premature born neonates are treated for bacterial infections with 
aminoglycosides such as gentamicin. Although acute toxicities are well described, 
there is uncertainty on developmental changes after treatment of premature born 
neonates. We studied the effect of gentamicin and ceftazidime on kidney development 
in the rat. Additionally we evaluated the modulating effect of extrauterine growth 
restriction.
Methods
Wistar rats were cross-fostered in normal food (NF) or food restricted (FR) litters at 
postnatal day (PND) 2 to simulate growth restriction and treated daily with placebo, 
4 mg/kg of gentamicin or 50 mg/kg ceftazidime until PND 8. Gentamicin pharmaco-
kinetics were studied in a separate group of animals. Kidneys were evaluated by qPCR 
on a set of developmental genes on PND 8, and by stereology on glomerular number 
and glomerular generation count at PND 35. 
Results
Gentamicin plasma concentration and exposure were found to be in a human clinical 
range (mean Cmax of 4.88 mg/L and Mean AUC0-4h of 10.71 mg.h/L for sexes combined) 
and did not affect any measured parameters. Ceftazidime reduced Renin expression 
by 1.7 fold (p<0.01). Extrauterine growth restriction resulted in a 22% body weight 
reduction by day 35 (p<0.001), 1.4-1.5 fold down regulation of Renin, Oat1 and Agtr1a 
(P<0.05) expression and a 12% reduction in glomerular numbers (mean 30841 vs. 35187, 
p<0.001). Glomerular generation count was unaffected.
Conclusion
Our experiments showed that gentamicin at clinical levels did not disturb kidney 
development, ceftazidime can affect Renin expression, and extrauterine growth 
restriction impairs kidney development, but did not modulate potential drug toxicity.
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Introduction
Antibiotics are routinely used to treat (suspected) bacterial infections in neonates on 
neonatal intensive care units. Gentamicin is a well-known aminoglycoside which is 
used as part of first line antibiotic treatment, but has a reputation for not being 
without harm. In neonates blood levels have to be carefully monitored because too 
high through concentrations may lead to oto- or nephrotoxicity (1, 2). 
 Although these acute toxicities are well known, there is much uncertainty on 
possible subtle developmental influences, which may play a role in long-term function. 
Gentamicin can enter cells by binding to the megalin receptor and is subsequently 
taken up via endosomes. In the cell it can either generate reactive oxygen species 
causing mitochondrial toxicity or induce the Bax BCl-2 apoptosis pathway (3). 
Disturbances of proliferation and apoptosis patterns can have major implications for 
renal development. 
 Indeed some studies have shown aminoglycosides to disturb kidney development 
in vivo or ex vivo (4-7), however other studies could not find an effect (8, 9). In the studies 
that did find a toxic effect, dose levels were high and one can argue that the level of 
acute toxicity had already been reached. In the other studies the kidneys were not 
affected by gentamicin treatment and dose levels were more similar to the clinical practice.
 An alternative for gentamicin treatment in daily clinical practice may be found in 
ceftazidime, a drug from the cephalosporin drug class. Ceftazidime is regarded as a 
less potent drug regarding acute nephrotoxicity (10), but one of our earlier studies 
identified it as a possible kidney development disruptor (8). In that study ceftazidime 
affected Gdnf and Fgf8, two important genes involved in the ureteric bud growth 
process of kidney development. To follow-up on these findings and investigate the 
true potential for ceftazidime as an alternative drug, we included it in this study.
 Most studies focus on the primary effects of drug treatment. This is a simplification 
from the clinical situation where a more complex interaction can be expected 
between drug treatment and other factors such as the gestational day at birth, 
malnourishment, growth restriction, and genetic background. It has been hypothesized 
that a multiple hit of these factors can influence organ development (11).
 The aim of this study was to investigate the effect of gentamicin and ceftazidime 
at neonatal clinical dose levels on kidney development after early postnatal 
administration. Additionally we used an in vivo model of food restriction to add 
extrauterine growth restriction as a factor to the intervention to model for a multiple 
hit situation as frequently noted in neonatal clinical practice. We evaluated the 
number of glomeruli and other renal parameters as a measure for altered renal 
development. Secondary we measured the expression of a selection of important 
gene targets in kidney development. These could give an indication of a proposed 
mechanism behind any effects observed.
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Material and methods
Main animal experiment
Timed-pregnant Wistar WU rats were ordered from Harlan (Horst, The Netherlands) 
and were delivered at the central animal laboratory of the Radboud University 
Nijmegen approximately one week before the expected date of birth. Animals were 
housed individually and checked at least twice a day for litters. The day that a litter 
was found complete was designated as PND 1. On PND 2 pups were cross-fostered to 
generate NF and FR litters of 12 and 20 pups, respectively. An additional NF and FR 
litter was formed to replace potential losses in the study population and maintain 
appropriate litter size. Starting on PND 2 animals were dosed with 0.9% NaCl (sham), 
4 mg/kg gentamicin (Sigma-Aldrich, the Netherlands) or 50 mg/kg ceftazidime 
(Sigma-Aldrich, the Netherlands) intraperitonealy (ip) for 7 days adjusted for daily 
body weight. This resulted in 6 treatment groups (n=6 animals per group) in total 
(sham-NF and FR, gentamicin-NF and FR, and ceftazidime-NF- and FR) per gender. 
Body weight was determined daily up to day 35. Experiments were approved by the 
Animal Ethics Committee (protocol 2013-109) at the Radboud University Nijmegen.
Gentamicin pharmacokinetic experiment. 
At PND 6, 15 pups/sex were injected once ip with gentamicin at 4 mg/kg. Blood was 
collected from 3 animals/sex/time point (5 time points in total) by exsanguination at 
20 min, 40 min, 1, 2 and 4 hours post dose. Blood samples were collected into Li-heparin 
containing tubes and were cooled and centrifuged for 10 minutes at 5000g within 
2 hours. Plasma was aspirated and stored at -80 °C until analysis for gentamicin 
concentration by the Cobas Integra 400 plus analyzer (Roche Diagnostics limited, 
Rotkreuz, Switzerland). 
 At PND 8, (at least) 3 animals/sex/group were sacrificed and kidneys were 
collected and weighed. The left kidney was frozen in liquid nitrogen for mRNA analysis 
and the right kidney was immersion-fixed in 10% formalin. At day 35 all remaining 
animals were sacrificed by exsanguination followed by perfusion-fixation with 10% 
formalin. Kidneys were collected, weighed and stored in 10% formalin and the right 
kidney was processed for stereology.
mRNA analysis
PND 8 left kidneys were pulverized in deep frozen state by a microdismembrator 
 (Sartorius-Stedim, the Netherlands), processed according to methods earlier described 
(8), and one μg of RNA was used in a subsequent reverse transcriptase reaction. qPCR 
was performed on a Bio-Rad CFX96 using gene expression mix and hydrolysis probes 
(table 1) as ordered from Applied Biosystems (Pleasanton, California) or Biolegio 
(Nijmegen, the Netherlands). The panel of transcripts included important targets 
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in the developmental pathway, transporters in different tubular sections and 
major players in the renin-angiotensin system, which were selected based on the 
‘GenitoUrinary Development Molecular Anatomy Project’ (GUDMAP) which analyzed 
expression patterns at different stages of development (12) or based on the importance 
of the targets in kidney function.
 Delta Ct (∆Ct) values were reported, which were calculated by correcting the 
threshold cycle (Ct) of the gene of interest to the Ct of the housekeeping genes.  Fold 
changes were calculated in case differences in ∆Ct values were flagged for statistical 
significance.
Glomerular generation counting
Glomerular generations were determined according to the method described in the 
paper of Hinchliffe et al. (13). The direct method was used and 5 radials were counted 
per slide. 
Stereology
Perfusion-fixed right kidneys were embedded in paraffin and sectioned exhaustively 
at 20 μm. Every 10th and 11th slide, starting at a random position (determined by a 
random number table), were taken and stained for haematoxylin-eosin. Subsequently, 
slides were scanned with the Olympus Olivia slidescanner and evaluation was 
performed with the Newcast module of the Visiopharm integrator system version 
3.6.5.0 (Horzholm, Denmark). 
 Briefly, a sample and its adjacent section were aligned manually and a counting 
frame was superimposed. Subsequently, a region of interest was drawn manually and 
a randomly oriented counting grid was placed on the region with x and y step lengths 
of 2500 μm. Glomeruli were then counted in all section pairs and the total number of 
glomeruli per kidney (N(glom)) was estimated by the physical fractionator/disector 
principle. On average 158 glomeruli were counted per kidney and the total number of 
glomeruli was estimated using the following formula: N(glom) = 1/SSF * 1/ASF * Ps/Pf 
* ∑Q- /2.
 In this formula SSF is the section sample fraction and ASF is the area sample 
fraction (calculated as counting frame area divided by (x-step length * y- step length). 
The factor Ps/Pf was introduced to correct for slides with artificial edges; Ps is the 
number of counting frame corners that hit kidney tissue, Pf is the number of counting 
frame corners that hit evaluated kidney tissue. Finally, ∑Q- is the number of counted 
glomeruli and the factor ½ was introduced for counting both ways between the slide 
pairs.
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Pharmacokinetic analysis
Non-compartmental pharmacokinetic parameters such as the time of maximum 
concentration (Tmax), the maximum concentration in plasma (Cmax) and the area under 
the plasma-concentration time curve up to the last measured concentration after 
4 hours (AUC0-4h) were analyzed by use of Phoenix 6.4 (Certara, Princeton, NJ). Based 
Table 1   Applied Biosystems primer probe sets used in this study
Gene 
symbol
Common name Primer-probe set
Reference
Actb Beta actin Rn00667869_m1
Hmbs a Hydroxymethylbilane synthase 5’-GGAGCCATGTCCGGTAACG-3’ (forward) 
5’-CCACTCGAATCACCCTCATCA-3’ (reverse) 
5’-CACAACCGCGGAAGAAAACGGCT-3’(probe-FAM)
Development
Wnt4 Wingless-type MMTV integration 
site family, member 4
Rn00584577_m1
Gdnf Glial cell line-derived  
neurotrophic facto
Rn00569510_m1
Bmp7 Bone morphogenetic protein 7 Rn01528889_m1
Fgf7 Fibroblast growth factor 7 Rn00573319_m1
Hgf Hepatocyte growth factor Rn00566673_m1
Lim Lim homeobox 1 Rn00595845_m1
Ret RET proto oncogene Rn01463098_m1
Gfra1 GDNF receptor alpha 1 Rn00564156_m1
Renin-angiotensin system
Renin Renin Rn00561847_m1
Agtr1a Angiotensin receptior type 1 Rn00578456_m1
Agtr2 a Angiotensin receptor2 5’-CCTTCCTGTATTGTTTCGTTGGA-3’ (forward) 
5’-TGGAGCCAAGTAATGGGAACTC-3’ (reverse) 
5’- CCGCTTCCAACAGAAGCTCCGTAGTG-3’(probe-FAM)
Tubular transporters
Oat1 Organic anion transporter 1 Rn00568143_m1
Casr Calcium sensing receptor Rn00566496_m1
Enac Epithelial sodium channel Rn00566891_m1
Nkcc2 Na+-K+-Cl- cotransporter Rn00568143_m1
Nhe3 Sodium hydrogen exchanger 3 Rn00561944_m1
Nhe8 Sodium hydrogen exchanger 8 Rn01423020_m1
Ncc Sodium-chloride symporter Rn00571074_m1
a Ordered at Biolegio
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on the curve shape, the AUC was calculated according to the linear up/log down 
trapezoidal method and no extrapolation of the area under the time-plasma curve 
from zero to infinity (AUC0-inf) was performed. 
Statistical analysis
Means with standard deviation (SD) are presented for all findings unless otherwise 
indicated. Parameters of interest were analyzed by univariate analysis using sex, nest 
type and treatment as fixed factors. Post hoc analysis was performed by Tukey. 
The time effect on body weight was analyzed between and within subjects with an 
analysis for repeated measures, using the Greenhouse-Geisser correction. The difference 
between left and right kidney weights was analyzed by ANCOVA. All analyses were 
performed by the use of SPSS version 20 (IBM, Armonk, NY) at the alpha 0.05 level.
Results
In vivo observations
Body weights of male and females were incidentally different on day 2 and day 30-35 
(p<0.001), but were pooled for analysis. Mean body weight was 7 (SD 0.6)g for ‘normal 
food’ (NF) and 6.4 (SD 0.6)g for food restricted (FR) animals at crossfostering 
at postnatal day (PND) 2, corresponding to a 9% weight difference (p<0.001). 
The difference between NF and FR increased over the course of the study (p<0.001) to 
22% (NF 14.11 (SD 1.1)g; FR 11.04 (SD 1.17)g) at PND 8 and 23% (116.7 (SD 12.4)g and 89.5 FR 
(SD 11.9)g) at PND 35 (figure 1). One male sham-FR animal died in the second week: 
we considered this to be related to the nature of the study (neonatal manipulations) 
but unrelated to the study interventions. No clinical signs were noted in the dosed 
rats. No effect of drug treatment was noted on body weight in the study period 
(p=0.081).
Pharmacokinetic analysis
A time concentration curve was constructed for both male and female rats dosed with 
a single dose of 4 mg/kg gentamicin on PND 6 (figure 2). The time of maximum 
concentration (Tmax ) was noted at the first time point of sampling (20 min after 
dosing). A mean concentration (Cmax) of 4.91 mg/L and a mean exposure (AUC0-4h) of 
11.3 mg.h/L were noted for males, and a mean Cmax and AUC0-4h of 4.85 mg/L and 10.2 
mg.h/L, respectively, were noted for females. The AUC0-inf could not be calculated due 
to non-linearity in the elimination slope.
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Gene expression
Gene expression analysis (figure 3) was performed on kidney tissue collected on PND 
8 and analyzed by non-parametric tests. Gender did not influence the gene expression 
of any target and therefore the analyses between litter size and drug treatment were 
performed with a pooled set of data. Comparing FR with NF animals a 1.4-1.5 fold 
down-regulation (P<0.05) of Renin, Oat1 and Agtr1a expression was noted. Additionally, 
drug treatment with ceftazidime resulted in a 1.7 fold reduction (P<0.01) in Renin 
compared with sham dosed animals. 
Renal morphology
Left, right and total absolute kidney weights (table 2) were approximately 20% lower 
(p<0.001) in FR rats compared with NF rats and a difference between sexes was 
detected (p<0.001). When corrected for individual body weight, kidney weights were 
comparable between sexes and were not influenced by drug treatment. Overall left 
relative kidney weight (7.1 (SD 0.9) mg/g) was lower than right relative kidney weight 
Figure 1   Body weights of study animals from postnatal day (PND) 2 up to PND 35
Lines of normal food (NF) and food restricted (FR) groups are indicated with dots and inversed triangles, 
respectively. Sham-dosed groups are indicated with a solid line, gentamicin groups with a striped line and 
ceftazidime groups with a dotted line. Body weight of FR animals was lower compared with the NF animals 
from day 2 onwards on all data points. Univariate analysis was performed with Tukey post-hoc. ***(P<0.001). 
n=15-16/group up to day 8; n=8-10/group for the remaining period.
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(7.5 (SD 0.8) mg/g) (p=0.005). This difference was not explained by sex, treatment, or 
food restriction, or any interactions between these parameters.
 Glomerular generation count (table 2) was performed and yielded on average 4.7 
(SD 0.34) generations in the sham-NF animals. The kidneys of other groups had a 
similar number of generations (range 4.6-4.8) and no effect of food restriction 
(p=0.76) or drug treatment (p=0.56) was noted. 
 FR animals showed a decreased number of glomeruli compared with NF animals 
(means: 30841 (SD 4075) vs. 35187 (SD 4026), respectively; p<0.001) on PND 35 (table 2) 
and females showed to have lower glomerular numbers in general (31564 (SD 4698) 
vs. 34102 (SD 4131); p<0.001). After stratification for sex, the difference for litter size 
remained statistically significant in both sexes (p=0.029 and p=0.004 for males and 
females, respectively). Drug treatment did not influence glomerular numbers (p=0.47). 
Figure 2   Time concentration curves in male (dot) and female (square) pups after a 
single interperitoneal administration of 4 mg/kg gentamicin on postnatal 
day 6. 
Means and SEM are shown. Cmax and AUC0-4h were 4.91 mg/L and 11.3 mg.h/L for males, and 4.85 mg/L and 
10.2 mg.h/L for females. n=3/sex/time point.
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Discussion
The aim of our study was to evaluate the impact of two antibiotics, i.e. gentamicin and 
ceftazidime, on kidney development. Based on our data we conclude that gentamicin 
treatment did not affect kidney development in the studied clinical dose range. Gene 
expression of targets known to play a role in gentamicin toxicity such as the Na-H 
exchange transporters, Casr or members of the renin-angiotensin system were 
unaffected (14-16). Parameters considered as an end-point of kidney development 
such as glomerular numbers were not different from sham-dosed animals. These 
findings are in line with other previously performed in vivo studies (9). The classical 
tubular gentamicin damage was not observed and was not expected due to the low 
dose level. 
 A pharmacokinetic profile was generated for a single dose of gentamicin to 
compare our experimental set-up with the normal therapeutic level of neonates and a 
similar dose range was confirmed. Of Interest, the plasma level at the 4 hour time 
Figure 3   Relative renal gene expression compared to Sham-NF of relevant 
transporters, growth factors and receptors in kidney development 
measured on day 8
Mean Delta-Delta Ct values with SEM are plotted for each target gene. Shown are sham (dot), gentamicin 
(square) and ceftazidime (triangle) treatment. Normal food (NF) and food restricted (FR) are distinguished by 
closed and open symbols, respectively. Statistical analysis was performed by multivariate analysis with Tukey 
post-hoc for treatment: * p<0.05 FR vs. NF or ## p<0.01 ceftazidime vs. sham. n=5-8/group.
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point showed an increase. This may be explained by individual variation in exposure 
because all time points were sampled from different animals. This higher plasma level 
prohibited calculation of the AUC0-inf and limited our exposure information to 4 hours.
 Nevertheless the profile we observed was similar to earlier reported pharmaco-
kinetic studies in neonatal animals (17,18). In general gentamicin administration in 
juvenile rats has a slightly lower peak level as well as slower elimination rate compared 
with adult rats (17,18). In addition, neonatal rats have been described to have a lower 
rate of gentamicin accumulation in the kidneys compared with adult rats (19), which 
may have implications for the susceptibility to gentamicin toxicity.
 The ceftazidime toxicity described by our group in an ex vivo model (8) was not 
confirmed in this in vivo study based on unaffected glomerular numbers. The nephro - 
genesis inhibiting effect may therefore be limited to the stage of very early kidney 
development, which holds more relevance to pregnant women than to preterm born 
neonates. The Gdnf and Fgf8 genes, important in early nephrogenesis, were associated 
with these finding, but Gdnf expression did not change in the current study. We did 
note a 1.7 fold reduction in Renin expression, which plays an important role in the 
formation of kidney vasculature (20). The reduction was relatively small, however, and 
no direct morphological consequences were noted. Therefore the biological relevance 
remains unclear.
 Our second aim was to evaluate whether extrauterine growth restriction could 
modulate the potential toxicity of drug treatment. Using the rat model of litter 
enlargement, we have previously shown that extrauterine growth restriction results 
in a reduction in nephron numbers (21). From the changes noted in body weight it is 
clear that a state of extrauterine growth restriction was induced, even though body 
weights were slightly different from the start of the study. Extrauterine growth 
restriction impaired kidney development evidenced by the 12% decrease in nephron 
numbers. Interestingly, the effect of extrauterine growth restriction was smaller in 
this study compared with the study of Schreuder et al, which reported a 25% difference 
(21). This variation in observed effect may be explained by the fact that the left kidney 
was sampled for stereology by Schreuder er al in contrast to the right kidney in the 
present study. It has been described before that the left kidney is more prone to 
congenital kidney and urinary tract abnormalities (22). Furthermore data from 
Simonetti et al. also showed that impaired intrauterine growth led to low birth weight 
and reduced left kidney weight in humans (23). We detected a difference in left vs. 
right kidney weight, but this was unrelated to our treatment or litter size, and is likely 
explained by normal anatomical left-right differences in rats.
 Nevertheless, the observed decrease in right kidney nephron numbers did not 
affect relative right kidney weight compared with the NF animals. This shows that 
kidney weight is a poor predictor for nephron numbers, an observation that was made 
previously by our group by analyzing human data (24). In the end, although extrauterine 
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growth restriction itself impairs kidney development, we did not find evidence that it 
modulated a potential toxicity response of gentamicin or ceftazidime treatment. 
 There were some limitations to our experimental set-up. We only counted 
glomeruli in one kidney, while our results suggest that it would have been better to 
analyze both kidneys. Furthermore, we did not include a functional follow-up of the 
kidney in this study to investigate the clinical outcome of the observed effect, which 
could have led to a better clinical translation. Finally a pharmacokinetic profile of 
ceftazidime would have been helpful to put the ceftazidime related findings into 
perspective. Nevertheless these study results are important for better understanding 
of the clinical outcome. Both studies of Kent et al. and this study did not find evidence 
that gentamicin (with or without growth restriction) shows nephron developmental 
toxicity (9,25). Therefore it seems that there is no direct concern for developmental 
nephrotoxicity after gentamicin treatment in premature born neonates. We proposed 
ceftazidime would be a possible alternative for gentamicin in the clinic and based on 
the study findings it can be used without affecting kidney development. Additionally 
our study showed that the nutritional status is much more potent to disrupt 
nephrogenesis compared with clinically dosed antibiotics. 
 In conclusion, our experiments showed that (i) a clinical relevant dose of 
gentamicin or ceftazidime did not directly disturb the process of nephrogenesis, (ii) 
extrauterine growth restriction reduces nephron endowment, but did not modulate 
potential drug toxicity.
 Based on these results there is no direct harm in using gentamicin or ceftazidime 
in neonatal practice concerning kidney development. Future experiments should 
focus on a functional follow-up and an additional challenge in later life to investigate 
any programming effects.
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Abstract
The kidney is one of the key organs in clearing foreign compounds. The effects of 
drugs on the developing kidney are relatively unknown. We studied the direct effect of 
furosemide, hydrochlorothiazide, ibuprofen and indomethacin on kidney development 
in an ex vivo embryonic kidney model. At embryonic day 13 metanephroi were dissected 
from mice and cultured in control media or media supplemented with various clinically 
relevant concentrations of drugs. The ureteric tree was visualized by whole mount 
staining and branching was evaluated by counting. Additionally gene expression 
levels of Wt1, Sox9, Bmp7, Fgf8 and Gdnf were investigated. 
 No distinct differences were noted on either ureteric tip development or gene 
expression analysis for each drug after 24 hours of exposure. Even though short term 
exposure to clinically relevant concentrations seems not to disturb renal development, 
future research is needed to study prolonged or repeated exposures. 
Keywords: NSAID, diuretics, kidney development, embryonic kidney model, nephrogenesis, 
toxicology 
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Introduction
The kidney is one of the key organs in clearing foreign compounds. Whether these are 
active toxins or (de)toxified metabolites, all drugs will pass through the kidney in one 
form or another when administered. Therefore a lot of research is being done on the 
mature kidney and how drugs are excreted, metabolized and of course which drugs 
are nephrotoxic (1).
 Less emphasis is put on the effects of drugs on the kidney as a developmental 
organ. This is an important field of research because the kidney already has to deal 
with drugs in its immature form (2). For instance, unborn children of pregnant women 
who take drugs or children who are born preterm and not yet have a completely 
developed kidney. In this study we focus on two classes of drugs, taken by both groups. 
 First, non steroidal anti inflammatory drugs (NSAIDs) like ibuprofen may be taken 
by pregnant women as an over-the-counter drug for pain, even though NSAIDs are 
contra-indicated during pregnancy, especially the last trimester (3). Secondly 
indomethacin may be prescribed as a tocolytic (4). Finally born children with a patent 
ductus arteriosis are treated with ibuprofen or indomethacin, depending on the 
geographical area of treatment. It is well known that these drugs may cause renal 
toxicity in preterm children, such as acute renal failure (5-7), but these drugs are also 
classified as potentially nephrotoxic drugs for adult use (8).
 Our second drug class of interest is the diuretics class. Pregnant women and preterm 
children may both be prescribed diuretics to control fluid homeostasis. A frequently 
used diuretic is furosemide. Although acute renal toxicity is not common, furosemide is 
associated with renal calcification in higher doses (cumulative dose >10 mg/kg) (9).
 The acute toxic risks of these drug classes may be limited by strict dose monitoring, 
but it is currently unknown whether low concentrations of these drugs may disrupt 
normal kidney development. This may result in a predisposition for renal disease in 
later life (2). 
 There are several leads that these drugs may influence kidney development. First 
of all, two studies in rats showed abnormalities in kidney tubuli after 5 days of 
treatment with indomethacin or ibuprofen, but these changes were not confirmed at 
necropsy on day 14 and long-term sequelae were not studied (10,11). Secondly, Mallie et 
al showed that prenatal furosemide exposure in rats tended to a lower number of 
differentiated glomeruli at birth and a functional deficiency in electrolyte handling at 
birth, which was still present, but somewhat less pronounced, at day 12 (12,13).
 Given these leads our hypothesis is that clinical and/or low doses of furosemide, 
indomethacin and ibuprofen can influence basic pathways of nephrogenesis and 
that hydrochlorothiazide might be an alternative for furosemide. Additionally we 
hypothesize that ibuprofen and indomethacin inhibit the cyclo oxygenase systems in 
our kidneys. We studied these hypotheses by determining the direct effect of these 
80
CHAPTER 6
drugs on ureteric tip development and several developmental gene expression 
markers in an ex vivo embryonic kidney model.
Materials and Methods
Drugs
Ibuprofen (I1892), indomethacin (I7378), furosemide (F4381) and hydrochlorothiazide 
(H2910) were all obtained from Sigma-Aldrich, The Netherlands. 
Organ culture
Experiments were approved by the Animal Ethics Committee at the Radboud 
University Nijmegen. Embryonic day 13 time pregnant HSD:ICR female mice (Harlan®, 
Horst, The Netherlands) were euthanized immediately after arrival by cervical 
dislocation and kidneys were dissected from the embryos by means of two small 
needles. Intact isolated metanephroi were held on ice in pre-cooled Leibovitz medium 
(Gibco®, Invitrogen™, Paisley, UK) until transfer to the organ culture system. Metanephroi 
were cultured on 0.4 μm pore size Millicell® cell culture inserts (Millipore™, Carrigtwohill, 
Ireland) placed in a six well plate containing DMEM/F-12 (1:1) medium (Gibco®, 
Invitrogen™, Paisley, UK), supplemented with 10 mg/L insulin, 5.5 mg/L transferrin and 
5 μg/L sodium selenite (Sigma-Aldrich®, St. Louis USA). Depending on treatment, 
drugs were added to the medium and metanephroi were incubated at 37°C and 5% 
CO2 for 24 hours or 3 days (medium was refreshed once after 48 hours). The following 
concentrations were used: 0.2–2–20 μM ibuprofen, 10-100-1000 nM indomethacin, 
70-700-7000 nM furosemide and 0.2-2-20 μM hydrochlorothiazide. Indomethacin and 
 hydrochlorothiazide required methanol as a co-solvent, which had a final concentration of 
0.1% in medium. A vehicle control group was included for each drug. Concentration 
levels were calculated as follows: The clinical human child dose was taken and 
corrected for plasma binding, and volume of distribution (14-19). A concentration at a 
factor 10 above and below was taken to deal with calculation uncertainties and to 
investigate a dose response relationship.
 All metanephroi from one litter were randomly assigned to one of the different 
treatment groups. Per litter, one drug was investigated to limit differences on basis of 
inter-litter variability. Multiple litters were studied per drug.
Ureteric tip imaging
Whole mount immunostaining of the metanephroi was performed to visualize the 
ureteric tree after 24 hours of culture. The metanephroi were fixed in ice-cold 
methanol for 10 minutes and washed with PBS for 15 minutes. Subsequently, the 
metanephroi were incubated in PBS containing 2% BSA for 12h to block non-specific 
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binding. After washing with PBS containing 1% Triton X-100 (PBS-T), metanephroi 
were incubated with an antibody against calbindin-D28k (Sigma Aldrich®, St. Louis, 
USA), diluted 1:100 in PBS-T, for 24h. Again after washing with PBS-T, incubation with 
an Alexa 488 IgG antibody (Invitrogen, Eugene, USA) was performed at a dilution of 
1:300 in PBS containing 2% BSA for 24h. All incubation and washing steps were 
performed at 4°C. After a final washing step in PBS-T of 15 minutes, the metanephroi 
were mounted on a slide in mounting medium (Dako, Carpinteria, USA) and sealed 
using paraffin.
 For each metanephros, ureteric branching was visualized by confocal laser 
scanning microscopy using a Leica TCS SP2 microscope. Optical sectioning was 
performed at a 4 μm interval at a magnification of 200x. Per metanephros, between 
15 and 30 images were acquired with a resolution of 1024x1024 pixels. Subsequently, 
the amount of ureteric tips was counted with the multipoint tool in FIJI. A tip was 
defined as an end point of the whole branching structure that did not show any signs 
of branching.
 Ureteric bud count was corrected for area surface of the metanephroi at the time 
of explantation as described by Bueters et al (submitted). Metanephric surface area 
was measured from photographs with FIJI/ImageJA version 1.45i (http://imagej.nih.
gov/ij/). Photographs of the metanephroi were obtained with a Canon EOS 1000D 
camera attached to a Zeiss Axiovert 25 microscope at a total magnification of 12.5x. 
Background light was set on maximal intensity and a shutter speed of 40 ms was 
used. The photographs were made at a resolution of 3888x2592 pixels.
Gene expression analysis
We selected five targets in pathways involved in nephrogenesis by using literature 
search and GUDMAP, i.e. Wt-1, Sox-9, Bmp-7, Fgf-8 and Gdnf (20-24).
 RNA was isolated from the metanephroi by combining the Trizol extraction 
method with the NucleoSpin® RNA II isolation kit (Machery-Nagel, Düren, Germany). 
The methanephroi were suspended in Trizol (Invitrogen, Carlsbad, USA) and incubated 
for approximately 15 minutes with occasional vortexing. After addition of chloroform 
(Merck), the samples were incubated on ice for 5 minutes and centrifuged at 14,000g, 
4°C for 15 minutes. The aqueous phase was added 1:1 to 70% ethanol to adjust binding 
conditions and loaded on the Nucleospin® column. Further purification was performed 
according to the manufacturers protocol. RNA concentration and quality was assessed 
with the Nanodrop 2000c spectrophotometer (Thermo Fisher Scientific, Wilmington, 
USA).
 Complementary DNA was generated on a Biozym MJ Research PTC-200 Peltier 
thermal cycler using random primers (Promega, Madison, USA), oligo dT (Promega, 
Madison, USA) and M-MLV reverse transcriptase (Invitrogen, Carlsbad, USA). mRNA 
levels were measured by quantitative PCR (qPCR) with Actb and Hmbs as internal 
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standards. Additionally, NSAID high dose treated samples were investigated for Ptgs1 
and Ptgs2 expression as a marker for the influence on the cyclooxygenase (COX) 
system and therefore drug delivery in the organ culture system.
 qPCR was performed on A biorad CFX96 using the gene expression mix and 
hydrolysis probes (Table 1) as ordered form Applied bioscience (Applied Biosystems, 
Pleasanton, USA). Delta-delta CT values were reported and investigated. 
Data analysis
Comparison of ureteric bud tip development and gene expression for each treatment 
class was investigated by one-way ANOVA followed with Tukey’s multiple comparisons 
as post hoc. For both assays, statistical significance was investigated at the α=0.05 
level.
Table 1   Applied Biosystems primer probe sets used in this study
Gene symbol Primer-probe set
Actb endogenous control
Hmbs Mm01143545_m1
Fgf8 Mm00438921_m1
Gdnf Mm00599849_m1
Sox9 Mm00448840_m1
Wt1 Mm00460570_m1
Bmp7
Ptgs1
Ptgs2
Mm00432102_m1
Mm00477214_m1
Mm00478374_m1
83
EFFECT OF NSAIDS AND DIURETICS ON NEPHROGENESIS
6
Results
Metanephroi were successfully stained and suitable for analysis (figure 1). 
 We tested three doses of each drug on their ureteric tip development as shown in 
figure 2. The number of ureteric buds/surface area t= 0 were comparable between our 
treated and untreated groups after the 24 hour incubation period, with a slight 
statistical significant decrease in the 100 nM indomethacine treatment group (figure 
2a). However no effect was observed at the 1000 nM concentration and a dose response 
relationship could not be established. 
We also studied a selection of targets in known nephrogenesis pathways by mRNA 
expression analysis. The measured CT levels of all our assays indicated that all targets 
were present in our metanephric organ cultures, as expected. Subsequently, we 
compared our treatment groups with the non-treatment groups as shown in figure 3. 
Treatment with the clinical and high concentrations of each diuretic treatment (figure 
3c & d) did not influence expression levels, which were similar to those of the control 
population.
 The NSAID treatments (figure 3a & b) resulted in more alterations, especially in 
Fgf8. However this response was only noted in the clinical tested dose. The higher 
dose tested did not result into a similar response. 
 Furthermore, we tested if expression of the Ptgs1 and Ptgs2 genes was affected in 
the NSAID treatment (data not shown). We did not see consistent results in this 
Figure 1   Representative immunohistochemic staining of ureteric bud development 
in metanephroi cultured for 24 hours (amplification 200x)
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experiment. Both ibuprofen and indomethacin did show Ptgs2 up-regulation in one 
out of three tested samples (respectively 2.3 and 2.2 times). 
 Finally a three-day exposure pilot was performed to investigate if lengthening the 
exposure time would make any difference on the noted response (figure 4a & b). 
A trend towards down regulation of Sox9 and Fgf8 (crossing the 2 fold threshold in the 
lowest dose) was noted in indomethacin treated samples. Ibuprofen did not show any 
response on our selected targets. Additionally we noted a 3.7x up regulation in Ptgs2 
after 3 days of ibuprofen treatment, but no other effects were noted on either Ptgs1 or 
Ptgs2 expression after 3 days treatment of indomethacin.
Figure 2   Quantitative analysis of ureteric buds in metanephroi cultured for  
24hours in media with indomethacin (A), ibuprofen (B), furosemide (C)  
or hydrochlorothiazide (D) 
Individual data points as well as means ± sd. per treatment group are presented. Low, clinical and high 
concentrations were tested. * p< 0.05.
 A  Indomethacin B  Ibuprofen
C  Furosemide D  Hydrochlorothiazide
*
85
EFFECT OF NSAIDS AND DIURETICS ON NEPHROGENESIS
6
Figure 3   Gene expression of important nephrogenesis pathway targets in 
metanephroi cultured for 24 hours in media with indomethacin (A), 
ibuprofen (B), furosemide (C) and hydrochlorothiazide (D) 
Means ± SEM are presented for three experiments with clinical or high dose concentrations. 6-9 metanephroi 
were pooled per experiment.
A  Indomethacin B  Ibuprofen
C  Furosemide D  Hydrochlorothiazide
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Discussion
Our main question was whether clinical and low doses of NSAIDs or diuretics would 
disrupt nephrogenesis and which pathways would play a role in such effects. Based on 
the current experiments, no significant effect of our four tested drugs on either 
ureteric branching morphogenesis or any of the targeted nephrogenesis pathways 
was found.
 These findings were unexpected as we hypothesized a response from the NSAID 
treatments because the COX systems are regarded important in kidney development 
(25-27). Indeed, a study by Kent et al hinted at increased tubular growth after 
administering low dose ibuprofen and indomethacin to rat pups (11). Although small 
differences were noted in Fgf8 expression between ibuprofen and indomethacin 
versus controls, we did not see any response of our investigated genes involved in 
tubular formation (Gdnf, Sox9). Additionally, we did not see any dose dependent 
response in Fgf8 expression, therefore the biological relevance of this small difference 
is questionable. Furthermore, we feel that all results under a 2-fold difference are 
more likely to occur due to sample and assay variation. 
 We could not support the rat study of Kent et al, which may be due to several 
factors. Most importantly, our model consists of a very rudimentary kidney organ and 
it could very well be that it behaves differently to the NSAID stimuli than the more 
mature kidney, which Kent used in his study (11). Furthermore, our study is limited in 
the number of genes tested, and therefore it could be that other genes are responsible. 
Finally there may be a species difference to NSAID treatment. 
Figure 4   Gene expression profile after 3-day culture pilot with ibuprofen or 
indomethacin (n=1) 
6-8 metanephroi were pooled per condition.
A  Indomethacin B  Ibuprofen
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 We investigated whether the metanephroi were fully exposed to the study drugs 
because we used a different exposure route compared to the in vivo situation. Our ex 
vivo culture model relies on diffusion to insert drugs into the target tissue because 
blood vessels are not yet developed. This may occasionally hinder drug delivery, 
depending on the particle type (28). However the noted up-regulation in the Ptgs2 
target in both the high concentration treated indomethacin and ibuprofen group 
after 24 hours show that uptake of these drugs by the tissue is likely.
 Besides the drug availability, we investigated if a longer (3-day) period of exposure 
influences the broad drug response. Even though we noted a trend towards down 
regulation in Sox9 and Fgf8 of our target genes after indomethacin treatment, the 
differences compared to controls were small. We did not observe any significant 
changes in ibuprofen treated samples. Therefore, the drug response in this pilot 
experiment was similar to the one after 24 hours of incubation. Currently we are 
unable to confirm these findings with ureteric branching experiments. After 
approximately 36 hours of culture the kidney tissue becomes too dense for our 
antibody to fully penetrate. Analyses at later time points are therefore unreliable and 
this is a limitation of our current model.   
 Both diuretic treatments did not show an influence on nephrogenesis. Mallie et al 
showed differences in glomeruli differentiation after exposure to furosemide, which 
made us expect alterations in the ureteric bud count (13). Comparing our studies, our 
kidney model is similar in development to one of the two used dosing periods. However 
we used a lower dose that is within normal clinical ranges and a shorter exposure 
time, which may well explain the difference in our findings.
 It is likely that the metanephroi are able to cope with the less optimal situation in 
our experiments, explaining the lack of toxicity. However, as we investigated only a 
few routes of possible nephrogenesis disruption, it is possible that toxicity is mediated 
via other pathways than the ones investigated in this study. Additional studies may be 
advisable where microarray techniques are used on multiple time points of 
development. 
 A potential limitation of our study could be found in the dosing that was based on 
exposure levels in neonates, whereas maternal dosing may be more relevant for this 
(early) stage of kidney development. Therefore, we also calculated the target exposure 
levels using adult pharmacokinetic data (14, 29, 30) and these are in the same order of 
magnitude as our tested doses (for instance indomethacin 30 nM). As these 
compounds all pass the placenta without restriction (30-33), we are confident that our 
dosing, and therefore results are applicable to in utero exposure as well.
 In summary we did not find significant differences in kidney development of 
mouse metanephroi after 24 hour of culture with a clinical or low dose of indomethacin, 
ibuprofen, furosemide or hydrochlorothiazide. However, it is too early to conclude that 
pregnant women and preterm children can safely be treated with these drugs with 
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regards to kidney development. Even though short term exposure to clinically relevant 
concentrations seems not to disturb renal development, future research is needed to 
study prolonged or repeated exposures.
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CHAPTER 7
Abstract
Background
Prematurely born children with patent ductus arteriosus are treated with ibuprofen or 
indomethacin, which may inhibit kidney development. We determined whether 
clinical doses affected kidney development and function, with or without extrauterine 
growth retardation.
Methods
Wistar rats were crossfostered in normal food (NF) or food restricted (FR) litters at 
postnatal day (PND) 2. On PND 3-4 three doses of 0.9% NaCl, 0.1 mg/kg indomethacin 
or 10 mg/kg ibuprofen were administered via intraperitoneal injection with 12h 
intervals. Kidneys were evaluated for apoptosis, proliferation, and gene expression at 
PND 8; stereological assessment of nephron number at PND 35; clinical pathology  and 
neutrophil gelatinase-associated lipocalin (NGAL) at 4 and 9 months. Blood pressure 
was measured at the ages of 4, 6 and 9 months.
Results
NF and FR bodyweight differed from PND 3 onwards, ranging from 16.5g at weaning 
(p<0.001) to 39g at necropsy (p=0.019).  Kidney proliferation/apoptosis ratio’s were 7:1 
and 3:1 (p=0.001). Different expression of Wnt4 (0.7x), Oat1 (1.3x) , Nphs1 (1.7x) and 
Aqp4 (1.3x) was noted, but the biological relevance was doubted. Nephron numbers 
were decreased by 12% (p=0.109) in the ibuprofen-NF group and 7.5% (p=0.237) in FR 
groups. This coincided with a tendency to increased NGAL at 9 months. No differences 
were noted in electrolytes, creatinine or urea clearence. No valid blood pressure results 
could be obtained. 
Conclusion
A clinical Ibuprofen dose showed potential to inhibit kidney development in neonatal 
rats. FR did not modulate these effects.
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Introduction
Nephrons are the functioning units of the kidney and form from the 5th gestational 
week onwards (1). The process of nephrogenesis in humans ends around the 34th to 
36th week of gestation. At that time a little under 1 million nephrons have been formed 
per kidney with a very large (i.e. 10-fold) interindividual range (2). Environmental 
influences during nephrogenesis, including growth restriction and medications, have 
a significant impact on final nephron numbers and may therefore explain a significant 
part of the range (3).
 Prematurely born children may suffer from patent ductus arteriosus and 
non-steroidal anti-inflammatory drugs (NSAIDs) are often used to treat this condition. 
Data from the Netherlands has shown that about 1 in 6 neonates born before 32 
weeks is treated with these drugs (Perinatal registry, Utrecht, the Netherlands). 
Ibuprofen and indomethacin are the most commonly used drugs for this indication, 
and both of these drugs have adverse effects on the kidney. These effects may range 
from a small reduction in glomerular filtration rate (GFR) to acute renal failure (4,5) 
which is more often noted in the less mature neonates (6,7). 
 As emphasis is put on direct adverse effects of the drugs, the long-term effects 
on the developing organs are less studied. Kent et al. studied the effect of both NSAID 
treatments on glomerulogenesis. They did not found any clear differences between 
treatments on glomerular numbers, but suggested that tubular development was 
altered (8). A baboon study, performed by Sutherland et al., identified a shortened 
nephrogenic zone after treatment with ibuprofen (9).
 Besides drug toxicity, other stressors play a role in the vulnerability of the developing 
kidney. For instance, being born preterm may on its own disturb kidney formation as 
nephron formation does continue after birth, but with an accelerated maturation (10). 
Rodriguez et al. described that being born before 32 weeks is likely to result in a lower 
nephron number (11). Additionally, preterm born neonates have a sub-optimal intake of 
nutrients and suffer from extra-uterine growth restriction (12), which has been shown 
to reduce nephron formation in an animal model (13) and leads to a decreased neonatal 
glomerular filtration rate (14). Whether the combination of growth restriction with drug 
use has an additional deleterious effect on nephrogenesis remains to be determined.
 Our goal was to determine whether clinical neonatal indomethacin or ibuprofen 
doses affected kidney development and function over short- and long-term periods. 
Additionally, we hypothesized that developmental effects may be modulated by the 
combination with extrauterine growth retardation as an additional stressor.
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Material and methods
Animal experiments
Timed-pregnant Wistar WU rats were ordered from Charles River laboratories 
(Sulzfeld, Germany) and were delivered at the central animal laboratory Nijmegen 
approximately one week before delivery. Animals were housed individually and 
checked at least twice a day for litters. The day that a litter was found complete was 
designated as postnatal day (PND) 1, all dams had littered within 2 days. On PND 2 pups 
were cross-fostered to generate control (normal food: NF) and food restricted (FR) 
litters of 12 and 20 pups, respectively. All litters consisted of an equal number of males 
and females and the presence of siblings in a litter was avoided as much as possible. 
An additional NF and FR litter was formed to replace potential losses in the study 
population. Starting on PND 3, three doses of 0.9% NaCl (sham), 0.1 mg/kg indomethacin 
(Liometacen, Chiesie, Parma, Italy) or 10 mg/kg ibuprofen (Pedea, Orphan Europe, 
United Kingdom) were administered intraperitoneally with 12-hour intervals. PND3 
was chosen as a starting point of the treatment because until PND8 the kidney is still 
developing in the rat, and PND12 is considered to be equivalent to term birth in humans (15). 
This indicates that a newborn rat can be considered similar to a very preterm born 
human, which mimics the situation of a preterm child with ongoing nephrogenesis, 
the clinical target population for the investigated treatment indication. In order to 
minimize mortality, either by too long or invasive handling or side effects of the drugs, 
we decided not to dose in very young pups.
 The dose levels and the treatment interval were chosen to be similar to clinical 
practice. Ibuprofen and indomethacin are administered parentally in the clinic and we 
selected the intraperitoneal route to approach the clinical route of administration. 
This resulted in 6 treatment groups in total (sham-normal food (NF) and food 
restricted (FR), indomethacin-NF and FR, ibuprofen-NF- and FR) per sex. Body weight 
was determined daily up to weaning (day 28) and weekly thereafter till 9 months of 
age. After day 35 only males were kept in study. One FR litter of  20 pups were lost 
to follow-up as the individual markings (by water-resistant tattoo pen) vanished 
overnight due to a leaking water bottle on PND6. Due to the loss of follow-up in the 
initial study cohort, a second cohort was run as a side arm of another study for 
completion of the day 35 analyses. In that second cohort study the littering and 
crossfostering conditions were similar to the conditions described above. All other 
endpoints were determined from the results of the first cohort only. Experiments 
were approved by the Animal Ethics Committee at the Radboud University Nijmegen.
At day 8, 3-4 animals/sex/group were sacrificed and kidneys were collected. No 
samples were collected from FR males because animals were lost from follow-up as 
described above and long-term follow-up was prioritized. The left kidney was frozen 
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in liquid nitrogen for mRNA analysis and the right kidney was fixed in 10% formalin. 
At day 35, 3-4 animals/sex/group were sacrificed by exsanguinations followed by 
perfusion with 10% formalin. Kidneys were stored in 10% formalin and the right kidney 
was processed for stereology.
 The remaining animals were followed until 9 months of age and were investigated 
for electrolyte balance, creatinine clearance and blood pressure at the age of 4, 6 and 
9 months.
Day 8 mRNA analysis
Left kidneys were pulverized in deep frozen state by a microdismembrator (Sartorius- 
Stedim, the Netherlands). Isolation of RNA was performed by combining the TRIzol 
extraction method (Invitrogen, Carlsbad, California) with the Nucleospin RNA II 
isolation kit (Machery-Nagel, Düren, Germany). The Trizol extraction manufacturer s´ 
protocol was followed up to the isopropanol separation step. Subsequently, the 
aqueous phase was added 1:1 to 70% ethanol and loaded on the nucleospin column. 
Further isolation and purification was performed according to the nucleospin 
manufacturer s´ protocol. RNA concentration and quality were assessed with the 
nanodrop 2000x spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts).
 One μg of RNA was used in a subsequent reverse transcriptase reaction using 
random primers (Promega, Madison, Wisconsin), oligo dT (Promega) and M-MLV 
reverse transcriptase (Invitrogen). mRNA levels of target genes were measured by 
quantitative PCR (qPCR) with Actb and Hmbs as internal standards. qPCR was 
performed on a Bio-Rad CFX96 using gene expression mix and hydrolysis probes (table 1) 
as ordered from Applied Biosystems (Pleasanton, California) or Biolegio (Nijmegen, 
Netherlands). Delta-Delta Ct (∆∆Ct) values were reported which were calculated by 
correcting the threshold cycle (Ct) of the gene of interest to the Ct of the housekeeping 
genes and normalizing to the Sham-NF group. Statistical evaluation was performed 
on the Delta Ct (∆Ct) values. Only fold changes >2 were considered biologically 
relevant.
Immunohistochemistry 
Day 8 right kidneys were fixed in formalin and subsequently processed for immuno-
histochemistry. Antigen retrieval was performed by citric acid and endogenous 
peroxidase activity was blocked. Additionally, slides were preincubated with goat 
serum and primary antibodies for Ki67 (1:500) (Abcam, Cambridge, UK) and Caspase-3 
(1:500)(BD Pharmingen, Breda, Netherlands) were used as markers of cellular 
proliferation and apoptosis, respectively. As secondary antibody, 1:200 goat anti-rabbit 
biotinylated antibody (Vector laboratories, Amsterdam, Netherlands) was used and 
signal was amplified with avidin-HRP. PowerDAB (Immunologic, California, USA) was 
used for detection.
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Stereology
Perfusion-fixed day 35 right kidneys were embedded in paraffin and sectioned 
exhaustively at 20 μm. Every 10th and 11th slide, starting at a random position 
(determined by a random number table), were taken and stained for haematoxy-
lin-eosin. Subsequently, slides were scanned with the Olympus Olivia slidescanner and 
evaluation was performed with the Newcast module of the Visiopharm integrator 
system version 3.6.5.0 (Horzholm, Denmark). 
 A sample and its adjacent section were aligned manually and a counting frame 
was superimposed. Subsequently, a region of interest was drawn manually and a 
randomly oriented counting grid was placed on the region with x and y step lengths 
of 2500 μm. Glomeruli were then counted in all section pairs. 
 The total number of glomeruli per kidney (N(glom)) was estimated by the physical 
fractionator/disector principle. On average 152 glomeruli were counted per kidney and 
the total number of glomeruli was estimated using the following formula: N(glom) = 
1/SSF * 1/ASF * Ps/Pf * ∑Q- /2.
 In this formula SSF is the section sample fraction and ASF is the area sample 
fraction (calculated as counting frame area divided by (x-step length * y- step length). 
The factor Ps/Pf was introduced to correct for slides with artificial edges; Ps is the 
number of counting frame corners that hit kidney tissue, Pf is the number of counting 
frame corners that hit evaluated kidney tissue. Finally, ∑Q- is the number of counted 
glomeruli and the factor ½ was introduced for counting both ways between the slide 
pairs.
Glomerular generation counting
Glomerular generations were determined according to the method described in the 
paper of Hinchliffe et al. (16). The direct method was used and 5 radials were counted 
per slide. 
Histopathology
Animals were sacrificed after 9 months and the right kidney was immersion-fixed in 
10% formalin.
 Samples were processed and 2 slides for each animal were stained for haema-
toxylin- eosin or periodic acid-Schiff. These slides were evaluated for glomerular and 
tubular abnormalities by an experienced renal pathologist that was blinded to 
treatment groups and sex, with exception of the NF-sham group in order to establish 
a reference. 
Blood pressure measurements 
Three males per group were surgically implanted with telemetry transmitters PAC40 
(Data Sciences International, St. Paul, Minnesota) with insertion of the catheter in the 
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abdominal aorta before the age of 4 months. Animals received buprenorphine and 
carprofen just before and on the first three days after surgery and were anesthesised 
with isoflurane 2.5% during the procedure. Surgical procedure was performed 
according to DSI surgical protocol for aortic cannulation. Animals were given at least 
two weeks to recover. 
 Telemetry signals were measured at 4, 6 and 9 months. All tracings were collected by 
Dataquest A.R.T. version 3.11 (Data Sciences International). Thirty-second measurements 
were collected every 6 minutes for 24 hours. 
Glomerular and tubular function
Animals were housed in metabolic cages for 24 hours at 4 and 9 months. Urine was 
collected for 24 hours and on exiting the metabolic cage a blood sample was collected 
from the tail vein. Blood was centrifuged at 3000 RPM and plasma was directly taken to 
the clinical laboratory for analysis of sodium, potassium, magnesium, phosphate, urea and 
creatinine. Urine samples were measured for volume, urea, creatinine and osmolality. 
Creatinine and urea clearances were calculated and normalized for body weight. 
NGAL measurement
Urine samples collected at 4 and 9 months were analyzed for the presence of 
neutrophil gelatinase-associated lipocalin (NGAL) protein levels using the rat lipocalin 
2 ELISA kit (R&D Systems, Abingdon, UK)with detection limit of (78.1) pg/ml.
Statistical analysis
Mean (standard deviation, SD) are presented for all findings unless otherwise 
indicated. Parameters of interest were analyzed by univariate analysis using food 
status and treatment as fixed factors and Tukey as post-hoc analysis. Observations of 
both sexes were pooled as no differences between sexes were noted (except for 
absolute kidney weight). One-way ANOVA was used followed by Dunnett post hoc if 
a direct comparison to the sham-NF was made. All analyses were performed by the 
use of SPSS version 20 (IBM, Armonk, NY) at the alpha 0.05 level.
Results
In life phase
Mortality was noted in the first week of the study. In total, five animals, belonging to 
different litter sizes (3 NF, 2 FR) and different treatments (2 sham, 2 indomethacin, 1 
untreated) were found dead. The mortality was considered to be related to the nature 
of the study (neonatal manipulations) but unrelated to specific drug treatment. Other 
than mortality, no abnormal clinical observations were noted over the study period. 
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 As shown in figure 1a and 1b, body weights were significantly different between 
NF and FR animals on every day from day 3 onwards until the end of study. The  body 
weight difference increased over the first three study months and was around 16.5g at 
the time of weaning (sham-NF 52.2g ; sham-FR 36.4g (both sexes); p<0.001)and 33g at 
wk 12 (Sham-NF 324g; Sham-FR 291g (males); p<0.05) . For the remainder of the study 
period the body weight difference remained between 35-50g and was 39g at necropsy 
Figure 1   (A) Body weights of  study animals from PND 3 up to PND 35 . (B) Body 
weights of study animals from PND 35 up to end of study (9 months) 
Values of normal food (NF) animals are plotted with dots and food restricted (FR) with triangles. Sham-dosed 
groups are indicated with a solid line, indomethacin groups with a striped line and ibuprofen groups with a 
dotted line. Body weight of FR animals was lower compared with the NF animals from day 3 onwards on all 
data points. Univariate analysis was performed with Tukey post-hoc. **(P<0.001), *(P<0.05). 
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(sham-NF 509.4g ; sham-FR 470.0g (males); p=0.019). After stratification for food 
status, no drug-related changes were noted. We did note a statistically significant 
increase in body weight on day 10 and 12 of indomethacin-treated vs. sham-treated 
NF animals (sham-NF 18.8g, indomethacin-NF 19.7g ; p=0.045). However, the finding 
was incidental and no clear trend was observed. Similarly, a slight difference 
between indomethacin and ibuprofen-treated FR animals was noted at week 11, 
but no difference with sham-dosed animals was present.  
Day 8 investigations
Based on the potential effects on nephron formation and tubular function, 22 
transporters, growth factors and receptors were selected (table 1), and  sham-NF 
normalized Ct measurements of the various treatments were reported in figure 2. 
Overall, the different treatment groups were close to the Sham NF- reference group. 
Statistically significant changes were noted between FR and NF animals for Wnt4 (0.7 
fold change, p<0.05) , Oat1 (1.3 fold change, p<0.05) , Nphs1 (1.7 fold change, p<0.001) 
and Aqp4 (1.3 fold change, p<0.05). Even though statistical significance was observed, 
the fold changes were small (<2 fold) and therefore it is doubtful if these findings have 
any biological relevance.
 Additionally, we investigated the balance between proliferation and apoptosis 
within the kidneys at day 8 (figure 3) and noticed a statistically significant difference 
between NF and FR animals (F=13.0, p=0.001). In NF animals, the ratio between 
proliferating and apoptotic cells was 7.8:1 (780 (SD 210) proliferating- and 100 (SD 20) 
apoptotic cells/mm2), whereas a ratio of only 3.5:1 (420 (SD 170) proliferating- and 120 
(SD 40) apoptotic cells/mm2) was noted in FR animals. There were no clear focused 
areas of either proliferating or apoptotic cells present in the kidney sections. No sex 
differences were noted (F=0.1, p=0.796) and drug treatment (F=0.9, p=0.479) had no 
effect on the balance between proliferation and apoptosis. 
Day 35 investigations
Kidney weight was significantly higher in NF animals compared with FR animals 
(F=29.2, p<0.001) (table 2). Furthermore a difference was noted between males and 
females (F 15.2, p<0.001). When corrected for body weight, both observed differences 
were no longer statistically significant (F=3.6, p=0.067 and F=0.8 p=0.375). 
 Glomerular numbers were estimated by stereology and were on average 34,492 
(SD 3,707) in the Sham-NF group. Treatment with ibuprofen showed a trend towards 
a 12% lower number of nephrons (sham-NF 34,492 ; ibuprofen-NF 30,329 ; p=0.109) in 
the NF group, but not within the FR group. Indomethacin did not show treatment- 
related effects. The application of food restriction (sham-FR) resulted in a 7.5% 
decrease in glomerular number compared to the sham-NF group (sham-NF 34,492 ; 
sham-FR 31,879 ; p=0.237). Pooling of the sham and drug-treated FR groups led to a 
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10% decrease when compared to sham-NF. All observed decreases were trends, no 
differences between sexes were noted (F=2.0, p=0.175). Additionally, food restriction 
did not modify the effects noted in the ibuprofen group. 
 Finally, glomerular generations were counted. No differences between treatment 
or sexes were noted (F=0.4, p=0.836). The means of all experimental groups were 
around 4.6 - 4.7 generations and no abnormalities were noted. No correlation was 
present between glomerular generation count and the number of glomeruli (Pearson 
correlation p=0.463).
Table 1   Applied Biosystems primer probe sets used in this study.
Gene symbol Primer-probe set
Actb Rn00667869_m1
Agtr1a Rn00578456_m1
Agtr2 a 5’-CCTTCCTGTATTGTTTCGTTGGA-3’ (forward) 
5’-TGGAGCCAAGTAATGGGAACTC-3’ (reverse) 
5’- CCGCTTCCAACAGAAGCTCCGTAGTG-3’(probe-FAM)
Aqp1 Rn00562834_m1
Aqp4 Rn00563196_m1
Bmp7 Rn01528889_m1
Casr Rn00566496_m1
Enac Rn00566891_m1
Fgf7 Rn00573319_m1
Gdnf Rn00569510_m1
Grf1a Rn00564156_m1
Hgf Rn00566673_m1
Hmbs a 5’-GGAGCCATGTCCGGTAACG-3’ (forward) 
5’-CCACTCGAATCACCCTCATCA-3’ (reverse) 
5’-CACAACCGCGGAAGAAAACGGCT-3’(probe-FAM)
Lim Rn00595845_m1
Ncc Rn00571074_m1
Nhe3 Rn00561944_m1
Nhe8 Rn01423020_m1
Nkcc2 Rn00568143_m1
Nphs1 RN00575235_m1
Nphs2 Rn00709834_m1
Oat1 Rn00568143_m1
Renin Rn00561847_m1
Ret Rn01463098_m1
Wnt4 Rn00584577_m1
a Ordered at Biolegio.
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Figure 2   Renal gene expression of relevant transporters, growth factors and 
receptors in kidney development measured on day 8 
Relative fold changes from Sham-NF (dotted line) with SEM are plotted for each target gene. Shown are sham 
(dot), indomethacin (square) and ibuprofen (triangle) treatment. Normal food (NF) and food restricted (FR) 
are distinguished by filled and cleared symbols. Univariate analysis was performed with Tukey post-hoc. FR vs 
NF * p<0.05, ** P<0.001. 
Figure 3   The balance between proliferating and apoptotic cells in day 8 kidneys 
Mean ratio's with 25%-75% percentiles and min-max values per treatment group are shown. Food restriction 
and normal food are indicated with NF and FR. Statistical analysis was performed by univariate analysis ** 
p=0.001. 
Lim
W
nt
4
Bm
p7
Gd
nf
Fg
f7
Hg
f
Gr
f1a Re
t
Ca
sr
En
ac
Np
hs
1
Np
hs
2
Nh
e3
Nh
e8
Oa
t1
Nc
c
Nk
cc
2
Aq
p1
Aq
p4
Ag
tr1
a
Ag
tr2
Re
ni
n
0.5
1
2
* * ***
fo
ld 
ch
an
ge
 (∆
∆C
t s
ha
m
 N
F)
NF
 sh
am
NF
 ind
om
eth
aci
n
NF
 ibu
pro
fen
FR 
sha
m
FR 
ind
om
eth
aci
n
FR 
ibu
pro
fen
0
5
10
15
**
Ra
tio
 be
tw
ee
n p
ro
life
ra
tin
g
 an
d a
po
pt
ot
ic 
ce
lls
104
CHAPTER 7
Ta
bl
e 2
   R
en
al 
pa
ra
m
et
er
s a
t d
ay
 35
.
Tre
at
m
en
t
Sh
am
-N
F
In
do
m
et
ha
cin
-N
F
Ib
up
ro
fe
n-
NF
Sh
am
-FR
In
do
m
et
ha
cin
-FR
Ib
up
ro
fe
n-
FR
St
at
ist
ica
l s
ig
ni
fic
an
ce
M
ea
n 
kid
ne
y w
eig
ht
 (g
)
0.6
7 
(0
.0
6)
0.7
0 
(0
.0
8)
0.6
8 
(0
.0
7)
0.5
6 
(0
.0
6)
0.5
7 
(0
.0
4)
0.5
7 
(0
.0
7)
FR
 vs
. N
F p
<0
.0
01
Ki
dn
ey
 / 
bo
dy
 w
eig
ht
 a  
(ra
tio
 x1
00
)
0.7
2 
(0
.0
6)
0.7
3 
(0
.0
6)
0.7
2 
(0
.0
6)
0.7
4 
(0
.0
7)
0.7
7 
(0
.0
5)
0.7
8 
(0
.0
6)
Gl
om
er
ul
ar
 ge
ne
ra
tio
ns
 
(co
un
t)b
4.7
 
(0
.18
)
4.6
 
(0
.12
)
4.7
 
(0
.30
)
4.6
 
(0
.0
7)
4.7
 
(0
.14
)
4.6
 
(0
.0
8)
Gl
om
er
ul
ar
 n
um
be
r 
34
,49
2 
(3,
70
7)
32
,45
9 
(4
,14
2)
30
,32
9 
(2,
73
3)
31
,87
9 
(2,
98
3)
30
,45
1 
(3,
51
4)
30
,70
6 
(1,
22
2)
a  B
od
y w
eig
ht
 ex
tra
po
lat
ed
 fr
om
 la
st
 kn
ow
n 
bo
dy
 w
eig
ht
 an
d g
ro
up
 gr
ow
th
 cu
rv
e.
Da
ta
 ar
e p
re
se
nt
ed
 as
 m
ea
n 
(st
an
da
rd
 de
via
tio
n)
, e
xc
ep
t f
or
 b  m
ea
n (
st
an
da
rd
 er
ro
r) 
an
d a
na
lys
ed
 w
ith
 un
iva
ria
te
 an
aly
sis
 w
ith
 Tu
ke
y p
os
t-h
oc
.
105
IMPACT OF EARLY POSTNATAL NSAIDS TREATMENT ON NEPHROGENESIS IN WISTAR RATS
7
Long-term follow-up in male rats
Plasma and urine profiles were determined at 4 and 9 months of the study. No 
differences were seen in electrolytes between treatments and creatinine and urea 
clearance were not affected (table 3a and 3b). Additionally, urine NGAL was measured 
as a biomarker of tubular damage. No effects were noted at the 4 months time point. 
At 9 months of age, a trend towards an increase in NGAL was noted in all FR groups 
(Mean FR 1.26 (SD 0.69) μg/ml; NF 0.90 (SD0.52) μg/ml; p=0.083). Additionally a trend 
was noted towards an increase in the ibuprofen-NF group at the end of the study 
period, but individual variation was high (Mean ibuprofen-NF 1.23 (SD 0.84) μg/ml; 
sham-NF 0.735 (SD 0.12) μg/ml ; p=0.237) (table 3 and 4). 
 Blood pressure was evaluated by telemetry and waveforms had the expected 
shape. However, the amplitude of some signals was low and not physiological. 
Additionally, signal amplitude further deteriorated in the long-term follow-up of the 
study. Altogether, the collected data was not suitable for a valid evaluation at the end 
of the study period.
 At the study end, mean kidney to body weight ratio was 5.9 mg/g (range 5.3- 
6.2 mg/g) in the sham-NF group and similar to the other experimental groups. Histo-
pathological investigation revealed minor changes within the normal biological variation 
(data not shown). 
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CHAPTER 7
Discussion
Our goal was to determine whether indomethacin or ibuprofen doses similar to those 
used clinically, affected kidney development and function on short- and long-term, 
and whether those effects might be modulated by the addition of extrauterine 
growth retardation as a stressor. To study these effects rats were dosed within a 
period of ongoing nephrogenesis and followed up for a large period of their life span 
to investigate accumulative wear and tear to the kidney as postulated in Brenner’s 
hyperfiltration theory (17). This theory states that an early reduction in glomerular 
numbers increases workload of the other glomeruli which eventually leads to glomer-
ulosclerosis.
 Based on our results, a clinical dose of 10 mg/kg ibuprofen, when administered in 
a dose regime mimicking the clinical practice, tended to lead to a decreased number of 
glomeruli in animals with a normal feeding regimen. Additionally, we noted a tendency 
to a slight increase in NGAL levels in the urine of these animals in our long-term 
follow-up. However, we did not find any functional or morphological impairments of 
concern. In contrast to our ibuprofen findings, we did not find any signs of toxicity in 
the indomethacin-dosed groups.
 Groups with FR were studied to determine the interaction of extrauterine growth 
retardation on drug effects. Although we noted effects of FR comprising of lower body 
weight, kidney weight, altered proliferation/apoptosis balance and a lower glomerular 
number on the animals, we did not see a clear modulating effect on drug toxicity. 
In the case of ibuprofen, glomerular numbers in NF and FR groups were similar. 
 Our findings on ibuprofen treatment were somewhat contrasting with the 
findings published earlier by Kent et al. (8). In their studies, no differences in glomerular 
numbers were found, but an increase in kidney weight was described, possibly linked 
to edema formation. We did not find any evidence of the edema but our time interval 
between the last ibuprofen treatment and necropsy for stereology was longer (1 
month vs. 1 week). Therefore, it could be that any edema present during treatment in 
the kidney has already recovered. In another study, tubular alterations were detected 
with light microscopy, and glomerular changes (primarily foot process effacement) 
were noted by EM-microscopy not only at a dose of 10 mg/kg but also at 0.1 mg/kg 
indomethacin (in a lesser degree) in neonatal rats (18). These glomerular findings 
could be the start of the cascade leading eventually to the reduction in glomeruli we 
observed at our time point of necropsy and should be investigated in a follow-up 
study. In our study, we did not detect any tubular alterations at day 35, but these could 
have been recovered as well. However, our analysis of tubular transporters by mRNA 
expression on day 8 did not show either indications of altered function or toxicity 
between ibuprofen and control-treated kidneys. 
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 In our long-term follow-up period we noted a trend toward a slight increase in 
NGAL levels in the urine after ibuprofen treatment. Its presence in the urine can have 
multiple causes. Due to its low molecular weight and positive charge NGAL undergoes 
normal glomerular filtration and is afterwards reabsorbed by the proximal tubules. 
Therefore, higher levels of NGAL in the urine could indicate proximal tubular damage 
(19). Additionally, the thick ascending limb and the collecting ducts may be sources of 
NGAL (20). Although NGAL is mostly known for its involvement as a stress protein in 
acute kidney injury responses, levels of this biomarker can also be higher in patients 
with chronic kidney disease (21). The observed trend may therefore be indicative for a 
possible developing chronic kidney injury in these animals. Recently, higher urine 
levels of NGAL were also associated with an increased prevalence of higher systolic 
blood pressure and cardiovascular events (22). The source cell type of the NGAL 
elevations in our study was unclear because kidney lesions were absent at the light 
microscopic examination at the end of the study period. With the absence of any his-
topathological correlation and the lack of changes in any serum or urine renal 
functional parameter, the relevance of this observed trend is doubted. But if these 
trends hold true, alterations of the kidney were still subtle and did not yet lead to a 
functional or morphological deficit of the kidney. In humans Rodriguez et al showed 
that glomerulogenesis does not continue in pre-term neonates after 40 days and the 
kidney is therefore less developed compared with term neonates (11). Concurrently, a 
prehypertensive state was associated with children born preterm (23). Therefore 
subtle alterations may render the subject more prone to the development of renal 
disease. To study such an option, future studies should be undertaken that are more 
directed at this specific effect. Our latest time point was 9 months, which 
approximately corresponds with a human age of 25 years (15) and could therefore be 
too early. Furthermore, performing similar experiments in Sprague Dawley rats may 
also be of interest, as they are known to be more prone to chronic kidney disease (24). 
 Our second goal was to study the modulating effects of growth restriction during 
nephrogenesis on the effects of ibuprofen or indomethacin on renal development. 
The litter enlargement model described by Huizinga et al (25) was chosen because of 
its described effects on glomerular count (13) and the similarity in timing of the 
growth restriction to the human situation of prematurely born neonates (15). In line 
with previous experiments (25), differences in body weight between NF and FR 
animals were found in the present study and is therefore similar to other models of 
early postnatal food restriction (26). As the total growth patterns are quite parallel 
and no significant loss of pups was noted in the FR litters, the mother can be considered 
to distribute her milk evenly between pups although it is difficult to have a good stan-
dardization of specific caloric, protein and nutrient (such as vitamin A) intake during 
FR. In addition to lower body weights, we noted a histological change in FR animals 
with fewer proliferating cells in the kidney. This histological difference may be linked 
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to the impaired growth during kidney formation, which has been shown to have a 
distinct impact on the kidney (13).
 The FR model showed a slight decrease in glomeruli and was not as evident as 
would be expected from earlier work where higher control values were reported (13). 
We are currently uncertain what the underlying cause is for this discrepancy.
 At the long-term follow-up, NGAL levels of male FR animals were in line with 
those noted after ibuprofen treatment alone, which contributes to an association 
between a lower glomerular number and the NGAL increase. Similarly, no functional 
or morphological deficits were noted after clinical pathology and histopathological 
examination at the end of treatment.
 We postulated that additional stressors might be required for low doses of drugs 
to influence renal development. It is evident that our food restriction model works as 
an additional stressor to the pups. However, this stressor did not seem to modulate 
the effect of either indomethacin or ibuprofen in our study because the values of the 
glomerular counts in the drug-treated FR groups were not different from the sham-FR 
group. Additionally, the ibuprofen-NF group was similar to the ibuprofen-FR group and 
there was no added or synergetic effect. At this moment in time not much is 
understood of the underlying working mechanism of either FR or ibuprofen regarding 
the decrease in glomerular numbers. Possible hypotheses are a common pathway 
with a limiting effect on the kidney, a partially antagonistic effect of both stressors or 
protection of one of the stressors against the other. These hypotheses should however 
be tested in subsequent studies.
 The debate remains whether ibuprofen or indomethacin is safer to use for closing 
the patent ductus arteriosis. Evidence is accumulating that both compounds have 
impact on the glomeruli. Akinola et al. showed hypoplastic glomeruli after repeated 
dosing of ibuprofen at 22 mg/kg/day for 5 days (27). However, we already showed 
trends at a clinical dose level. Although patent ductus arteriosis has to be treated, care 
should be taken for the co-administration of other potential nephrotoxic drugs such 
as aminoglycosides. Long-term renal and eventually cardiovascular health should be 
kept in mind when treating newborns.
 In summary, 10 mg/kg ibuprofen when administered in a clinical dose regime to 
neonatal rats tended to reduce glomerular numbers by 12% at day 35 and resulted in a 
trend towards an increased urine NGAL in individual male animals after a 9 month 
follow-up, without overt functional or morphological renal alterations. Postnatal food 
restriction resulted in a 7.5% reduction in glomerular numbers, a reduced body weight 
and altered proliferation/apoptosis balance and also a trend towards increased NGAL 
over time. No added or synergistic effects of FR on the effects of ibuprofen or 
indomethacin treatment were noted. Taken all these findings into account, ibuprofen 
showed potential to cause a subtle reduction in kidney glomerular count that may 
render the treated person more prone to later renal disease. As an alternative NSAID, 
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indomethacin did not show any effects in this study and may be less toxic with regard 
to nephrogenesis, even though in clinical practice more side-effects are seen. 
Additional studies should be performed to confirm the findings in this study, elucidate 
the underlying mechanism of ibuprofen toxicity regarding nephrogenesis and explore 
whether effects of ibuprofen treatment on the kidney may be mitigated.
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Abstract
Background
Diuretics are administered to neonates to control fluid balance. We studied whether 
clinical doses affected kidney development and function and whether extrauterine 
growth retardation (EUGR) could be a modulator.
Methods
Wistar rats were cross-fostered in normal food (NF) or food restricted (FR) litters at 
postnatal day (PND) 2 and treated daily with 0.9% NaCl, 5 mg/kg furosemide or 5 mg/
kg hydrochlorothiazide up to PND 8. Kidneys were evaluated on proliferation, apoptosis 
and a set of mRNA target genes at PND 8, glomerular- and glomerular generation 
count at PND 35, clinical pathology parameters at 3- and 9 months, NGAL at PND 8, 3 
and 6 months, monthly blood pressure from 3 months onward and histopathology at 
study end.
Results
Treatment with furosemide or hydrochlorothiazide did not have relevant effects on 
measured parameters. Extrauterine growth retardation resulted in lower body weight 
from day 3 onwards (-29% at weaning; p<0.001. -10% at necropsy; p<0.001), less 
glomerular generations (4.4 ± 0.32 vs. 5.0 ± 0.423; p=0.025, males only), decreased 
glomerular numbers (27,861 ± 3,468 vs. 30,527 ± 4,096; p=0.026), higher creatinine 
clearance (0.84 ± 0.1 ml/min/kg vs. 0.77 ± 0.09 ml/min/kg; p=0.047) at 3 months and 
lower plasma creatinine (25.7 ± 1.8 μmol/l vs. 27.5 ± 2.8 μmol/l; p=0.043) at 9 months. 
Conclusion
Furosemide and hydrochlorothiazide did not influence kidney development or function 
when administered in a clinically relevant dose to rat pups at a stage of ongoing 
nephrogenesis. EUGR led to impaired kidney development but did not modify 
furosemide or hydrochlorothiazide findings.
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Introduction
From a historical perspective neonatal medicine has been mainly reliant on the 
translation of scientific data from the adult population. This perspective is changing 
because more evidence shows that neonates are different in ways of drug handling 
(1). The neonate population also has another important aspect regarding the practice 
of medicine, which is the interaction of treatments with the still ongoing development 
of many organs. This is especially important if born preterm. It has been hypothesized 
that low birth weight or early life damage may have impact on the kidney and its 
functions in later life (2,3). Already it has been shown that environmental influences 
during nephrogenesis, including growth restriction and medications, have a significant 
impact on final nephron numbers (4). Nephrons are formed from the 5th gestational 
week onwards and formation ends around the 34th to 36th week of gestation in humans 
(5). At that moment a little under 1 million nephrons have been formed per kidney, but 
there is a very large interindividual range (i.e. 10-fold) (6). In rodents the timing of 
nephrogenesis is different and is completed approximately  7 days after birth (7). 
 Diuretics are the most common drugs administered to control fluid balance in 
neonates, especially in children with chronic lung disease after very premature birth 
(8). But there is a risk of kidney toxicity. Although acute kidney toxicity is not expected 
or seen, higher dose levels of furosemide are associated with renal calcification in 
children (9). Regarding kidney development, the described effects are more 
controversial. In the past, effects of furosemide on kidney development have been 
studied in vivo. Mallie et al. showed that prenatal furosemide exposure in rats tended 
to lower the number of differentiated glomeruli at birth and disturbed electrolyte 
handling (10,11). This effect was still present after a 12-day follow-up. In contrast, a 
recent study by our group did not identify effects on early kidney development after 
exposing metanephroi in vitro to more clinically relevant dose levels (12).
 Our goal was to determine if a clinical neonatal dose of furosemide or hydrochlo-
rothiazide (HCTZ) impaired  kidney development and function on short and/or 
long-term. Hydrochlorothiazide was selected as a second drug because it has not been 
associated with nephrotoxicity. While the nephrotoxic potential of both furosemide 
and hydrochlorothiazide itself is low, they are often co-administered with other drugs 
and may thereby play a role in multi-hit toxicity. Additionally, we hypothesized that 
the potential effects of these drugs on kidney development may also be modulated by 
additional stressors such as extrauterine growth retardation. 
 In this study we investigated these hypotheses by inducing postnatal food 
restriction by means of litter enlargement to model extrauterine growth retardation 
in the rat. Either furosemide or hydrochlorothiazide were administered for 7 days to 
investigate interactions on development, and vehicle and control treatments were 
included. Early effects on proliferation/apoptosis, a set of mRNA target genes, 
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glomerular- and glomerular generation count on the kidney were evaluated. 
Furthermore, clinical pathology parameters, NGAL, blood pressure and renal 
histopathology were evaluated in a long-term follow-up. Finally, body weight was 
measured to monitor overall animal health and determine the extent of extrauterine 
growth retardation. 
Material and methods
Animal experiments
All experiments were approved by the Animal Ethics Committee at the Radboud 
University Nijmegen.
 Timed-pregnant Wistar WU rats (Charles River laboratories, Sulzfeld, Germany) 
were delivered at the central animal laboratory Nijmegen approximately one week 
before delivery. Dams were housed individually and checked for litters at least twice 
daily. The day a full litter was found was labeled as postnatal day (PND) 1. Pups were 
cross-fostered on PND2 to generate control (NF, 12 pups per litter) and food restricted 
(FR, 20 pups per litter) animals. Additional NF and FR litters were formed in order to 
replace potential losses in the study litters. Rats had ad libitum access to water and 
food (Ssniff R/M-H diet, Soest, Germany) with a sodium, potassium and chloride 
content of 0.24%, 0.91% and 1.00% respectively. Animals received a daily intraperito-
neal dose of 0.9% NaCl (sham), 5 mg/kg furosemide (Lasix, Aventis Pharma BV, Gouda, 
Netherlands) or 5 mg/kg hydrochlorothiazide (H2910) (Sigma-Aldrich, the Netherlands) 
for 7 days starting on PND 2. In total, 6 treatment groups per gender were formed 
(sham-NF and FR, furosemide-NF and FR, HCTZ-NF and FR). 
 Body weight was measured daily up to weaning (day 28) and weekly thereafter till 
9 months of age. After day 35 only males were kept in the study as they are generally 
more prone to develop hypertension (13). Some mortality was noted in the first weeks 
of the study (5 animals: 2 male NF (sham and furosemide), 2 female FR (sham and 
furosemide), 1 non-treated NF animal). This was considered to be related to the nature 
of the study (neonatal manipulations) but unrelated to the study interventions. 
 At day 8, (at least) 3 animals/sex/group were sacrificed and kidneys were collected. 
The left kidney was frozen in liquid nitrogen for mRNA analysis and the right kidney 
was fixed in 10% formalin. 
 At day 35, (at least) 3 animals/sex/group were sacrificed by exsanguinations 
followed by perfusion with 10% formalin. Kidneys were stored in 10% formalin and the 
right kidneys were processed for  stereology.
 The remaining (male) animals were followed until 9 months of age and were 
sampled for electrolyte concentrations and creatinine clearance at the age of 3 and 
9 months. Blood pressure was recorded monthly from 3 months of age onwards.
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mRNA analysis
Day 8 left kidneys were pulverized by a microdismembrator (Sartorius-Stedim, the 
Netherlands) in deep frozen state. Isolation of RNA was performed by combining the 
TRIzol extraction method (Invitrogen, Carlsbad, California) with the Nucleospin RNA II 
isolation kit (Machery-Nagel, Düren, Germany). The manufacturer s´ protocol for Trizol 
extraction was followed up to the isopropanol separation step. Subsequently, the 
aqueous phase was added 1:1 to 70% ethanol and loaded on the nucleospin column. 
Further purification was performed according to the nucleospin manufacturer s´ 
protocol. RNA concentration and quality were assessed with the nanodrop 2000x 
spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts).
 One μg of RNA was used in a subsequent reverse transcriptase reaction using 
random primers (Promega, Madison, Wisconsin), oligo dT (Promega) and M-MLV 
reverse transcriptase (Invitrogen). mRNA levels were measured by quantitative PCR 
(qPCR) on a Bio-Rad CFX96 using gene expression mix and hydrolysis probes (table 1) 
as ordered from Applied Biosystems (Pleasanton, California) or Biolegio (Nijmegen, 
Netherlands), with Actb and Hmbs as internal standards. Delta Ct (∆Ct) values were 
reported which were calculated by correcting the threshold cycle (Ct) of the gene of 
interest to the Ct of the housekeeping genes. Fold changes were calculated in case 
delta Ct values were statistically significant.
Immunohistochemistry 
Day 8 right kidneys were fixed in formalin and subsequently processed for immuno-
histochemistry. Citric acid was used for antigen retrieval and endogenous peroxidase 
activity was blocked. Additionally, slides were preincubated with goat serum and 
primary antibodies for Ki67 (1:500) (Abcam, Cambridge, UK) and Caspase-3 (1:500)(BD 
Pharmingen, Breda, The Netherlands) were used as markers of cellular proliferation 
and apoptosis, respectively. As secondary antibody, 1:200 goat anti-rabbit biotinylated 
antibody (Vector laboratories, Amsterdam, The Netherlands) was used and signal was 
amplified with avidin-HRP. PowerDAB (Immunologic, California, USA) was used for 
detection.
Stereology
Perfusion-fixed day 35 right kidneys were embedded in paraffin and sectioned 
exhaustively at 20 μm. Every 10th and 11th slide, starting at a random position 
(determined by a random number table), were taken and stained for haematoxy-
lin-eosin. Slides were scanned on a Olympus Olivia slidescanner and evaluation was 
performed with the Newcast module of the Visiopharm integrator system  software 
package (version 3.6.5.0, Horzholm, Denmark). 
 A sample and its adjacent section were aligned manually and a counting frame 
was superimposed. Subsequently, a region of interest was drawn manually and a 
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randomly oriented counting grid was placed on the region with x and y step lengths 
of 2500 μm. All section pairs were then scored for presence of glomeruli. 
 The total number of glomeruli per kidney (N(glom)) was estimated by the physical 
fractionator/disector principle. On average 141 glomeruli were counted per kidney and 
the total number of glomeruli was estimated according to the following formula: 
N(glom) = 1/SSF * 1/ASF * Ps/Pf * ∑Q- /2.
 In this formula SSF is the section sample fraction and ASF is the area sample fraction 
(calculated as counting frame area divided by (x-step length * y- step length). The factor 
Ps/Pf was introduced to correct for slides with artificial edges; Ps is the number of 
counting frame corners that hit kidney tissue, Pf is the number of counting frame 
corners that hit evaluated kidney tissue. Finally, ∑Q- is the number of counted glomeruli 
and the factor ½ was introduced for counting both ways between the slide pairs.
Table 1   Applied Biosystems primer probe sets used in this study.
Gene symbol Primer-probe set
Actb Rn00667869_m1
Hmbs a 5’-GGAGCCATGTCCGGTAACG-3’ (forward) 
5’-CCACTCGAATCACCCTCATCA-3’ (reverse) 
5’-CACAACCGCGGAAGAAAACGGCT-3’(probe-FAM)
Wnt4 Rn00584577_m1
Gdnf Rn00569510_m1
Bmp7 Rn01528889_m1
Fgf7 Rn00573319_m1
Hgf Rn00566673_m1
Lim Rn00595845_m1
Ret Rn01463098_m1
Renin Rn00561847_m1
Grf1a Rn00564156_m1
Agtr1a Rn00578456_m1
Agtr2 a 5’-CCTTCCTGTATTGTTTCGTTGGA-3’ (forward) 
5’-TGGAGCCAAGTAATGGGAACTC-3’ (reverse) 
5’- CCGCTTCCAACAGAAGCTCCGTAGTG-3’(probe-FAM)
Oat1 Rn00568143_m1
Casr Rn00566496_m1
Enac Rn00566891_m1
Nkcc2 Rn00568143_m1
Nhe3 Rn00561944_m1
Nhe8 Rn01423020_m1
Ncc Rn00571074_m1
a Ordered at Biolegio.
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Glomerular generation counting
Glomerular generations were determined with “the direct method” as described in 
the paper of Hinchliffe et al. (14). Five radials were counted per slide.
Histopathology
Animals (male) were sacrificed after 9 months and the right kidney was immersion- 
fixed in 10% formalin.
 Samples were processed and stained for haematoxylin-eosin or periodic acid- 
Schiff (2 slides/animal). These slides were evaluated for glomerular and tubular 
abnormalities by an experienced renal pathologist (SF) that was blinded to treatment 
groups, with exception of the sham-NF group in order to establish a reference. 
Blood pressure measurements
Blood pressure was measured non-invasively in all animals (male) from 3 months onwards 
by volume pressure recording on the CODA apparatus (Kent Scientific Corporation, 
Torrington, Conneticut) with software version 1.0. Prior to the measurements the 
room was heated to be above the ambient temperature of 22 °C. Additionally, animals 
were kept warm by the heating plate of the apparatus during the experiment and the 
tails were covered by a cloth to further stimulate thermo-regulation of the animals. 
Before recording, animals were acclimatized for 10 minutes in the restrainers and 
subsequently twenty blood pressure measurements were collected. The first ten 
measurements were used to train the animal and were discarded. The last 10 
measurements were evaluated by the software and if in acceptable boundaries 
regarding blood flow, they were averaged per animal. Pulse pressure was calculated 
manually from the output data of the apparatus. Blood pressure was measured on 
three subsequent days in all animals in each month and an average of these three days 
was reported. This resulted in a robust average for each animal for each time point 
except for the 9-months time point. At 9-months representative results could only be 
obtained in 2/3 of the animals and these were reported.
Glomerular and tubular function
Animals were housed in urine collection cages for 24 hours at 3 and 9 months of age. 
Urine was collected for a period of 24 hours and on exiting the urine collection cage a 
blood sample was collected from the tail vein. Blood was centrifuged at 3000 RPM 
and plasma was directly taken to the clinical laboratory for analysis of sodium, 
potassium, magnesium, phosphate, urea and creatinine. Urine samples were measured 
for volume, urea, creatinine and osmolality or stored for possible future analysis. 
Creatinine and urea clearances were calculated and normalized for body weight. 
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NGAL measurement
Urine samples collected at 3 and 6 months, and plasma collected at day 8 were 
analyzed for the presence of neutrophil gelatinase-associated lipocalin (NGAL) protein 
levels as a marker of tubular damage using the rat lipocalin 2 ELISA kit (R&D Systems, 
Abingdon, UK) with detection limit of 78.1 pg/ml.
Statistical analysis
Mean (standard deviation, SD) are presented for all findings unless otherwise 
indicated. Parameters of interest were analyzed by univariate analysis using sex, litter 
size and treatment as fixed factors. Post hoc analysis was performed by Tukey. 
The time effect on blood pressure was analyzed between and within subjects with a 
multivariate analysis for repeated measures, using the Greenhouse-Geisser correction. 
Gene expression data was analyzed by the Kruskal Wallis test for non-parametric data. 
Interaction between glomerular generation and glomerular numbers was analyzed 
with linear regression. All analyses were performed by the use of SPSS version 20 (IBM, 
Armonk, NY) at the alpha 0.05 level.
Results
Body weight
Body weights were evaluated in the study to follow-up on general animal health and 
to evaluate the effect of postnatal food-restriction.
 Body weights of male and females were only different incidentally (Day 2, 3 and 35) 
and were therefore pooled for analysis. Mean body weight was 6.4 (SD 0.5 and 0.6)g 
for NF and FR, respectively) for both normal food (NF) and food restricted (FR) animals 
at cross-fostering on PND 2.
 From day 3 onwards (figure 1a) body weight of FR animals was lower compared 
with NF animals: on day 3 NF mean 6.9 (SD 0.7)g, FR mean 6.7 (SD 0.6)g, p<0.001; on 
the day of weaning NF mean 59.8 (SD 3.3)g and FR mean 42.2 (SD 5.3)g, difference 29%, 
p<0.001. Relative body weight difference declined after weaning. However, an 
absolute body weight difference of 30-40 grams was observed for the remainder of 
the study (p<0.001) (figure 1b). No drug treatment-related effects were detected on 
body weight, except for an incidental difference between furosemide and hydro-
chlorothiazide on day 10 within NF animals (p=0.037). At day 189, by chance the 
heaviest and lightest animal of the sham-NF and the hydrochlorothiazide-FR groups, 
respectively, were excluded from the routine body weight measurement due to urine 
sampling. This resulted in the observed abnormality in the body weight evolution 
graph. 
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Figure 1   Body weight evolution of all study animals is shown from PND 2 up to PND 
35 (A). Body weight evolution of study animals (male) is shown from PND 35 
up to end of study (9 months) (B).  
Evolution of normal food (NF) animals are indicated with dots and food restricted (FR) with triangles. 
Sham-dosed groups are indicated with a solid line, furosemide groups with a striped line and hydrochlorothi-
azide groups with a dotted line. n= 19-20/group up to PND 8; n=11-14/group up to PND 35; n=4-6/group for 
the remainder of the study. Body weight of FR animals was lower compared with the NF animals from day 3 
onwards on all days of measurement. Drug treatments within food regimes were well within each other’s 
standard deviation (not shown for clarity). Univariate analysis was performed with Tukey post-hoc. 
***p<0.001.
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Day 8 investigations (gene expression, proliferation/apoptosis ratio)
To determine direct effects of treatment on kidney development gene expression and 
proliferation/apoptosis and NGAL were examined on PND 8.
 Gene expression analysis on kidney tissue, collected on day 8 (figure 2), showed a 
0.7 fold change of Fgf7 in FR animals (p=0.009) and 0.68 fold change in furosemide 
treated animals versus sham (p=0.031). Casr and Gdnf genes were down-regulated in 
furosemide treated animals with fold changes of 0.67 (p=0.04) and 0.72 (p=0.02), 
respectively and Grfa1 was up-regulated in FR animals compared with the NF animals 
(1.39 fold, p=0.002). All gene expression analyses were performed on pooled samples 
of both genders as no gender effect was noted. Gene expression of the loop diuretic 
sensitive Nkcc2 and the thiazide sensitive Ncc transporters did not change.
No difference was noted on the ratio between proliferating and apoptotic cells in 
kidney tissue on day 8 of the study (figure 3). Means for males and females were 47.1 
(482 (SD 358) proliferating- and 13 (SD 8) apoptotic cells/mm2, and 29.8 (430 (SD 244) 
proliferating and 14 (SD 4) apoptotic cells/mm2, respectively (f=2.852, p=0.10). Similarly, 
Figure 2   Renal gene expression of relevant transporters, growth factors and 
receptors in kidney development measured on day 8 
Delta Ct values from all individual animals are plotted for each target gene. Shown are sham (dot), furosemide 
(square) and hydrochlorothiazide (triangle) treatment. Normal food (NF) and food restricted (FR) are 
distinguished by closed and open symbols (n=5-8 per group). Statistical analysis was performed with 
Kruskal-Wallis one-way ANOVA. * p<0.05  furosemide vs. sham; # p<0.05 , ## p<0.01 FR vs. NF. 
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no differences were noted between NF and FR treated groups (means: 40.3 (516 (SD 
378) proliferating and 15 (SD 6) apoptotic cells/mm2) vs. 38.0 (380 (SD 158) proliferating 
and 12 (SD 6) apoptotic cells/mm2), respectively; f=0.107, p=0.75). No influence of the 
drug treatment (mean ratio’s: sham 44.0 (357 (SD 192) proliferating and 11 (SD 6) 
apoptotic cells/mm2), furosemide 45.8 (621 (SD 380) proliferating and 16 (SD 8) 
apoptotic cells/mm2) and HCTZ 28.5 (420 (SD 300) proliferating and 15 (SD 3) apoptotic 
cells/mm2); f=1.032, p=0.37) and no interactions between the different variables were 
detected.
 Ngal (table 4) was investigated in plasma as a marker for acute kidney damage. 
Plasma values were on average 0.168 (SD 0.031) and 0.149 (SD.0.028) μg/ml in NF and 
FR, respectively, and did not differ significantly (f=3.880, p=0.58). Additionally no 
changes were noted between the different drug treatments and the sham control.
Day 35 investigations (kidney weight, glomerular number  
and glomerular generation count)
On Day 35, the impact of the treatments on kidney organogenesis was assessed. To 
investigate whether the kidney developed normally, kidney weight, glomerular 
number and glomerular generation count were determined. 
 Mean kidney weight (table 2) in FR animals was lower compared with NF animals 
and a difference between the sexes was detected (males 0.64 (SD 0.07) g, females 
Figure 3   The balance between proliferating and apoptotic cells in day 8 kidneys 
Mean ratio's with standard deviation per treatment group are shown (n=5-8/group). Normal feeding and 
food restriction regimes are indicated with NF and FR, respectively. Statistical analysis was performed by 
univariate analysis and no statistically significant differences were noted. 
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0.57 (SD 0.08) g; f=12.745, p=0.001). Corrected for body weight (x100) these were 0.72 
(SD 0.07) and 0.73 (SD 0.09). No differences were noted for the treatments studied 
(sham 0.61 (SD 0.09) g, furosemide 0.61 (SD 0.07) g, HCTZ 0.58 (SD 0.1) g; f=0.274, 
p=0.762) and interactions between the variables sex, litter size and treatment were 
not present. When corrected for body weight, kidney weight in FR animals was higher 
compared with NF animals (0.77 vs. 0.69; f=15.511, p<0.001) and an interaction between 
treatment and litter size was detected (f=4.812, p=0.015). The higher kidney weight in 
the FR group could be attributed to the slightly higher kidney weights in the HCTZ-FR 
group.
 Glomerular generation count (table 2) was performed and yielded on average 4.6 
(SD 0.66) generations in the sham-NF dosed animals. FR animals had on average less 
glomerular generations (4.4 (SD 0.39)) compared with the NF animals (4.7 (SD 0.41)) 
(f=5,666, p=0.025). This decrease was dependent on sex (f=4,260, p=0.049) and was 
detected in males, but not females (male NF 5.0 (SD 0.23); FR 4.4 (SD 0.32), female NF 
4.5 (SD 0.41); FR 4.5 (SD 0.44)). Overall analysis did not show a difference between 
sexes (male 4.7 (SD 0.40), female 4.5 (SD 0.42); f=1.861, p=0.18) or drug treatments 
(sham 4.5 (SD 0.61), furosemide and HCTZ 4.6 (SD 0.31 and 0.27, respectively); f=0.553, 
p=0.58). 
Table 2   Renal parameters
Treatment Sham NF Furosemide NF Hydrochlorothiazide NF Sham FR Furosemide FR Hydrochlorothiazide FR Statistical significance
Day 35
Body Weight (g) 94.0 (4.47) 93.5 (9.76) 96.7 (8.78) 72.9 (4.97) 78.3 (9.12) 67.5 (9.55) NF vs. FR p<0.001
M vs. F p=0.005
Right kidney weight (g) 0.67 (0.05) 0.65 (0.05) 0.63 (0.12) 0.54 (0.06) 0.57 (0.08) 0.55 (0.07) FR vs. NF p<0.001
M vs. F p=0.001
Right kidney / body weight  
(ratio x100)
0.71 (0.04) 0.70 (0.05) 0.65 (0.08) 0.74 (0.06) 0.73 (0.09) 0.81 (0.05) FR vs. NF p<0.001
Attributed to HCTZ (p=0.015)
Glomerular generations  
(count)
4.6 (0.66) 4.8 (0.20) 4.7 (0.28) 4.3 (0.59) 4.4 (0.23) 4.6 (0.26) FR vs. NF (p=0.025) only in males
Glomerular Number 29,454 (4,022) 30,640 (4,272) 31,488 (4,366) 29,648 (4,446) 26,394 (3,433) 27,540 (1,961) FR vs. NF (p=0.026)
End of experiment
Body weight (g) 483 (27.4) 496 (8.7) 498 (23.9) 435 (12.7) 455 (21.7) 456 (20.4) FR vs. NF (p<0.001)
Right kidney weight (g) 2.98 (0.13) 3.13 (0.07) 3.14 (0.12) 2.75 (0.10) 2.96 (0.12) 2.7 (0.43) FR vs. NF (p=0.002)
Right kidney / body weight  
(ratio x100)
0.62 (0.02) 0.63 (0.01) 0.63 (0.02) 0.63 (0.03) 0.65 (0.02) 0.59 (0.10)
Data are presented as mean (standard deviation). PND 35: n=5-8 / group; end of experiment n= 4-6/group. 
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 FR animals showed a decreased amount of glomeruli compared with NF animals 
(means: 27861 (SD 3468) vs. 30527 (SD 4096); f=5.492, p=0.026) on day 35 (table 2). 
Treatment (f=0.626, p=0.54) or sex (f=1.938, p=0.17) did not influence the glomerular 
number. However, an interaction was detected between treatment, sex and litter size 
(f=3.922, p=0.031). In contrast to all other groups, average glomerular number was 
comparable between male sham-FR (29,394) and male sham-NF (29,454) animals. 
 Glomerular generation count did not correlate with the total number of glomeruli 
(Pearson’s correlation 0.046) indicating that glomerular generation counts are not a 
suitable predictor for glomerular numbers.
Long-term follow-up (clinical chemistry, NGAL, blood pressure  
and histopathology)
Long-term endpoints were included in the study to investigate any delayed effects of 
the food restriction and drug treatments.
 Clinical biochemistry analysis at 3 months of age (table 3a) showed a higher 
creatinine clearance in FR animals compared with the NF animals (NF 0.77 (SD.0.09) 
ml/min/kg, FR 0.84 (SD 0.1) ml/min/kg; f=4.374, p=0.047). Additionally, an interaction 
was detected between treatment and nest type (f= 6.443, p=0.006) indicating 
Table 2   Renal parameters
Treatment Sham NF Furosemide NF Hydrochlorothiazide NF Sham FR Furosemide FR Hydrochlorothiazide FR Statistical significance
Day 35
Body Weight (g) 94.0 (4.47) 93.5 (9.76) 96.7 (8.78) 72.9 (4.97) 78.3 (9.12) 67.5 (9.55) NF vs. FR p<0.001
M vs. F p=0.005
Right kidney weight (g) 0.67 (0.05) 0.65 (0.05) 0.63 (0.12) 0.54 (0.06) 0.57 (0.08) 0.55 (0.07) FR vs. NF p<0.001
M vs. F p=0.001
Right kidney / body weight  
(ratio x100)
0.71 (0.04) 0.70 (0.05) 0.65 (0.08) 0.74 (0.06) 0.73 (0.09) 0.81 (0.05) FR vs. NF p<0.001
Attributed to HCTZ (p=0.015)
Glomerular generations  
(count)
4.6 (0.66) 4.8 (0.20) 4.7 (0.28) 4.3 (0.59) 4.4 (0.23) 4.6 (0.26) FR vs. NF (p=0.025) only in males
Glomerular Number 29,454 (4,022) 30,640 (4,272) 31,488 (4,366) 29,648 (4,446) 26,394 (3,433) 27,540 (1,961) FR vs. NF (p=0.026)
End of experiment
Body weight (g) 483 (27.4) 496 (8.7) 498 (23.9) 435 (12.7) 455 (21.7) 456 (20.4) FR vs. NF (p<0.001)
Right kidney weight (g) 2.98 (0.13) 3.13 (0.07) 3.14 (0.12) 2.75 (0.10) 2.96 (0.12) 2.7 (0.43) FR vs. NF (p=0.002)
Right kidney / body weight  
(ratio x100)
0.62 (0.02) 0.63 (0.01) 0.63 (0.02) 0.63 (0.03) 0.65 (0.02) 0.59 (0.10)
Data are presented as mean (standard deviation). PND 35: n=5-8 / group; end of experiment n= 4-6/group. 
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plasma magnesium concentration in the HCTZ-treated groups to be lower in NF 
animals (0.74 (0.03) mmol/l) compared with FR animals (0.81 (0.04) mmol/l). No other 
changes were detected.
 At 9 months of age (table 3b) plasma creatinine was lower in FR animals compared 
with the NF animals (NF 27.5 (SD 2.8) μmol/l, FR 25.7 (SD 1.8) μmol/l; f=4.551, p=0.043), 
but this did not result in differences changes in creatinine clearance. No other 
differences were noted.
 NGAL levels (table 4) in urine reduced by 25% between 3 and 6 months of age in 
the long-term follow-up  period. This effect was similar within all the different 
treatment groups. No differences were noted between feeding regimes and/or drug 
treatment.
 Blood pressure was measured monthly from 3 months of age onwards (figure 4) 
and analyzed over the course of the study. Diastolic blood pressure (DBP) and mean 
blood pressure (MBP) declined over the course of the study within NF (f=3.728, 
p=0.018) and FR groups (f=3.161, p=0.027). No effects were noted on systolic blood 
pressure (SBP) or pulse pressure (PP).
 No differences were detected between the treatment groups on the individual 
time points except for the measurement at the age of 9 months. DBP, SBP and MBP 
were all increased in NF animals and PP was slightly reduced compared with FR animals 
(DBP (NF 88.6 (SD 23.0) mmHg, FR 69.1 (SD 11.4) mmHg; f=7.688, p=0.016); SBP 
(NF 128.6 (SD 18.3) mmHg, FR 114.9 (SD.10.7) mmHg; f=4.647, p=0.050); MBP (NF 101.4 
(SD 21.1) mmHg, FR 84.8 (SD 11.4) mmHg; f=5.770, p=0.032); PP (NF 40.3 (SD 6.2) 
mmHg, FR 45.8 (SD 5.8) mmHg; f=5.334, p=0.038)). 
Table 4   NGAL measurements.
Sham-NF Furosemide-NF Hydrochlorothiazide-NF
PND 8 plasma (μg/ml) 0.161 (0.027) 0.187 (0.031) 0.155 (0.028)
3-months urine (μg/ml) 0.699 (0.152) 0.628 (0.118) 0.655 (0.121)
6-months urine (μg/ml) 0.507 (0.114) 0.467 (0.031) 0.480 (0.053)
Sham-FR Furosemide-FR Hydrochlorothiazide-FR
PND 8 plasma (μg/ml) 0.155 (0.030) 0.152 (0.035) 0.140 (0.020)
3-months urine (μg/ml) 0.633 (0.116) 0.652 (0.139) 0.648 (0.124)
6-months urine (μg/ml) 0.492 (0.100) 0.502 (0.059) 0.481 (0.129)
Data are presented as mean (standard deviation) and statistical analysis was performed with univariate 
analysis with Tukey post-hoc. No statistically significant findings were noted. n=6-8 at PND 8; n= 4-6 at 
3- and 6-months.
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 Kidney weight at the end of the experiment (table 2) was significantly lower in FR 
animals compared with NF animals (mean 2.80 (SD.0.27) g vs. 3.08 (SD.0.12) g; f=11.440, 
p=0.002). After correction for body weight, no difference could be noted. Neither 
drug-related effects nor abnormal findings were observed on tubular and glomerular 
morphology in the kidney after microscopic evaluation.
Figure 4   Blood pressure measurements in rats over the study period showing 
diastolic blood pressure (A), systolic blood pressure (B), mean blood 
pressure (C) and pulse pressure (D) 
Means ± SD of normal food (NF) animals are plotted with dots and food restricted (FR) with triangles. 
Sham-dosed groups are indicated with a solid line, furosemide groups with a striped line and hydrochloro-
thiazide groups with a dotted line. n=4-6 /group, with exception of 9-month time point where n=2-4/group. 
Univariate analysis with Tukey post-hoc test was performed for all individual time points. * NF vs. FR p≤0.05). 
A multivariate analysis for repeated measurements was performed to investigate the effect of study time 
and showed a decrease of diastolic and mean blood pressure within nest type over course of the study period 
(p=0.018).
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Discussion
The goal of this study was to determine whether the clinical neonatal dose of 
furosemide and hydrochlorothiazide affected kidney development and function on a 
short and/or long-term basis.
 Overall, we concluded that these drugs do not impact kidney development. 
Furosemide was able to induce slight changes in Fgf7, Casr and Gdnf gene expression 
levels. However, these changes were less than two-fold and therefore the biological 
relevance of these changes with respect to a disturbed organ development is 
questionable. Indeed, no alterations in any of the structural renal parameters were 
noted (table 2). In addition, no abnormalities in any of the renal functions tested were 
observed. A renal concentration effect, as was noted after prenatal dosing of 
furosemide (10), could not be found within our experimental conditions. It may 
therefore be concluded that the renal phenotype after prenatal and postnatal 
furosemide exposure is different. However, more plausibly we did not find this effect 
because we administered more clinically relevant dose levels which are significantly 
lower compared with the dose levels used in that study (i.e. 75 mg/kg). 
 Similar to furosemide, treatment with hydrochlorothiazide did not change any 
parameters of kidney development. No alteration in Ncc expression level was noted, 
which was contrary to our expectations because hydrochlorothiazide blocks this thia-
zide-sensitive Na+Cl- cotransporter and it has been shown to affect gene expression 
(15). The lack of effect could be due to either the slightly lower dose levels used in this 
study, the different route of administration or the time between the last dose 
administration and sampling. Similarly, we did not see any response on Nkcc2 after 
furosemide treatment. 
 Our second hypothesis stated that a multi-hit on the kidney may modulate 
developmental pathways and that extrauterine growth retardation would modify 
drug toxicity. Based on our results, such a modulating effect of the combination of 
growth restriction with diuretic treatment could not be demonstrated. The inter - 
actions noted between treatment and nest type were limited to hydrochlorothiazide 
and FR leading to a slightly higher kidney weight at day 35. No interactions were 
detected between furosemide and extrauterine growth retardation.
 Our model was successful in obtaining growth retardation evidenced by the 
changes in body weight observed throughout the study. Additionally, we confirmed 
that extrauterine growth retardation has an impact on glomerular numbers (12), 
which were decreased by 11% after food restriction. Of note was the absence of any 
difference between the male sham-FR and sham-NF animals. This may indicate that 
the decrease noted in the FR group was more drug driven, but this was not confirmed 
in our analysis. In other studies, the effect between NF and FR was more pronounced 
also substantiated with the higher average total count of glomerular numbers, which 
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was relatively low in this study (16)(Bueters et al. unpublished). Therefore, we believe 
that the observation of low glomerular numbers in the sham-NF group was probably 
related to chance. However a more drug driven effect could be explained as well. 
Although the changes that were observed were small and we question the biological 
relevance, furosemide did down-regulate the gene expression of Gdnf and Fgf7, which 
both are considered important for ureteric bud development and nephron formation 
(17-19). This observation in combination with the added stressor of food restriction 
could lead to a state where nephrogenesis is disturbed. Such a link is less clear for hy-
drochlorothiazide. Main effect on the kidney described for hydrochlorothiazide is 
activation of the renin angiotensis system (RAS), but no changes in our mRNA targets 
of the RAS after either food restriction or hydrochlorothiazide treatment were seen. 
Woods et al showed that maternal protein restriction in rats resulted in decreased 
glomerular numbers but also in a suppression of the RAS (20). Other studies have 
been performed investigating the relations between reduced nephron endowment 
and the RAS in sheep, but are not in agreement whether there is a real role for the RAS 
system or not (21,22). At the moment the relation between the RAS and nephron 
endowment is not clear.
 The changes in glomerular number did not correlate with the number of 
glomerular generations, which were slightly reduced in male FR vs. NF animals. Again 
changes in mRNA expression of two targets, Fgf7 and Grfa1 with a role in kidney 
development were detected (17,18,23). The observed changes were very small and the 
impact on organogenesis was questionable. However, it may be that the effects of 
small reductions in several pathways cumulate into a significant reduction in the final 
common pathway, i.e. nephron formation.
 Brenner et al. described in the hyperfiltration hypothesis that glomerular damage 
leads to hyperfiltration, and that the first sign of kidney damage is mostly noted by an 
increase in creatinine clearance caused by hyperfiltration (24) instead of the classical 
creatinine clearance decrease which is more evident in more serious kidney damage 
(25). In this study this was evidenced by a minimally higher creatinine clearance in FR 
at 3 months and the lower creatinine plasma levels at 9 months. Although these 
findings are in line with our hypothesis, the observed changes are very small and 
without any confirmed histopathological kidney abnormalities at the end of the 
experiment it is difficult to determine whether these were related to treatment.
 In the same hypothesis, Brenner described that hyperfiltration would lead 
eventually to a systemic increase in blood pressure (24). Indeed, it has been described 
that intrauterine growth retardation leads to a reduced glomerular number (26) and 
an increase in blood pressure (27). However there are also studies performed in which 
this phenomenon was not observed (28). We could not detect any differences in blood 
pressure variables between our groups. This might be because the effects noted in 
the study of Schreuder et al. were quite small in absolute values and a larger variation 
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was noted with our experimental set-up (27). Although we detected an increase in the 
MBP of the NF groups at the 9-month time point, we believe this may be caused by a 
bias in the measurements because we were not able to record signals of approximately 
half of the animals on that time point. This was probably related to the age of the 
animals, which resulted in a suboptimal tail blood flow.
 There are some limitations to the experimental study design. Although this 
experiment tried to simulate a multi-hit of both drug use and extrauterine growth 
retardation, these can actually only approach the real situation in the neonatal care 
units. By example there is no full control on the nutrients that every rat food restricted 
pup received. Although the mothers are well fed with a balanced diet, it is unknown 
whether the reduced food intake of the pups might have led to an imbalance of 
nutrient intake and whether this is similar to the clinical practice. Additionally, our rat 
pups were healthy pups in contrary to the patients, which are likely suffering from 
chronic lung disease and are therefore fluid restricted. This physiological condition 
could potentially modify the adverse effects on nephrogenesis as well and should be 
investigated separately in fluid restriction models. Because of the multi-factorial 
situation in the clinic, our results are most likely an underestimation of the true effect.
 Another limitation was the use of a non-invasive blood pressure technique (tail 
cuff) instead of a golden standard technique such as telemetry. Another option to 
measure blood pressure is the transducer method, which is considered a terminal 
experiment. For a long term follow-up study this would have resulted in adding many 
animals to the study. All methods have their advantages and disadvantages (29). 
Although telemetry has a very sensitive read-out it does require the rats to undergo 
surgery and requires an expensive set-up. Due to extensive drop-out in a previous 
telemetry study, we decided to use the tail cuff.
 In conclusion, furosemide and hydrochlorothiazide did not influence the 
development or function of the kidneys when administered in a clinically relevant 
dose to young rat pups at a stage of ongoing nephrogenesis. Growth retardation 
based on the increase of litter size led to a reduction in glomerular numbers but had 
no modifying effect on furosemide or hydrochlorothiazide treatment. In the future, 
experiments should be performed in which the neonatal environment is even more 
precisely simulated preferably in a disease model to investigate other potential 
synergies. In regard of neonatal safety, care should be taken to avoid growth 
retardation as best as possible.
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A  Methodological considerations
To be able to answer the questions stated in chapter 1 we assessed different endpoints 
in kidney development. These endpoints needed to relate to either short- or long term 
effects on kidney morphology or function. Additionally a method to model for extra - 
uterine growth restriction was included. A more thorough rationale for our considered 
methodology is written in the following paragraphs.
A.1 Evaluation of short-term effects on early kidney development
A.1.1 Considerations for the selection of an ex-vivo model
We used embryo’s from CD-1 mice to investigate early effects on direct pathways of 
nephrogenesis in our studies. The rudimental kidneys (metanephroi) were explanted 
13 days after gestation and cultured on filters in DMEM supplemented with insulin, 
transferrin and sodium selenite. In the field of developmental kidney biology most 
models used are varieties of this particular model. Depending on the research question 
there are subtle changes in the models. For instance the time point of explantation 
may be slightly different (1,2). Other changes are different consistencies of culture 
medium such as adding fecal bovine serum, or the use of different matrices, such as 
gels to better preserve the 3d structure of the rudimentary organ (3,4). Generally, the 
models used are quite similar and most are established in the mouse, however there 
are reports of successfully applying similar methodology in rats (5-7). 
 Apart from this “classic” ex vivo approach, genetic modification of mice is used to 
improve the read-out of these models by expressing fluorescent proteins in specific 
morphological structures of the kidney. A good example of such a model is the HoxB7 
modified mouse developed in the lab of Frank Costantini (8). Other models rely on 
fluorescent expression after crossing animals using lox-cre techniques to specifically 
express a fluorescent protein in a renal specific structure (9,10). Using these mice, 
whole mount staining procedures for complex structures are no longer necessary and 
more standardized results may be obtained. We did not have access to these models, 
therefore we stained the embryo’s via a calbindin D28k whole mount staining method, 
which had been reported to provide good results in immunofluorescent ureteric bud 
visualisation (11).
A.1.2 Nephrogenesis endpoints in the ex vivo model
The ex vivo experiments were performed in the budding phase of development, an 
early phase of nephrogenesis. In this phase the ureteric bud (part of the ureteric tract) 
starts to branch due to reciprocal interactions with the metanephrogenic mesenchyme 
(12). Many of the genes of the molecular pathways involved in this process have been 
identified in the last decade and have been summarized in a large project called the 
‘GenitoUrinary Development Molecular Anatomy Project’ (GUDMAP, www.gudmap.
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org) which analyzed expression patterns at different stages of development (13). Still 
the function and interaction of all the identified targets has not yet been elucidated. 
We selected five relatively well-described targets, which were shown to be important 
in the general pathway of developing nephrons. These targets were Wt1, Sox9, Gdnf, 
Bmp7 and Fgf8. Additionally genes for the prostaglandin synthetase 1 and 2 were 
added in the NSAIDs experiments as their respective proteins are targets of these 
drugs. More detailed roles of the investigated genes are described in table 1 below.
Table 1  Selected targets and their role in kidney function/development
Gene 
symbol
Common name Role
Actb Beta actin Cytoskeleton protein, used as high abundance 
reference gene.
Hmbs Hydroxymethylbilane synthase Heme production enzyme, used as medium 
abundance reference gene.
Wt1 Wilms Tumor 1 Essential for mesenchyme survival. (14,15)
Sox9 Sex determining region Y-Box-9 Controls epithelial branching by activating  
Ret. (16,17)
Gdnf Glial cell line-derived  
neurotrophic factor
Important player in ureteric bud differentiation 
processes. Loss results in agenesis. (18-22)
Bmp7 Bone morphogenetic protein 7 Inhibits and induces ureteric bud growth and 
maintains nephrogenic progenitors. (23-25)
Fgf8 Fibroblast growth factor 8 Maintains nephrogenic progenitors. (26-27)
Ptgs1 Prostaglandine synthetase 1 Enzyme converts arachidonate to prostaglandin 
H2 and is a target of NSAIDs.
Ptgs2 Prostaglandine synthetase 2 Enzyme converts arachidonate to prostaglandin 
H2 and is a target of NSAIDs.
In addition to these molecular markers morphology-based endpoints were used. 
Multiple types of immunostainings have been described in the ex-vivo models to 
identify branching (calbindin D28k, keratin) or ureteric buds (lectin, peanut agglutinin, 
e-cadherin). Other methods rely on morphometric characteristics such as surface 
area or tissue circumference. We started out to use metanephron surface area 
and Calbindin D28k immunohistochemistry as morphology markers for kidney 
development as had been used by the research groups of Woolf and Davies (2,28). 
However after the initial experiments, metanephron surface area was considered to 
be an endpoint of low value regarding the prediction of kidney development as is 
demonstrated in chapter 4 of this thesis. It can be used however to partially standardize 
for slightly different individual stages of growth and development at the time of 
explantation as demonstrated in the same chapter. Therefore we used the combination 
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of ureteric bud count (using surface area at explantation for correction of 
developmental stage) and mRNA target expression to identify drug effects on early 
kidney development. Protein expression analysis was considered, but abandoned due 
to the large amount of embryo’s required to obtain a sufficient sample size for analysis.
A.1.3 Rationale for dose selection
Doses selected for the ex vivo studies were calculated based on the clinical pediatric 
dose and were corrected for the drug plasma binding and volume of distribution as 
determined from the literature (29-50) to determine an appropriate tissue target 
dose. In addition, concentrations at a factor of 10 above and below were studied to 
account for calculation uncertainties and to investigate a potential dose response 
relationship.
A.2  Evaluation of short and long term effects in an in vivo model 
including extrauterine growth retardation 
A.2.1 Selection of an extrauterine growth restriction model 
Premature infants are prone to suffer from extra uterine growth restriction (EUGR). 
Literature reports frequencies up to 67% for infants born ≤ 32 weeks (51,52). A supply 
of nutrients in the right amount and consistency should be delivered to the newborn 
infant to mimic normal development occurring during the last trimester in utero. 
Although there are charts and literature available for clinicians to monitor a neonate’s 
growth and identify the onset of EUGR, providing the optimal balance of nutrients 
remains a challenge (53-56). Therefore, despite careful monitoring of growth velocity, 
median weight of neonates at hospital discharge is often lower compared with the 
birth weight of term neonates of the same postmenstrual age (57). 
 The rodent species was chosen because kidney development, in contrary to 
human kidney development, is not yet completed at birth and continues up to 8-10 
days after birth. This provides a window to dose the pups in a stage of ongoing 
nephrogenesis. Wistar rats were chosen because they are a strain commonly used in 
general toxicology work (which meant the ample availability of reference data) and by 
using an outbred strain, we may avoid characterizing a specific genotype only, by 
accident. More importantly, most EUGR models are established in the rat.
 The method of inducing extrauterine growth retardation was selected out of 
multiple established models for ‘malnourishment’ of pups. Although all models lead 
to a similar phenotype, they are based on different mechanisms. Most models rely on 
low protein/low caloric feeding regime’s for the maternal animals before or during 
lactation (58-60). Other models rely on adaptation of lactation to litter size. In this 
model a decrease of litter size with the right timing causes a reduction of mother milk 
production, which eventually leads to food restriction of the animals (61). We chose a 
model in which litter size enlargement leads to food restriction of all pups and induces 
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a general lower consumption of total energy. This approach avoids to trigger only 
specific pathways by creating an imbalance in the diet consistency. One may argue 
that survival of the fittest may occur in such a situation. The variation on the average 
litter body weight between normal food and food restricted animals was similar, 
however, and no increased mortality was observed in our studies performed in 
chapters 5, 7 and 8. Additionally this specific extrauterine growth retardation model 
specifically was known to reduce nephron numbers (59,62), which enabled this model 
for identifying additive or synergistic interactions between drug treatment and EUGR. 
A.2.2 Short term endpoints of in vivo kidney development
A.2.2.1 Important mRNA targets
A panel of mRNA targets was selected to investigate direct effects of early postnatal 
treatment on different parts of the kidney (table 2). It included targets in the 
developmental pathway, transporters in different tubular sections and major players 
of the renin-angiotensin system. Although some targets may play a larger role in early 
kidney development we believe that the most important targets were captured in this 
list.
A.2.2.2 General parameters of kidney growth & development
To get a general idea of kidney development we examined kidney weight relative to 
body weight, although we have demonstrated in Chapter 3 that (at least in adult 
humans) kidney size is a poor predictor for nephron count. Nevertheless, differences 
in size observed shortly after treatment can be indicative of a disturbed general 
growth process. 
 Besides morphometric parameters such as kidney weight, we investigated the 
balance between proliferating and apoptotic cells as organogenesis can be generally 
described in cycles of controlled proliferation and apoptosis. Stainings for Ki67 or 
caspase 3 were used to investigate these respective processes. Ki67 is a very general 
proliferating marker and stains all cells that are not in G0 phase (91). Caspase 3 stains 
all cells that are apoptotic, but does not indicate all intermediate phases of apoptosis. 
An alternative staining for the caspase 3 could have been a TUNEL staining, which 
detects DNA fragmentation. Both staining determines the same phase, however, and 
the overall outcome should therefore be similar. (92,93). 
A.2.2.3 Glomerular numbers and generations
To identify glomerular numbers we used the current gold standard methodology 
being stereology with the physical fractionator/disector principle. This technique 
replaced the old acid maceration technique and has proven to be an invaluable tool in 
kidney research (94-97). Paraffin was used to embed the kidneys and glomerular 
count was determined. Morphometric parameters such as volume and density of 
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Table 2   Selected mRNA targets for in vivo studies and their role in kidney function/
development
Gene 
symbol
Common name role
Reference genes
Actb Beta actin Cytoskeleton protein, used as high abundant 
reference transcript.
Hmbs Hydroxymethylbilane synthase Heme production enzyme, used as medium 
abundant reference transcript.
Developmental pathway genes
Bmp7 Bone morphogenetic protein 7 Inhibits and induces ureteric bud growth and 
maintains nephrogenic progenitors (23-25).
Fgf7 Fibroblast growth factor 7 Promotes ureteric bud growth and branching 
formation (63).
Gdnf Glial cell line-derived neurotrophic 
factor
Important player in ureteric bud differentiation 
processes. Loss results in agenesis (18-22).
Grf1a Gdnf receptor alpha 1 Receptor for Ggnf in Ret signaling  Loss results 
in agenesis (64).
Lim Lim homeobox 1 Involved in multiple phases of kidney 
development from the intermediate mesoderm 
up to the mature glomerulus (65). 
Hgf Hepatocyte growth factor Involved in branching morphogenesis and 
metanephric growth (66).
Ret Ret proto oncogene Receptor for Gdnf-family ligands. Loss results in 
agenesis (67,68).
Sox9 Sex determining region Y-Box-9 Controls epithelial branching by activating Ret 
(16,17).
Wnt4 Wingless-type MMTV integration 
site family, member 4
Regulates nephron progression to S-shaped 
body state (69,70).
Wt1 Wilms Tumor 1 Essential for mesenchyme survival (14,15).
Nphs1 Nephrin Important in development and function of the 
glomerular filtration barrier (71,72).
Nphs2 Podocin Important for correct slit diaphragm formation. 
knockout results proteinuria during the 
antenatal period and renal failure shortly after 
birth (73).
Transporters and water channels
ENaC Epithelial sodium channel Located in the cortical- and outer medullary 
collecting duct  and plays a major role in Na+ K+ 
homeostasis (74).
Nhe3 Sodium hydrogen exchanger 3 Localized to the proximal tubule, thin and thick 
loop of Henle and maintains sodium balance. 
Detected from late stages of S-shaped body (75).
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glomeruli were not obtained based on the observed shrinkage of the tissue. Paraffin 
embedding is known to cause deformation effects, however the precise nature of the 
deformation determines if the Cavalieri principle is still valid and unbiased observations 
may be made (98). Additionally we investigated the glomerular generations to 
determine whether a reduction in glomerular number was caused by a total arrest of 
Table 2   Continued
Gene 
symbol
Common name role
Transporters and water channels
Nhe8 Sodium hydrogen exchanger 8 Expressed in the proximal tubule where it 
contibutes to apical membrane transport to 
maintain sodium balance 76.
Ncc Sodium-chloride symporter Reabsorbs sodium and cloride from the tubular 
lumen of the distal convoluted tubule and 
important in maintaining blood pressure (77,78). 
Also target of hydrochlorothiazide.
Nkcc2 Na+-K+-Cl- cotransporter Reabsorbs sodium and potassium in the thick 
ascending limb and is important in maintaining 
blood pressure (78). Also target of furosemide.
Oat1 Organic anion transporter 1 Basolateral organic anion uptake transporter in 
the proximal tubule which is inhibited by most 
of our tested drugs (79-81).
Aqp1 Aquaporin 1 Present in both apical and basolateral 
membranes and most prominent in the 
proximal tubule (82) and functions as a water 
reabsorption channel (83). 
Aqp4 Aquaporin 4 Basolateral waterchannel localized in the inner 
medullary collecting duct (84) and has a role in 
urine concentration.
Regulatory proteins
Renin Renin Important protein for renal vasculature 
formation and regulation of fluid homeostasis 
(85).
Agtr1a Angiotensin receptor type 1 Receptor for angiotensin 1 involved in postnatal 
vasculature development (86,87).
Agtr2 Angiotensin receptor 2 Receptor for angiotensin 2: Plays a 
counterregulatory role to the function of 
angiotensin 1 in renal development (88,89). 
Casr Calcium sensing receptor Present throughout the nephron either 
luminal or basolateral and plays roles in 
Calcium/inorganic phosphate homeostasis, 
cation transport, urinary acidification and 
concentration, and renin release (90).
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glomerular growth or whether the effect was diffuse and individual glomeruli are 
affected. The direct method of medullary ray counting as described by Hinchlife was 
used (99).
A.2.3 long-term endpoints of in vivo kidney development
A.2.3.1 Clinical biomarkers
A basic panel of established clinical markers for kidney damage or deteriorated kidney 
function (blood: sodium, potassium, magnesium, phosphate, urea and creatinine 
concentrations; urine: urea and creatinine concentrations, volume and osmolality; 
calculated creatinine and urea clearances) was included in our studies. Additionally we 
included NGAL to serve as a biomarker for kidney damage: Higher levels of NGAL in the 
urine could indicate proximal tubular damage (100), damage to the thick ascending 
limb and/or the collecting ducts (101). Additionally NGAL was found higher in patients 
with chronic kidney disease (102). Therefore it can be used as a marker for both acute 
as well as chronic kidney damage.
A.2.3.2 Blood pressure measurements
We selected radio- telemetry in free moving animals because this is the most accurate 
and animal friendly way of obtaining blood pressure as recommended by the 
Professional and Public Education of the American Heart Association Council (103). Its 
greatest advantage is that animals are in an awake state, the influence of circadian 
rhythms can be detected, animals can be followed-up for a long period of time and 
overall there will be a very low variation due to the large amount of data points 
collected. The biggest disadvantage is its high operational cost and relatively low 
throughput. We encountered difficulties maintaining stable and physiological 
meaningful signal intensities in our studies and switched to a non-invasive tail vein 
volume pressure measurement system to perform the study described in chapter 8. 
This method has some disadvantages compared with the radio telemetry method 
because it required the rats to be restrained and warmed for a certain period of time 
introducing stress as another variable and more variation was introduced as a result. 
Nonetheless the method is considered to be appropriate for identifying larger signal 
differences between groups (103).
A.2.3.3 Histopathological examination
At the end of the study period microscopic examination was performed to investigate 
the kidney for any persistent tubular or glomerular damage that may have occurred as 
a result of the interventions. Special attention was given to focal glomerular sclerosis, 
a condition one may expect based upon the hyperfiltration hypothesis by Brenner 
(104). To be able to detect this glomerular damage, Periodic Acid Schiffer staining was 
performed in addition to the classical heamatoxyline eosine staining. All slides were 
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evaluated by an experienced renal pathologist, who was blinded to all treatment 
groups except the non-food restricted control.
A.2.4. Rationale for dose selection
The dose levels and the treatment interval were chosen to be similar to clinical practice. 
Because the drugs are administered parentally in the clinic, we selected the intraperi-
toneal route to circumvent first-pass metabolism and approach the clinical route of 
administration. From the range of dose levels administered in neonates we always 
selected the highest dose level without correction for allometric scaling. We made 
this choice to enable easier comparison with other studies in the field. If this correction 
is applied we have a slight overestimation of the human neonatal dose. For gentamicin 
we studied the actual plasma levels in our rat pups and concluded that these were 
more or less within the same range as human neonates (Chapter 5). This may however 
not be the case for all the drugs we have tested. Gentamicin does not have major 
metabolites and is excreted mostly unchanged as is hydrochlorothiazide. On the other 
hand NSAIDs and furosemide are metabolized which could result in a larger species 
difference. However it has been shown that the metabolic pathways are rather similar 
between rats and humans for these compounds (105-107). More importantly it is 
known that neonates of both species have a different and slower metabolism 
compared with the respective adults in whom kinetic data was generated (108-110). 
Therefore without having measured exposure levels in all our studies, this is an 
uncertainty and limitation of our research. 
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B  General discussion 
In the introduction of this thesis we formulated some specific questions we aimed to 
answer by the work performed in this thesis. In the paragraphs below I will elaborate 
on our findings to each of these questions.
B.1  Are currently used kidney morphometric parameters 
such as size or surface area good predictors for the state of  
kidney development?
In chapter 3 and 4 we investigated kidney morphometric parameters such as size or 
surface area and their prediction for the state of kidney development in humans and 
mice respectively. Both studies indicated that these kind of measurements are 
generally poor predictors for the actual state of kidney development as determined by 
glomerular counting or ureteric bud branching. Nonetheless metanephron surface 
area at the time of kidney explantation can partially predict the amount of bud 
formation after 24 hours, as we discussed in chapter 4 and can therefore be used as a 
marker for the state of development at the time of explantation. 
 The field of imaging is advancing rapidly and intravital imaging of the kidney by 
means of multiphoton microscopy is slowly becoming a standard (111). Although these 
are large improvements for researchers, this does not directly translate to the clinic. 
There, the advances in magnetic resonance imaging resolution are more closely 
followed. Bennet et al. were able to visualize glomeruli within a 10% range from 
stereological assessment in the rat kidney in a magnetic field of 11.7 Tesla (112). It is 
definitely possible that in the future such methods may find an application in the 
clinic. However until that moment no easy way of identifying structural kidney 
developmental damage in human individuals exists.
B.2  What is the impact of drug treatment on early- and late kidney 
development? How does such an impact affect the function  
of the kidney in later life? Are there alternatives for drugs used  
in the current first-line treatment?
One of the main aims of this thesis was to study clinical dose levels of frequently used 
drugs and identify whether these cause subtle kidney toxicity that would not have 
been noted in regulatory (general) toxicity studies, but may result in long term 
sequelae. Drugs from three different classes (antibiotics, NSAIDs and diuretics) were 
studied and the results and implications are described in the following paragraphs.
B.2.1 Impact of antibiotics 
We showed that the aminoglycoside gentamicin did not affect the rudimentary 
kidney development in the mouse (Chapter 4). This was an unexpected finding 
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because Gilbert et al showed effects of gentamicin in the past, be it at a higher dose 
level (5,6). The subsequent in vivo study we performed at a later stage of development 
in chapter 5 did also not identify any effect of gentamicin on kidney development, but 
was in line with the findings of other researchers in the field (113, 114). Overall no 
impact of gentamicin on kidney development was noted at clinically relevant dose 
levels. 
 The cephalosporin ceftazidime showed more potential for disturbing normal 
kidney development. Most cephalosporins are less associated with kidney toxicity 
compared with the aminoglycoside drug class, but can have effects on the proximal 
tubule (115). However the cephalosporin ceftriaxone was reported to reduce the 
number of glomeruli in an ex vivo model of early kidney development (116). Our 
experiments described in chapter 4 showed down-regulation in expression of Fgf8 
and Gdnf, two important genes in nephrogenesis, and reduced ureteric bud formation 
in metanephroi. Fgf8 is important in cell survival of renal progenitor cells, which are an 
important source of Gdnf production (26,27). Gdnf is considered the major protein 
involved in ureteric outbud growth and loss results in agenesis. However even a 
decrease was reported to impact glomerulogenesis (21). It may be questioned whether 
a general apoptosis process was ongoing, but unchanged expression levels in Bmp7, 
Caspase 3 and Caspase 9 mRNA targets did not indicate general progenitor cell loss 
or large apoptotic insults (24,117). Although these results were obtained in a 
developmental phase of less importance for neonatal treatment, it is important to 
consider when prescribing this drug to pregnant women. Ceftazidime can readily pass 
the placenta barrier and the dose levels administered to the metanephroi cultures are 
comparable with adult human dose levels (118). These findings alone do not indicate 
that the pregnant population is at risk. For once there can be species dependency as 
we have used mouse embryos. Secondly our ex vivo model is a static model and does 
not account for drug elimination. Therefore the actual intracellular concentration in 
our model may be much higher than would be the case in an in vivo situation, where 
the equilibrium might be completely different. This reasoning is supported by the data 
provided in the FDA label for this compound. A 40-fold of the human dose was dosed 
to pregnant rats without observed abnormalities in the pups. However no pregnant 
women were included in the clinical trials. 
 The ceftazidime findings of these ex vivo studies were not confirmed in our in vivo 
study (Chapter 5) where Gdnf expression was not affected and no direct effect was 
noted on glomerulogenesis in the kidney. The only effect of ceftazidime noted was a 
slight down-regulation of renin expression, however it is doubted whether this has 
implications for development.  
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We selected ceftazidime as a possible alternative treatment for gentamicin, however 
the results obtained in chapter 4 and 5 showed that the potential of disrupting 
nephrogenesis and kidney development is higher for ceftazidime compared with 
gentamicin. Another broad spectrum alternative meropenem was only tested in our 
ex vivo model and did not show any effects on early nephrogenesis. The effect of 
meropenem on kidney development in vivo has yet to be determined. Putting all these 
results into perspective it shows that the acute toxicity profile of gentamicin is of 
more concern in the clinic, compared with the concern of disturbing organ development 
and based on our data there is no direct reason to change existing treatment protocols.
B.2.2 Impact of non-steroidal anti-inflammatory drugs
At present, there is an ongoing debate whether indomethacin or ibuprofen is safer to 
use as treatment for patent ductus arteriosus. There are reports of toxicity for both 
compounds and multiple studies investigated or compared the safety profiles 
resulting in either a similar profile or a slightly less favorable profile for indomethacin 
(119-126). All these papers studied acute endpoints (spontaneous intestinal perforation, 
necrotizing enterocolitis, renal blood flow changes or dysfunction, death), but less is 
known on subtle changes which may influence kidney programming. In the ex-vivo 
studies described in chapter 6 we showed that both compounds do not seem to 
affect the ureteric budding process and did not find a potential for impairing 
nephrogenesis. We anticipated effects because the cyclo oxygenase systems, 
especially COX-2, are regarded important in kidney development (127-131). However the 
time point of our experiment may have been too early to evaluate a full effect of both 
NSAID compounds as the most prominent role of the cyclo oxygenase system may be 
found at the vascular developmental phase, which starts around embryonic day 16 
(130). 
 In the in vivo study, described in chapter 7, ibuprofen, but not indomethacin, 
showed some slight potential to reduce glomerular numbers. These findings were 
different compared with the earlier work performed by Kent et al, who did not observe 
differences in glomerular numbers (114), but detected glomerular alterations in the 
form of extensive foot process effacement for both NSAIDs after a 3 or 5 day neonatal 
treatment period (132). A more recent publication of this group confirmed the absense 
of findings on glomerular numbers 30 days after dosing, but did show a decrease in 
glomerular numbers 6 months after a 3-5 day postnatal indomethacin, but not 
ibuprofen treatment (133). 
 Although our study showed a slight decrease on glomerular numbers after 
ibuprofen treatment, no delayed effects were noted in other measured parameters, 
but for a slight tendency to an increased NGAL concentration 9 months after 
treatment.
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The current data on effects of ibuprofen and indomethacin regarding to kidney 
development remain sparse and are not in full agreement. There are not very large 
differences between treatment protocols of different study groups, however all 
changes together may tip the balance from coping to toxicity for either compound. 
More research is therefore required to provide a definite answer whether these two 
drugs have an effect on kidney development at low clinical dose levels. 
B.2.3 Impact of diuretics
Both our performed ex vivo (Chapter 6) and in vivo (Chapter 8) studies did not 
demonstrate an effect of furosemide or hydrochlorothiazide dosed in a clinical range 
on either early or late stage kidney development. These results were somewhat 
expected because the described effects regarding furosemide toxicity in human 
neonates are few (134). Malie et al, however identified furosemide to affect kidney 
development after prenatal exposure, but the dose levels used in their experiments 
were much higher compared with the clinically used dose levels (135,136). Concerning 
hydrochlorothiazide, there could have been an effect on the renin angiotensin system 
which is debated (137-139), but our results do not support such a link. 
B.3  Does an additional stressor in the form of extrauterine  
growth retardation indeed modulate drug toxicity according to  
the two-hit hypothesis?
We confirmed the presence of extra-uterine growth retardation in our in vivo studies, 
described in chapters 5, 7, and 8 based on the significantly decreased body weight of 
pups in the enlarged litters. Additionally we showed that the intervention caused a 7.5 
to 20% reduction of glomeruli in a single right kidney. This was lower than expected 
based on the earlier publication of Schreuder et al., which showed a 25% reduction 
(62). The explanation for this different observation may be related to the kidney 
sampled. In our studies the right kidney was examined contrary to the left kidney in 
the study of Schreuder et al. There are indications that the left kidney is more prone to 
abnormalities compared with the right kidney (140,141). Therefore glomerular numbers 
may be affected differently between the kidneys as well.
 Interestingly we did not see any clear long term sequelae of these reductions in 
glomeruli in the food restricted group. This could have remained undetected because 
our follow-up time was too short. According to Sengupta et al. at the time of necropsy 
our rats were still relatively young compared with human years (approximately 25 
years old) (142). At a comparable age in humans, effects on human blood pressure 
after intrauterine growth restriction were substantial from a clinically point of view, 
but small in the absolute sense (143). Therefore our used measuring methods may not 
have had enough discriminative power to detect changes at this stage.
153
DISCUSSION AND FUTURE PERSPECTIVES
9
A second explanation may be that the glomerular reduction was too small to lead to 
significant hyper filtration or still has overcapacity for its normal function. This means 
there is a threshold to be exceeded before showing negative effects. This supports the 
multi-hit toxicity theory in chronic kidney disease, where the adult kidney needs 
multiple, prolonged, or toxic stressors in combination with a congenital defect before 
the function of the organ is reduced to a state as noted in renal disease. Significant 
effects in renal function may therefore only be apparent when challenged in 
adulthood.
 We showed that postnatal food restriction has a direct structural effect on kidney 
development, and we hypothesized that it may have synergistic effects if combined 
with other interventions. However we could not find evidence that this occurred. 
Glomerular numbers were not substantially more affected in any of the groups 
combining drug treatment and food restriction and therefore the combination did not 
lead to further developmental impairment. 
 Although we did not find any direct evidence for additive effects or synergism 
between food restriction and drug treatment in our studies, the multi-hit hypothesis 
for congenital defects remains plausible. Initial work of our group identified a 20% 
decrease after gentamicin treatment in combination with food restriction (not 
published). These rat pups were suffering from an unintentional additional stressor in 
the form of heat stress (approximately 30-35 °C) due to an inadequately performing 
climate control system. However the combination of all these stressors also resulted 
in more than average mortality among the pups and resulted in a poorly controlled 
study, hence this was not published. However when we repeated this study, under 
standard laboratory conditions (without heat stress) in chapter 5, the gentamicin 
effects could not be reproduced. Whether the reason was the absence of heat stress 
or a better standardized study remains to be determined. A separate study will be 
needed to confirm this, but it suggests that the interaction of the specific 
environmental circumstances, the specific stressor type and the total amount of 
stressors may be important for the final congenital effect on glomerulogenesis.
B.4 Translation of the research outcomes to the clinic
The findings of ceftazidime in our ex vivo studies raises cause for concern for the use 
of ceftazidime in pregnant women. Currently no warning label is present for pregnancy 
as these findings were not identified in the regulatory toxicity studies. Nonetheless 
the current strategy for ceftazidime usage in pregnant women is to avoid these drugs 
unless necessary, which seems a sufficient precaution considering the data available. 
We did not observe clear effects of drugs affecting kidney development in neonatal 
rats with or without food restriction, this does not mean that there is no cause for 
concern. We only studied one additional stressor, which is a simplification of the 
actual situation in the neonatal care unit, where the number of stressors is ample. 
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Each of these stressors may have a different interaction with the other stressors and 
therefore it is important that these interactions are investigated. 
Additionally our experiments were performed in neonatal, but healthy rats. This 
situation is again quite different from the clinical practice, where the neonate suffers 
from an actual disease condition for which he requires the specific drug treatment. It 
is difficult to predict whether a neonate in a disease state will react similarly to the 
additional stressors compared with a healthy neonate.
 Food restriction in rats was identified in three separate experiments to cause a 
decrease in glomeruli compared with normally fed rats. Although clinicians are already 
well aware that extra uterine growth retardation should be limited as much as 
possible, the findings in this thesis show once again the importance of doing so. This 
is not an easy task because the required drug treatments often have a negative effect 
on the nutrient status. By example NSAID’s may cause gastrointestinal side effects. 
 There remains no easy way in determining whether kidney development in 
children is disturbed. Morphometric data such as size or surface area do not predict 
whether structural loss of nephrons has occurred. But even if we could determine the 
amount of nephrons, the reported large intra-human variation renders it difficult to 
evaluate the result of such measurements. Advancements in imaging techniques may 
overcome this hurdle in the future, by counting glomeruli in vivo and establishing a 
more standardized reference number of the general population. To accomplish this 
advancement, stronger magnetic fields would have to be used in the clinic and 
specially developed contrast agents such as the recently demonstrated polymer-based 
contrast agent by Hlushshuk et al will have to be proven safe in general toxicity studies 
(144).
B.5 Conclusion
In conclusion, all drugs tested in this manuscript (gentamicin, ceftazidime, meropenem, 
ibuprofen, indomethacin, furosemide and hydrochlorothiazide), when dosed in a 
clinically similar dose, did not cause a direct toxic effect on nephrogenesis or glomer-
ulogenesis except for ceftazidime, which was toxic in early kidney development. 
Postnatal food restriction by litter enlargement results in a significant decrease of 
glomeruli, but did not enhance or modify the effect of drug treatments nor showed 
long-term sequelae. Therefore a two-hit interaction between these stressors was not 
observed. Finally kidney surface area or size are poor markers for renal development 
and should not be used.
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C  Future perspectives & recommendations
1.  The mechanisms behind decreased glomerular numbers after extrauterine 
growth retardation should be better understood. Although we could identify that 
food restriction has a direct impact on many kidney parameters, we did not find a 
lead to a proposed mechanism. The investigated kidney developmental- and 
transporter mRNA expression were not affected by food restriction and the 
findings noted on cytotoxicity were not convincing. A big-data approach including 
proliferation/apoptosis, developmental and energy metabolism pathways at 
multiple time points would be a logical next step to identify the disturbed 
processes. By elucidating the responsible pathways, drugs and environmental 
stressors may be tested in a more targeted approach. 
2.  It will be interesting to further evaluate the possibility of a programming effect as 
there were no clear long-term sequelae of the reduced glomerular numbers in a 
healthy state. Additional studies may be performed with a longer follow-up time 
to study the effect at increasing age, where more ‘wear and tear’ damage is 
expected. Another possibility is to challenge the kidney function by putting it 
under great stress. One could combine extrauterine food restriction with 
subsequent challenges of different drugs that increase the workload of the kidney 
or are slightly toxic and observe whether the kidney is still able to cope and 
responds similarly to a normally developed kidney.
3.  A follow-up experiment may be performed to study the risk of early pregnancy 
ceftazidime treatment. Although the regulatory studies showed that a severe 
effect on nephrogenesis as was noted in our experiments does not occur in vivo 
in rats, a dedicated study in pregnant rats to evaluate the effect on glomerular 
numbers would be informative to determine ceftazidime’s potential of subtle 
developmental toxicity and programming effects. 
4.  Morphologically the left- and right kidneys are not completely the same and 
left-right susceptibility differences are described in the literature. Currently these 
differences are poorly understood and we need to generate more data to 
understand better if these susceptibility differences are true and in which 
situations they become relevant. To gather this data it will be important to always 
study both kidneys for each end-point in future research projects. In many study 
designs, including ours, kidneys are examined unilateraly for separate end points 
or are even used as a control-treatment pair. These kinds of designs should be 
avoided as much as possible or if unavoidable at least the influence of left-right 
susceptibility should be described. Additionally the time point at which the 
kidneys start to differentiate in terms of susceptibility should be determined, 
which can be done with time-related experiments.
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5.  In the recent years many researchers were involved in investigating nephrogenesis 
and possible programming effects. However all studies were performed in 
animals or tissues because the tools to evaluate these processes in the clinic are 
currently lacking. Although recent advances in imaging techniques and 
contrasting agents are very promising, more effort and research is required 
before these can actually be adapted to the clinic. Continuing this field of research 
and finding the technical solutions will be paramount for fully understanding the 
process of nephrogenesis in humans. Stem cell research may also greatly 
contribute to this understanding, but may also be used to better evaluate the 
translatability of all animal research. 
6.  In this thesis we studied a two-hit scenario of different drugs and extra-uterine 
growth retardation, which is a simplification of the real clinical environment for 
neonates. To fully study the impact on nephrogenesis more complex studies are 
needed where multiple stressors are introduced at the same time and interactions 
can be described both in healthy and in disease models. This will allow ranking of 
stressors in order of importance for development and will give clinicians tools to 
build risk mitigation strategies.
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Summary
Currently preterm neonates have a relatively good survival rate from 24-25 weeks of 
gestation onwards and this will likely improve even more in the future due to the 
continuing expansion of knowledge of neonatal physiology, drugs and the better 
integration of this knowledge with engineering and computational models. However 
there is a high level of uncertainty on the impact that preterm birth, with concurrent 
treatments, has on (late) gestational organ development and organ function. There is 
growing evidence that events around birth program the physiology of our organs 
for direct optimal survival, but has implications for later life with an increased 
susceptibility to disease. With regards to the kidney there is currently limited data 
available, however these suggest that a reduced fetal growth could result in less 
glomeruli being formed. This paradigm is strongly related with the hyperfiltration 
hypothesis in kidney disease. The hypothesis states that a low glomerular number, 
after progressing through several phases, ultimately results in renal disease. 
 The total number of glomeruli is normally completed just before term birth, with 
little to no regeneration capacity in later life. Possible risk factors for a lower glomerular 
number have been previously identified. In this thesis we studied the impact of two 
factors, being drug treatment and extrauterine growth restriction, and their 
interaction. 
 We selected to study (1) antibiotics, (2) NSAIDs and (3) diuretics, which are used to 
treat three different neonatal indications: (1) sepsis/infection, (2) closure of a patent 
ductus arteriosis and (3) fluid retention. The use of these drugs is quite frequent as for 
the three drug classes 62%, 16% and 19% of neonates born before 32 weeks in the 
Netherlands receive treatment, respectively. In addition to neonatal treatment, the 
drugs may also be taken by pregnant women (although contraindicated) for similar or 
other indications (infections, water retention/high blood pressure, pain killer or as 
tocolycant), resulting in intrauterine exposure. 
 Extrauterine growth restriction was included was as a second stressor. Due to the 
immaturity of the intestines and all the necessary treatments (and accompanied side 
effects) in preterm born children, extrauterine growth restriction is very difficult to 
prevent in the neonatal care unit. Furthermore, research up till now has mainly focused 
on evaluating only a single stressor at a time, simplifying the actual situation in the 
neonatal intensive care unit. We believe it is crucial to study additive or synergic 
interactions between stressors to make a better risk prediction for preterm born 
children. 
 In chapter 2 we started out by providing a more thorough background overview 
on the known effects of congenital abnormalities and drug treatment with regard to 
the kidney. One of the early questions that rose was how kidney development could 
be monitored in the clinic. Currently estimations are made based on renal weight and/
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or renal size. We questioned the value of these morphometric predictions and 
investigated the validity of renal size in chapter 3 by performing a meta-analysis on 
the available data in the literature. Papers were included when both renal sizes were 
reported for individual subjects as well as unbiased results for glomerular numbers 
using stereology. Our analysis of the available data showed that renal size is a poor 
predictor for the number of glomeruli and should therefore not be used to evaluate 
kidney development. 
 Morphometric markers for kidney development were further examined in chapter 4, 
where we assessed the validity of metanephron (early fetal kidney) surface area 
measurements for ureteric bud formation, a well-studied kidney development 
endpoint. The fetal kidneys were explanted from mice embryo’s and cultured for 24 
hours. Our study showed that there was no correlation between the surface area and 
the ureteric bud formation in untreated specimens. Therefore we concluded that the 
use of the surface area of fetal kidneys as a study endpoint is also not wise. We did 
show that metanephron surface area at the time of kidney explantation is partially 
predictive for the bud formation after 24 hours and can therefore be used to gauge 
and correct for small differences in the state of kidney development at the time of 
explantation. 
 In the same chapter 4 we investigated the impact of the antibiotic drugs 
gentamicin, ceftazidime and meropenem in an approximated clinical dose range on 
early kidney development. With these experiments we showed that ceftazidime has 
a detrimental effect on ureteric bud formation ex vivo and down-regulated the 
Gdnf and Fgf8 genes, which are important in this process. No effect of gentamicine 
nor meropenem was demonstrated. The observed findings for ceftazidime in this 
developmental stage are more relevant to pregnant women than neonates, especially 
because ceftazidime can easily pass the placenta.
 Effect of antibiotics on kidney development were further investigated in chapter 5, 
where we studied the effect of gentamicine and ceftazidime on glomerular numbers 
when administered in a clinical neonatal dose range, which we measured and confirmed 
for gentamicin by pharmacokinetic analysis. This experiment was performed in rats 
just after birth, which is a comparable developmental stage to that of a human 
preterm neonate with regards to the kidney. Additionally, we introduced a ‘second hit’ 
in this chapter by food restricting a subgroup of the rats by using litter enlargement to 
model for extrauterine growth retardation. This allowed us to study both stressors 
and their interaction. The effects on development were evaluated by determining 
glomerular numbers, proliferation/apoptosis and expression of important genes in 
renal development or renal function. Methods used for the determination were 
stereology, immunohistochemistry and quantitative polymerase chain reaction. Our 
results indicated that food restriction caused a decrease in glomerular number, but 
drug treatment did not. There was no added or synergistic effect by combining drug 
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treatment with extrauterine growth restriction and the multi-hit hypothesis was 
therefore not confirmed in this study.
 The effects of the NSAID’s ibuprofen and indomethacin, and the diuretics 
furosemide and hydrochlorothiazide were studied in our ex vivo model in chapter 6. 
These drug classes are not only frequently administered to premature neonates, but also 
to pregnant women. Similar endpoints for toxicity evaluation were used as in chapter 3 
and no effects were noted on either ureteric bud formation or important developmental 
pathways. We concluded that furosemide, hydrochlorothiazide, ibuprofen and indo- 
methacin did not have an intrinsic effect on early kidney development in a clinically 
relevant dose range. 
 These drugs were further studied in chapters 7 and 8 for their effects on late 
kidney development in rats. In chapter 7, the impact of ibuprofen and indometacin 
was studied in a similar study setup as in chapter 5. Additional endpoints were added, 
however, to study long term sequelae. Kidney function was monitored by determining 
electrolytes and creatinine clearance up to 9 months-of-age and radio telemetry blood 
pressure measurement devices were used to follow-up on blood pressure. We 
identified a slight decrease in glomerular numbers after ibuprofen treatment, but no 
delayed effects were noted in the long-term treatment parameters, except for a slight 
tendency to an increased NGAL concentration 9 months after treatment. Unfortunately, 
blood pressure measurements were not reliable to analyze. Additionally, our study 
outcome contrasted some of the results of other researchers in the field. Therefore 
more studies should be performed to provide a definite answer whether there is a real 
effect of these drugs. The effect of food restriction on glomerular numbers was small 
and no interaction between drug treatment and food restriction was observed.
 In our final experimental chapter (chapter 8) we studied the effects of clinical 
dose levels of furosemide and hydrochlorothiazide treatment with a similar protocol 
as described in chapters 5 and 7. Due to the unsuccessful telemetry, we used tail cuff 
blood pressure measurements in this study. In this study we noted a decrease in 
glomerular number by food restriction, but drug treatment did not have an effect and 
no interaction between food restriction and drug treatment was noted. Nor did we 
see any effect on long term endpoints.
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All considerations for our choice of techniques and the overall implications of the work 
combined in this thesis are discussed in chapter 9. Based on this we conclude that all 
drugs tested (gentamicin, ceftazidime, meropenem, ibuprofen, indomethacin, furosemide 
and hydrochlorothiazide), when dosed in a clinical relevant dose, did not cause a direct 
toxic effect on nephrogenesis or glomerulogenesis except for ceftazidime, which was 
toxic in early kidney development. Postnatal food restriction by litter enlargement 
results in a significant decrease of glomeruli, but did not enhance or modify the 
effect of drug treatments nor showed long-term sequelae. Therefore a multiple-hit 
interaction between these stressors was not observed and adding age had no effect. 
Finally kidney surface area or size are poor markers for renal development and should 
better not be used.
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Samenvatting
Hedendaags hebben te vroeg geboren kinderen een redelijk goede overlevingskans 
vanaf week 24-25 en in de toekomst zal dit waarschijnlijk verder toenemen vanwege 
de groeiende kennis op gebied van neonatale fysiologie, medicatie en de betere 
integratie van techniek en computersimulaties. Desondanks is er een grote onzekerheid 
over de invloed die vroeggeboorte, met de bijbehorende behandelingen, heeft op de (late) 
ontwikkeling van organen en hun functioneren. Er is groeiend bewijs dat gebeurtenissen 
rondom de geboorte de orgaanfunctie programmeren en optimaliseren voor directe 
overleving, maar wat gevolgen heeft voor de vatbaarheid voor aandoeningen op 
latere leeftijd. Voor dit effect op de nier zijn er op dit moment beperkte onderzoeks-
gegevens beschikbaar, maar deze suggereren dat een gereduceerde foetale groei 
mogelijk een vermindering in aanleg van het aantal glomeruli ten gevolg kan hebben. 
Dit paradigma is sterk verwant met de hyperfiltratie theorie in het veld van nierziekten. 
Deze theorie beweert dat een laag aantal glomeruli, na progressie via verscheidene 
stadia’s , uiteindelijk kan leiden tot nierziekte. 
 Het totaal aantal glomeruli is normaal gesproken volledig aangelegd vlak voor de 
geboorte en het lichaam heeft weinig tot geen herstelmogelijkheid indien deze 
glomeruli verloren gaan. Mogelijke risicofactoren voor een lager aantal glomeruli zijn 
voorheen geïdentificeerd. In dit proefschrift is de impact van twee factoren: medici-
jngebruik en extra uterine groeivertraging, en de interactie daartussen bestudeerd. 
We hebben gekozen om (1) antibiotica, (2) NSAIDs en (3) diuretica te bestuderen, welke 
gegeven worden ter behandeling van 3 verschillende neonatale indicaties: (1) sepsis/
infectie, (2) sluiting van een persisterende ductus arteriosis en (3) vocht retentie. Het 
gebruik van deze medicijnen is frequent aangezien voor de 3 medicijnklassen respecti-
evelijk 62%, 16% en 19%, van de neonaten geboren in Nederland vóór 32 weken 
hiermee worden behandeld. Naast neonatale behandeling, kunnen deze medicijnen 
ook gebruikt worden door zwangere vrouwen (ook al contrageïndiceerd) voor 
vergelijkbare indicaties (infecties, vocht retentie/hoge bloeddruk) of als pijnstiller of 
weeënremmer, resulterend in intra uterine blootstelling. Een tweede prikkel was 
geïntroduceerd in de vorm van extra uterine groeivertraging. Vanwege de onvolgroe-
idheid van de darmen en alle noodzakelijke behandelingen (en bijbehorende 
neveneffecten) bij te vroeg geboren kinderen is het zeer moeilijk om dit te vermijden 
in een neonatale care unit. Wetenschappelijk onderzoek heeft zich tot op heden 
voornamelijk gefocussed om één enkele prikkel tegelijkertijd te bekijken, waardoor de 
daadwerkelijke situatie in de neonatale intensive care unit sterk vereenvoudigd wordt. 
Wij geloven dat het cruciaal is om additieve en synergetische interacties tussen 
prikkels te bestuderen om zo een betere risico evaluatie te kunnen maken voor te 
vroeg geboren kinderen. 
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In hoofdstuk 2 geven we een achtergrond overzicht over bekende effecten van 
aangeboren afwijkingen en medicijngebruik op de nier. Een van de eerste vragen die 
opkwam was hoe nierontwikkeling opgevolgd zou kunnen worden in de kliniek. Dit 
wordt momenteel gedaan door het bepalen van nier gewicht en/of nier grootte. Wij 
betwijfelden de waarde van deze morphometrische voorspellingen en hebben daarom 
de validiteit onderzocht in hoofdstuk 3 door een meta-analyse uit te voeren op 
beschikbare data in de literatuur. Onderzoeks artikelen werden geïncludeerd wanneer 
zowel niergrootte alswel objectieve metingen het behulp van stereologie voor het 
aantal glomeruli in individuele proefpersonen werden gerapporteerd. Onze analyse 
van de beschikbare data toont aan dat niergrootte geen goede voorspeller is voor het 
aantal glomeruli en zou daarom niet gebruikt dienen te worden om een voorspelling 
voor nierontwikkeling te geven. 
 Morphometrische merktekens voor nierontwikkeling zijn verder bestudeerd in 
hoofdstuk 4 waarin we de validiteit van metanefron (vroege foetale nier) oppervlakte 
voor ureterknop formatie, een goed bestudeerd eindpunt van nierontwikkeling, 
hebben bepaald. De foetale nieren werden geëxplanteerd vanuit muizen embryo’s en 
24h in kweekcultuur gebracht. Onze studie toonde aan dat er geen correlatie was 
tussen de oppervlakte en ureterknop formatie bij onbehandelde specimens. Daaruit 
concludeerden we dat het gebruik van oppervlakte van de foetale nier als een studie 
eindpunt ook niet verstandig is. Bijkomend toonden we aan dat de oppervlakte van de 
foetale nier op het moment van explanteren gedeeltelijk voorspellend is voor de knop 
formatie na 24 uur. De oppervlakte meting kan daarom wel gebruikt worden om het 
stadium van nierontwikkeling te schatten op het moment van de explantatie en voor 
kleine verschillen daarin te corrigeren.
 In hetzelfde hoofdstuk 4 hebben we het effect van de antibiotica gentamicine, 
ceftazidime en meropenem in een benaderde klinische doserings range, op vroege 
nier ontwikkeling onderzocht. Met deze experimenten toonden we aan dat ceftazidime 
een negatief effect op ureter knop formatie heeft ex vivo en de expressie van twee 
belangrijke genen in dit proces, namelijk Gdnf en Fgf8, verminderd. Behandeling met 
gentamicine of meropenem liet geen effect zien. In dit ontwikkelingsstadium zijn de 
bevindingen bij ceftazidime behandeling meer relevant voor zwangere vrouwen dan 
neonaten, voornamelijk omdat ceftazidime ook zonder moeite de placenta kan passeren.
 De effecten van gentamicine en ceftazidime op nier ontwikkeling zijn verder 
onderzocht in hoofdstuk 5, waarin we het effect op het aantal glomeruli bestudeerd 
hebben na een klinische relevante dosering. In het geval van gentamicine hebben we 
deze ook gemeten en bevestigd door middel van farmacokinetische analyse. Dit 
experiment is uitgevoerd in ratten, welke kort na de geboorte gedoseerd werden. 
Op dat moment is het stadium van nierontwikkeling vergelijkbaar met dat van een te 
vroeg geboren kind. Tegelijkertijd introduceerden we de tweede prikkel in dit hoofdstuk 
door voerrestrictie toe te passen (d.m.v. nestvergroting) op een subpopulatie van de 
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ratten om extra uterine groeivertraging te modelleren. Daarmee konden de 2 prikkels 
en hun interactie bestudeerd worden.
 De effecten op ontwikkeling zijn geëvalueerd door het aantal glomeruli te 
bepalen, proliferatie/apoptose te bekijken en door expressie van belangrijke genen in 
nier ontwikkeling of nier functie te meten. De methoden die gebruikt werden voor de 
experimentele bepalingen waren stereologie, immunohistochemie en kwantitatieve 
polymerase ketting reactie. Onze resultaten lieten zien dat voerrestrictie een verlaging 
van het aantal glomeruli veroorzaakt, maar medicijn behandeling niet. Er was geen 
additief of synergetisch effect aanwezig in de kombinatie van medicijn behandeling 
en extra uterine groei restrictie en de meervoudige ‘treffer’ hypothese was daarom 
niet bevestigd in deze studie.
 De effecten van de NSAIDs ibuprofen en indometacine, en de diuretica furosemide 
en hydrochloorthiazide hebben we bestudeerd in ons ex vivo model in hoofdstuk 6. 
Deze medicijnklassen worden niet alleen frequent gegeven aan te vroeg geboren 
kinderen, maar ook aan zwangere vrouwen. Voor de evaluatie van toxiciteit zijn 
vergelijkbare eindpunten als in hoofdstuk 3 gebruikt. We vonden geen effecten op 
zowel ureterknop formatie als belangrijke genen in ontwikkeling. We concludeerden 
daaruit dat furosemide, hydrochloorthiazide, ibuprofen en indomethacine geen 
intinsiek effect op de nierontwikkeling hebben in een klinische relevante doseer range.
 Deze medicijnen zijn verder onderzocht in hoofdstuk 7 & 8 voor effecten op late 
nier ontwikkeling bij ratten. In hoofdstuk 7 is de impact van ibuprofen en indometacine 
bestudeerd volgens een vergelijkbaar protocol als in hoofstuk 5. Extra eindpunten zijn 
echter toegevoegd echter om mogelijke lange termijn gevolgen op te volgen. De 
nierfunctie werd gemonitord door electrolieten concentraties en creatinine klaring te 
bekijken tot een leeftijd van 9 maanden, en radio telemetrie bloeddruk meters zijn 
ingezet om bloeddruk op te volgen. Na ibuprofen behandeling zagen we een lichte 
afname van de hoeveelheid glomeruli, maar verdere effecten werden nier gevonden 
in de lange termijn eindpunten. De uitzondering hierop was een lichte stijgende trend 
in NGAL concentratie 9 maanden na behandeling.
 Helaas bleken de verkregen bloeddruk resultaten niet betrouwbaar genoeg om te 
analyseren. Daarnaast waren de bevindingen uit onze studie tegenstrijdig met de 
resultaten van andere wetenschappers in het werkveld. Daarom zullen er meer studies 
nodig zijn om een definitief antwoord te vinden of er daadwerkelijk een effect is van 
deze medicijnen. Het effect van voerrestrictie op nier ontwikkeling was klein en er is 
geen interactie waargenomen tussen medicijn behandeling en voerrestrictie.
 In het laatste experimentele hoofdstuk (hoofstuk 8) hebben we de effecten van 
een klinisch relevante dosering furosemide en hydrochloorthiazide bestudeerd 
volgens een vergelijkend protocol zoals beschreven in hoofdstukken 5 en 7. Vanwege 
de mislukte telemetrie experimenten, zijn er dit maal bloeddrukken gemeten met een 
staartcuff. In deze studie zagen we wederom een afname van glomeruli in de 
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voerrestrictie groep, maar medicijn behandeling had geen invloed en ook werd er geen 
interactie waargenomen. Tevens zagen we ook hier geen effecten in de lange termijn 
eindpunten.
 Alle overwegingen met betrekking tot de toegepaste technieken en de algehele 
bevindingen van het gecombineerde werk in deze theses zijn bediscussiëerd in 
hoofdstuk 9. Hierin concluderen we dat all geteste medicijnen (gentamicine, ceftazidime, 
meropenem, ibuprofen, indomethacine, furosemide en hydrochloro thiazide), wanneer 
gedoseerd in een klinisch relevante dosering niet een direct toxisch effect op nefrogenese 
of glomerulogenese hebben, met uitzondering van ceftazidime, welke schadelijk was in 
vroege nier ontwikkeling. Postnatale voerrestrictie door middel van nestvergroting 
leidde tot een significante afname van glomeruli, maar beïnvloede niet het effect van 
medicijn behandeling, noch liet het een lange termijn consequentie zien. Daardoor is 
een meervoudige treffer interactie tussen deze prikkels niet aangetoond en had 
gevorderde leeftijd geen effect. Ter afsluiting, nier oppervlakte of grootte zijn 
ongeschikte markers voor nier ontwikkeling en kunnen beter niet gebruikt worden.
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Dankwoord
Veel personen hebben in de afgelopen jaren op één of andere manier een bijdrage 
geleverd aan het tot stand komen van dit proefschrift. Waaronder alle medewerkers 
van Laboratorium geneeskunde, kindernefrologie, pathologie en het centraal 
dieren laboratorium van het Radboud UMC/ Radboud universiteit. Naast hulp bij 
experimenten en veel wetenschappelijke conversaties zijn er ook vele leuke activiteiten 
georganiseerd zoals o.a. een luxe overnachting op vakantiepark de Berckt met een 
(bijna) privé zwembad, culinair eten en drinken bij Café de Beugel, pubquizzen en de 
whiskey proeverij bij Versailles (zeker géén Velpon Roel!). Buiten de bijzondere uitjes 
zoals deze waren de regelmatige bijeenkomsten in de Aesculaaf of Maxim ook zeer 
memorabel (Maurice, ik ben je nog steeds een wiel schuldig....). Naast mijn oud- 
collega’s in Nijmegen wil ik ook mijn huidige collega’s bij Janssen bedanken voor alle 
steun. Zonder al deze mensen tekort te doen (maar vooral om deze sectie kort te 
houden) wil ik een aantal mensen nog speciaal bedanken.
 Bert en Michiel, allereerst wil ik jullie graag bedanken voor de mogelijkheid om de 
experimenten die beschreven staan in dit proefschrift beschreven staan uit te voeren. 
Tevens was jullie inzicht en soms andere kijk op data van grote waarde voor mijn 
 wetenschappelijke ontwikkeling. Michiel, ik wil je uitzonderlijk bedanken voor je 
feilloze instinct om me bij te sturen op de momenten waar ik weer (te) kritisch was 
over de resultaten van mijn experimenten. Ondanks dat ik nog steeds zeer kritisch blijf 
heb ik geleerd dit beter te relativeren en te kunnen plaatsen in een groter geheel.
 Annelies, ik wil je graag bedanken voor al het werk wat je verricht hebt voor de 
experimenten beschreven in dit proefschrift. Menig dag zul je naar huis gegaan zijn 
met een lamme arm van het snijden van coupes voor het stereologie werk. Alhoewel 
de uiteindelijke analyses niet de vooropgestelde hypotheses bevestigden hebben we 
enkele leuke publicaties kunnen schrijven. Ik wens je veel succes in je carrière en veel 
geluk en gezondheid samen met je gezin.
 Mijn andere directe research nephro collega’s: Dineke, Carolien, Elena, Thea en 
Nicole dank voor al jullie wetenschappelijke input op mijn experimenten en vooral 
voor alle flauwekul daaromheen. Bij de voortdurende stroom aan hypothese 
ontkrachtende data is het fijn om dit te kunnen delen met zulke fijne collega’s. Niet te 
vergeten wil ik ook mijn stagiair Lisanne bedanken. Naast al het werk wat je gedaan 
hebt, heb ik ook door jou leren coachen. 
Buiten mijn collega’s wil ik ook enkele familieleden niet onbesproken laten.
 Pap, Mam, ik wil jullie bedanken voor alle liefde, steun en kansen die jullie mij 
gegeven hebben. Jullie opvoeding heeft mede geholpen om mij te vormen tot wie ik 
nu ben. Het verplicht moeten aanhoren van klassieke muziek op de zondagochtend 
(na een hele week van rock en metal) heeft zijn nut gehad. Ik heb ondervonden dat het 
180
CHAPTER 11
uiterst concentratieverhogend werkt bij het uitvoeren van stereologie analyses. 
Verder wil ik jullie bedanken voor alle keren dat ik even lekker heb kunnen klagen over 
alles en niets aan de eettafel om het hoofd weer leeg te krijgen.
 Carin,Oscar (Damian, Jessica): wanneer je zoveel tijd en energie investeert in één 
project raak je er soms in verstrikt. Ik heb jullie te danken om de inhoud van het directe 
werk te relativeren en om in te zien dat er ook nog andere belangrijke zaken zijn, zoals 
bijvoorbeeld barbecueën met familie! Niklas, waar ik uiteindelijk niet verder gekomen 
ben dan een paar setjes in Dollars tijdens de 4daagse, bespeel jij nu hele festival 
menigtes. Jouw toewijding aan de muziek is voor mij een grote inspiratiebron geweest 
om te blijven doorzetten en dit proefschrift te voltooien. Tjerk, Sandra (Lisa, Tycho), 
jullie eerdere ervaringen vanuit het promoveer traject en als mede vakgenoten hebben 
mij geholpen om het einddoel voorogen te blijven houden en te begrijpen wat ik 
daadwerkelijk geleerd heb tijdens dit traject. Tjerk, laten we onze PubMed competitie 
in stand houden als voorlopig de enige twee ‘Buetersen’ ter wereld die in de auteurslijst 
voorkomen. Je hebt misschien een “lichte” voorsprong wat betreft het aantal artikelen, 
maar bij het schrijven van dit dankwoord staat er een van mij bovenaan!
 Mijn schoonfamilie: Riekie, Gerard, Bart & Krista (Eef), Paul: Dank voor al jullie 
steun en interesse in mijn werk. Jullie warmte heeft er mede voor gezord dat ik 
gemotiveerd bleef om dit werk te voltooien naast mijn functie bij Janssen. Gerard, Ik 
vind het zeer spijtig dat je de voltooiing van dit manuscript niet meer mag meemaken, 
want ik weet zeker dat je van de verdediging zou genieten. Toch ga ik nog zorgen dat 
er een boekje bij jou terecht komt.
 Verder wil ik al mijn vrienden, buren en kennissen bedanken voor al hun steun, 
gezelligheid, maar voornamelijk begrip. Ik heb menigeen verjaardagfeestje en activiteit 
overgeslagen vanwege de vervaardiging van dit proefschrift en dat was zeker niet 
makkelijk. Met het afronden van dit manuscript gaan we daar verandering in brengen.
Ten laatste, maar niet ten minste wil ik mijn vriendin Anke toespreken.
 We hebben samen wat pittige jaren gehad, waarin ik een grote belasting op jouw 
schouders heb gelegd. Door mijn grote tijdsinvestering, kwam een groot deel van de 
huishoudelijke taken bij jou terecht, naast jouw eigen voltijdse baan. Ik voelde me dan 
ook vaak schuldig als ik na een weekend werken uiteindelijk niet veel op papier 
gekregen had, maar zoals je weet de raderen in het hoofd draaien altijd (en soms iets 
te veel). Met het voltooien van dit proefschrift komt er weer ruimte om samen meer 
leuke dingen te doen en hoef je niet meer alleen naar verjaardagen. Eén ding is zeker, 
zonder jouw onvolwaardelijke steun was dit proefschrift niet tot stand gekomen. 
Laten we daar nu samen van gaan genieten. 
En nu heb ik geen goesting meer om te schrijven, cheers!
Ruud
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List of abbreviations
ACEIs: Angiotensin converting enzyme inhibitors
Actb: Beta actin
Agtr1a: Angiotensin receptor type 1
Agtr2: Angiotensin receptor 2
ANCOVA: Analysis of covariance
ANOVA: Analysis of variance
Aqp1: Aquaporin 1
Aqp4: Aquaporin 4
ARBs: angiotensin receptor blockers
ASF: Area Sample Fraction
AUC: Area Under the Curve
BAX: B-cell lymphoma 2-like protein 4
BCL-2:  B-cell lymphoma 2
BMI: Body Mass Index
Bmp7: Bone morphogenetic protein 7
BSA: Bovine Serum Albumine
BSA: Body Surface Area
CAKUT: Congenital Abnormalities of the Kidney and Urinary Tract
Casp3: Caspase 3
Casp9: Caspase 9
Casr: Calcium sensing receptor
Cmax: Maximum concentration
COX: Cyclooxygenase
CT: Cycle time
DBP: Diatolic Blood Pressure
DMEM: Dulbecco’s Modified Eagle Medium
DNA: Deoxyribonucleic Acid
DOHaD: The developmental origins of health and disease
ELISA: Enzyme-Linked Immuno Sorbent Assay
EM: Electron Microscopy
ENaC: Epithelial sodium channel
ESRD: End Stage Renal Disease
EUGR: Extrauterine Growth Retardation
FDA: Food and Drug Administration
Fgf7: Fibroblast growth factor 7
Fgf8: Fibroblast growth factor 8
FR: Food restricted (regime)
Gdnf : Glial cell line-derived neurotrophic factor
GRf1a: Glial cell line-derived neurotrophic factor receptor alpha 1
GUDMAP: Genitourinary development molecular anatomy project
HCTZ: Hydrochlorothiazide
Hgf: Hepatocyte growth factor
HIV: Human immunodeficiency virus
Hmbs: Hydroxymethylbilane synthase
HRP: Horse radish peroxidase
Lim: Lim homeobox 1
MBP: mean blood pressure
MCDK: multicystic dysplastic kidney
M-MLV: Moloney Murine Leukemia Virus
MRI: magnetic resonance imaging
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mRNA: messenger Ribonucleic Acid
Ncc: Sodium-chloride symporter
NF: Normal Food (regime)
NGAL: Neutrophil Gelatinase-Associated Lipocallin
N(glom): Number of glomeruli
Nhe3: Sodium hydrogen exchanger 3
Nhe8: Sodium hydrogen exchanger 8
Nkcc2: Na+-K+-Cl- cotransporter
Nphs1:Nephrin
Nphs2: Podocin
NSAIDs: Non Steroidal Anti Inflammatory Drugs
Oat1: Organic anion transporter 1
PBS: Phosphate Buffered Saline
PBS-T: Phosphate Buffered Saline - Tween80
PDGF-B: Platelet Derived Growth Factor subunit B
Pf: Number of counting frame corners that hit evaluated kidney tissue
PND: Post Natal Day
PP: Pulse Pressure
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Ps: Number of counting frame corners that hit kidney tissue
Ptgs1: Prostaglandin synthetase 1
Ptgs2: Prostaglandin synthetase 2
qPCR: quantitative Polymerase Chain Raction
RAS: Renin-angiotensin system
Ret: Ret proto oncogene
RNA: Ribonucleic Acid
SBP: Systolic Blood Pressure
SD: Standard Deviation
Sox9: Sex determining region Y-Box-9
SSF: Section Sample Fraction
TUNEL: Terminal deoxynucleotidyl transferase dUTP nick end labeling
Wnt4: Wingless-type MMTV integration site family, member 4
Wt1: Wilms Tumor 1
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